var title_f37_62_38880="Cyclosporine: Patient drug information";
var content_f37_62_38880=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cyclosporine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/52/6980?source=see_link\">",
"       Cyclosporine (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/28/40390?source=see_link\">",
"       Cyclosporine (systemic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12348 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_62_38880=[""].join("\n");
var outline_f37_62_38880=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/52/6980?source=related_link\">",
"      Cyclosporine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/28/40390?source=related_link\">",
"      Cyclosporine (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_62_38881="Telangiectasia of the lower extremity";
var content_f37_62_38881=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62119%7EPC%2F70438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62119%7EPC%2F70438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Telangiectasia (spider veins) of the lower extremity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Telangiectasias are dilated intradermal venules less than one millimeter in diameter. Synonyms include: spider veins, hypen webs and thread veins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrick C Alguire, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Telangiectasia, reticular veins and mild ankle edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 235px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reticular veins are dilated bluish subdermal veins, one to three millimeters in diameter. The deeper blue reticular veins contrast the bright red, fine telangiectasias. Mild ankle edema in this patient is evident at medial ankle below the malleolus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrick C Alguire, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_62_38881=[""].join("\n");
var outline_f37_62_38881=null;
var title_f37_62_38882="Delivery of posterior arm";
var content_f37_62_38882=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The effect of the Barnum maneuver in reducing the obstructing part of the fetal shoulder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 231px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The operator has already inserted a hand into the vagina and delivered the posterior arm by sweeping it across the fetal chest, and thus delivered the posterior shoulder as well (not shown). A 13-cm bisacromial diameter becomes an 11-cm axillo-acromial diameter upon delivery of the arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Poggi, SH, Spong, CY, Allen, AH. Prioritizing posterior arm delivery during severe shoulder dystocia. Obstet Gynecol 2003; 101:1068. Copyright &copy; 2003 American College of Obstetricians and Gynecologists.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_62_38882=[""].join("\n");
var outline_f37_62_38882=null;
var title_f37_62_38883="Camphor and menthol: Patient drug information";
var content_f37_62_38883=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Camphor and menthol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/0/44034?source=see_link\">",
"     see \"Camphor and menthol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Men-Phor [OTC];",
"     </li>",
"     <li>",
"      Mentholatum&reg; [OTC];",
"     </li>",
"     <li>",
"      Sarna&reg; [OTC];",
"     </li>",
"     <li>",
"      Soltice Quick-Rub&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691826",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain from muscle and sports injuries.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to camphor, menthol, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care when a large part of the skin is involved or where there are open wounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use. Do not wash your hands after use if putting this on your hand.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11440 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_62_38883=[""].join("\n");
var outline_f37_62_38883=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144864\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012790\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012789\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012794\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012795\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012797\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012792\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012793\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012798\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012799\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/0/44034?source=related_link\">",
"      Camphor and menthol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_62_38884="Abdomen anatomy adult";
var content_f37_62_38884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Adult abdominal anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 576px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJAAgUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACig00tRcB1FN3U7NK4BRTHbHQ80m4+tFwJKKj3H1o3N60XAkoqPc3rQrHPJp3AkooooAKKKKACiiigAooooAKKKKACiiigAoopC1AC0UgNLmgAooyPWk3CgBaKjLH1pN7UAS0VFvb1o3t60AS0VHuPrRuPrQBJRUe8+tG8+tAElFR7z60bj60ASUVHuPrRvPrQBJRUe4+tKHPtQA+im7x3FG9fWgB1FAIPQg0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIzBRk0tIwB60AVmvI+cA1E136D9a5G81Nob6aLd/q3K1LDqe8ckVwPFX0O/6rZXOnFyx7iniXd1Jrn1vvepo74etCxCJeHZvK4NOBFYy33vU8d4D1NaxrpmUqMkagxSjFUUuge9Si4BrVVEzNwaLVGKriYetL5w9afOhWZNj3oBPqah833pfN96fMgsT5PrRlqgEo9RR5o9RRzIVifJ9aNx9ar+d7ik833FHOg5SzknvS8+tVxLUgkGOaakHKSjPrRTA4pd4p3FYQ5z3pcH3o3Cm+YM0roLMdg00rS7xSFqLoeooBpwHFM3D1pd4ouFmOxRj1NNMgppkHrRcVhzdabxUbSj1pnmj1pc6HysnozUHnD1pDKPWlzoOVljNJmq3nD1pPOFL2iHyMs5ozVXzxR9oFL2iDkZazS5qn9pHrTTcr60vaofs2XtwpNwrNe8HrULXvvUuukWqLZr7x60hkHrWKb4jqail1IL3qHiUi1hpM3WmUVG1wtcvcaxtOA1VjrGf4qh4tGqwcjtrR/MLMOg4q3WZ4dbzdMSU/xsT/AE/pWnXZTd4pnHUXLJrsFFFFWQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUHpRQelAHlnj2M2evO4+5MoYfXpWPZ3ucDNdX8UbUtbWlyP4WKH8eR/KvPbeTa2M18/ik4VZJH0uEaqUYtnWxXO4cGrMcxrEtJMgVpRNyKxU2VOFjQWVvWpkuGHeqseCKkAq1JnPKKLiXbDvUy35Hes/FJ0q1UaM3TizUF+fWpVvs96xfpTwTWirsl0Uba3me4p4uvesRXNSCQ1oq7M3RNj7T704XJ9ayBIacJDT9syXSNb7R70ouKyxIe9PEhqvbE+yNP7VSreYrM3H1pCxo9sxeyRri9FKb4etYhYjvTDIe5pfWWh/V0bTagMdaiN+PWsVpDTd5qHiJFrDo2zqIHeopNVwfvVjSuQDVCWUk1LxUkawwsWdPHqm4/eqwL7I+9XJ2rnd1rTibinHEyZM8PFG0Lwnoaa1wT/ABVQhPNWeMVqqzZg6aTHm49zSfaD61XdRmoyMVLqMpQiy39oNBuPeqLHFMLmodWRSpIvG596abn3qiWppapdVlqii610fWozdn1qize9MJzUuqy1SiXjeEd6Y14fWqJBpcVPtGUqcSw10T0phuDiosUxqlyZSih7zkg81nXVyRnJqeRuKyL+TjGahyZvTjqU728IY81ThvWaUKCST2qteSHJPrVrwZZtqPiOziIypkDN/ujk1KvJpLqdMrQi5Poe56VALXTbaADBSNQfrjn9atUd6K+mirKyPkpPmbbCiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAwvGNj9u0K6jAy6r5i/Uc14nJ8r5FfQs43RMK8K8V2J07WLiDGF3bk/3TyK8nMaeqmvQ9rK6t06b9SXTpcgDNbELciuWsZsMK6G3kDKOea8zY9Scbo2IG9asjFZkLkGrqv8ALx1q0zknEJrqKLqcn0FUptUCfwgD3NVriGVScoceoqg4mU5i2lunzjNNGsaUbGtDqyOcEKf901dhuo5PunB965eC0ne5EsmMjsorbtLSZiMrtUdzT2FOnFK5rBvWnAj1pqoQKdsqkczsOVqlQ5qJYz6VKi+tWkZuxIpzTxikUU8LirSM2xBS0pwKaT+dDAY1RHrUjUwioZaIWqMtgVLJ1qtK1Q2axVxszcVRlNWJH61VkOcVnJnTTjYmtyd1aULGsy3OTWnD0pxZnURaibFWlfIqknWp1OK6IM45xuSueaiY0/cDUbGm2JIaSajanMaYeahlojammnng001DRomMIrLvdQKMVixn161qkZBBrHutOlDlocMPQ9alm1Plb1Kwv7tjw5P0UU1dZlSXy5WIb/aXFQTWd2vCb429RVM6XdySBpZHfB7ilZHRyxOjt9QEv3gPqKsMwIBB4rLtLSRfvjAq8OAPQUjKUUnoRzvhTWDfy9a076Xg4rn76Tr6UmzWnEz7uTJwOpr0T4RaYC91qDj7gESfXqf6V5qSXlr3T4e2n2TwraZGGmzKfxPH6AV04CHPVT7anPmNTkotLrodGKKQHNLXvHzgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFec/FqwDJZXqKBy0TkD8R/WvRq5/wAc2YvPDV6gGWRRKv1Xr+ma58VDnpSR04Op7OtFnhsTFHrbsbjoCaxJU5yKmtpSpFfPH1COuglDCrkT8Vz1rcnAya1be4BAyaEzKcDUR6lUK3JVT+FU43BqzG+K0TOaUbFlUHYCpAtRLIMVIsmatGLuP2UmylDZqQVSIbaBVNOC+1Apc1aIY4HHagtTdwppf3p3CwpNMLGgtTCahspIUmgmm01mwKlspIZK1U5Tk1PI2artyCazZvBEB6GomHSp2GBTMZxUmyY63GCK0YjxVKNcVZjbFUjGepbU1KjVWU04NzWidjFxLBppOaQOMUhNU2QkFJxQTSE1NyhCB3ppxQxphbFJspICaTNNZ6YWqWy0h7MKgd/SlZs1GxpFJDSc9TUMr4BxRJKB1NZ91dAA80m7GsYtshvZQAa5y9kyxI9auXlzvJGazmBkas73OuKsrCWsZZ6+itLjEOl2kajhIUUfgorwK0jAlQe4r6CgwLWLHTYP5V6eWbyfoeRm20F6kiDApaRTS16yPEYUUUUwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACo7iITwSxN0dSp/EYqSih6gtD57mh8ueWJuqMVP4GoGhIOV61reI4/I8R6jH2E7Y/PNQRKGr5aa5ZNH2FN88UyrDIydeKvwXApj22eg4qAwMrcUitjcguQMc1djuAe9c2jOo5qeOdsii5EoJnTRz571ZjlFc/BKxxzxV6NzjrVqRhKmbSSrUwfismFz1NWRKelWpHPKmXfMpC9VVcmn7jVcxHJYmLUm6od1LmlzD5SQH1p1Rg0tFxWFJwKhkanOaiIyaTKSG9aa44qYLgZpjCky4kBGc0Rp0qZVp6JSsVzWGYAGDS4xTL0lDBj1INTTr/o5Yda6IUeaN0K17MEan5rKsJ2a7MbdCDWnWc48rsKcOV2Y8NShqjozU3JsP3Um6mGii4WFJpjGlNNNIpDaRjSnIFQTSHFIoWSQKKo3N0FBwahuJmyQBWbNvYnNJs0jFDri85PNZk9wznAqy1szH2qSKwyeahm8bIy1jZz3qxHbbRkjmtT7OsYqCXAHFItMqIMTIfcV7ujkW1uPVB/KvByf3q/WvdSMRW49EH8q9LL9Ob5HlZpryfP8AQsI2amHSq0dWFr1os8WSFoooqyAooooAKKKKACiiigAooooAKKKKACivMPiF8TZ/C/ja28PwWumfvrFbwXF/eNApJkZPLG1Gyflz+fpW8nxD0STxFe6RELt3sneO5uFi/cwsi7m3HO4AAfexj3oA7GiuFt/ij4flsL27lXULaO3shqKie2KNPbFtoljHdckeh5HFZniH4q21oIE06yuzdJqdnaXNtc2ziUwT7sSRIOWJCnA654IoA9Norhv+FmaOfD8urLaap5UF49jPC1uElglQbirhmAHBHfvjrTJvip4dWxs7u2F/eR3Fi+pMLe3LNBbISrSSDjaAysO/INAHeUVx03xG0CHTtWvnkuPI0u2tbq4IiOQlwMx4Hc46+lS6V480nVfFNzoWnxXs1xbTSW806w/uo5EBLKTnIwRjOME8A8igDrKKKKAPF/HsfleLL3/aKt+aisy26iug+JsJTxMX/wCekSN/T+lYFuOBXzWJVqsl5s+rwjvSi/JGjCoIxU32YMOlQwcVp2pB4NYo1m7Ge1mP7tM+xgHpXQiFT2pGthV8ph7Yxo4AB3q0kYFXPs+O1OWHB6UconVuMij4qdUxUkaYGDT8VaRi5jAMUuKdilxTsRcbilApcUtFhXEApaKKYDSM0gWn0UWC401GRzUp6U3FJjTGgCnDijFHekMr6gP3UbejirWN9kahvF3Wr+o5/Kp7L95asPau7Du6sVf3V5M5y2fy9Vj9C2PzrocVzmoqYbwN6HNdIpDKGHQjIrGutUzSv0kNxRin0YrCxz3GYpNtSYpMUWHcjxTSKmIphFIaZA3tUEiE1bK0wj2pWLTKDQ56imfZAegFXymTShQKRalYoCzA6iholQHAq8xqvP0NJ6FxbZk3JxmsuZucVfu25NZsx5qLnRFEUQL3MSjqzgfrXvssf3D2AxivCNJXfrVgg5LXEYx/wIV76wzgV62Wx0l8jyM2laUF6/oRItSgUAYpa9RKx4zdwooopiCiiigAooooAKKKKACiiigAooooA47xH4Dt9a8Up4gi1rWtL1FbIWG6wljQNEHL4O6NjncfXsKr3nwy0S/8UtrmpS3l5MWkYQymPYu9SpXcqCQrgkBS5A9K7migDzDWPhTbjwvq9lpN9dXGo3GmjS7STUpgUtoAwYRLsTIXIHJDHgc1o2vwx0wSQ3V9f6neakt5aXzXMsqFi1vny4xhABGMngAE55Nd9RQBwd78MNHubh7gXupw3J1SbVhLHJGSksqKjqAyFduFGMgsD0Ncv4j+El3Fptlp/g+88iNNMl0qa5ursq8kDuz7XRYWDgF2PBQ9smvZKKAPNtR+EOkalayQ3GqaxALmxt7K7S0nWOO4ECgI7KVbkY9ce1a1v8O9Ji8aL4nlub641BJJJYllMe2MuCCAVQOwAJAVmYAdK7OigDBvvBvhi/u5bq+8N6Lc3Up3STTWMTu59SxXJqD/AIQHwd/0Kfh//wAFsP8A8TXS0UAeMfEvwd4cstQs/snh/SIEeI5EVlGoJB68L71y9r4a0JsZ0XTD9bWP/CvUvivFm206UD7rupP1A/wrgrQ/NXgY2Uo1pJM+lwEYyoRbRBH4X0AnnQ9K/wDASP8Awq9B4U8O550HST9bOP8Awq3H96tGFeK5lUl3OipTh2Rnx+FPDXfw9o//AIBRf/E1YTwl4YP/ADLujf8AgDF/8TWgFIqRMitVUl3OOVOPYz/+EO8MH/mXdG/8AYv/AImj/hDvDH/Qu6N/4Axf/E1rq/rUytmq55dzPkXYw/8AhDvDH/QuaN/4Axf/ABNH/CHeGP8AoXNG/wDAGL/4mt2inzy7i5Y9jC/4Q7wx/wBC5o3/AIAxf/E0f8Id4Y/6FzRv/AGL/wCJrU1C/tNOgM19cRwR+rnk/QdT+FcRrHxIt49yaTbGUjjzZ+F/BRz+ZFOPPLZmkKDqfDE6P/hDvDP/AELmjf8AgDF/8TUVx4W8JWy5udD0GEeslpCv8xXnM/ibxFq3mCO6uAp6JbptH5qM/rWFeeXFLu1PUbOBsfMJJxJJn/dTcwP1rVU59ZG/1OMfjaR6dcW/w9t8+Zp/h44/uWMb/wAlqk1z8OQSF0fSnx/d0tP/AImvMJdV0RAFN7dTY/542p/m7L/Kmtrmkt/yy1Rx16Rr/U1XJ/eYexwy6/19x6f9r+HI66NpY/7haf8AxNXreH4d3AHl2Hh4Z/v2UafzWvIv7a0fj/R9TQjuPLb+oqe11fQvtELTvqKxK2WX7KhyO44ko5P7zB0sNbR/h/wD2q38MeELkA22i6BMD/zztYW/kKlPg3wyDz4c0b/wBi/+JrmYfG/gK7Co7CEAYBnsWUj8VBroNM1LQb1Qmka/Fz91I73n8FkOfwxWjw0n8M7nmurFfFBr5E3/AAh3hn/oXdG/8AYv/iaP+EO8M/8AQu6N/wCAMX/xNX/K1CMbo7qOZOn7+HH/AI8hH8qct1dJgTWJPq0Mqt+jbTWUsPXiVGrRls1/XqZzeDfDJUgeHdGBIxn7DF/8TTNK8J+Gt43eHtH3jofsUWQf++a1P7UtVbEzSW5/6bxsg/MjH60lvKgvG8l0dT8wKsDwfpToynGVpXOiEIyi1Yi8QW/zbh9ataXJ5ljCc8qNp/CrOooJoc+1ZOlSeTcPAxwrHK/WnXjdXRt8dL0NeiiiuQwCiiigAoIoooAaVpNlPprMBSsFyMrioyaez1A7GpsWmIxAHWqdxKMHFSzMcVQmY5rOR000Z943Ws92zV666Gs5zzUo6iXRif7e0/b1+0R4/wC+hX0AeorwLw3g+JtMH/TzH/6EK98/iFexlq92R4WbfFH0Fooor0zyAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOV+JEPm+HGbH+rlVvp2/rXl1tw1ew+MovO8NaguORHvH4EH+lePW/3zXh5irVb+R9DlUr0muzNKPtWxYJ5hwOyk/lWOnQVt6Kf3//AAB//QTXnxO2s7RZmxa7am6MBdQ4cpjPfOK3vLrw7WpGg8T3p3HCXj/+h5r3UHPPrXW4JJNdTHEU+SzXUiMdOUEVJVbUb2306ylurt/LgjGWOMn2AHcn0qbHMrvQmlljhieWZ1jiQbmdjgKPUmvPvEvxBVC1voO1jjm6kXgf7q/1P5Vz3iTxDfeJbpbeKKSK23Yht4zuLnsW9T+grk7/AFe10p2t7NIL6/Xh5j80MR9FHSQj1Py/71dMKSWsjrjRhSXNU37GjfNNJs1DV73ylc/6+4JJf3RfvN+AxWRceI7S2dl0ayM79PPvBx/wGIHH/fRP0rEnFxfXLXF5NJNM/wB55Dkn/wCt7VYhtQOgrW/YJVZz0WiGX97qeqkfb7yaRB0jztRfogwo/Kq8dgo7Vrx2jHoKtR2LHsaVjPlXUxUslHap1twO1bH2EgdKQ2pHaiw9DK8gelNaEegrV+zn0oNrmnYd0YzQKf4aie0RuwrbNpTDaGlYNGZ2n32qaRL5ulahdWj+sMpUH6jofxr0vwP8TLy9nj0vXUt2vJCEtrsjy1lbskgHAJ7MMDPB9a8/e2I7VUurPep4P4VcJyg7o562HhVR78viwRyPFeafcQup2sEYNg/TirN5qWgC2S61WS1skf7jXmIXb/dzyfwrN8KvF4k0vRtUnw07Fbe9z1MiEBif94Yb/gVeIa/Jc6vrt9fX7F7iSVs5/gUEgIPQAYAHtXZVrKMU0r3PKw+HlObV7WPfbPVtFusJpXie3yeFQXiSD/vl8mrU+nanxKkltKvVXKNHn8RkV8zvpyMOQPyqzp9xqelsG0zUry0I/wCeMzIPyBxXN7WL+KJ6MaVen8M/vVz6bjvboAC406UHu0UiOD+oP6Uk2s2dsha8M1qg6tNCyr+eMV4TY/EfxdYgCS9hvUHa5t1Y/wDfQwf1qzq/xNuNY077JqmjRLznzLWdk/Rg386ylSotaXQoqrzJTSt5Ht9trOmXOPI1Gzkz2Ey5/LNX0IcZQhh6ryK+aodV0eZRvmvLVvSSASKPxVs/pWhaXEYYHTtatN/otw0DH/vvbWPsezOz2NJ/DM+haK8Vh1XxRaR747u/aIfxK3nL+fIq9ZfEPV4MLdR2116hl2N+n+FS6Mh/VJbxaZ6y7cVCxzXF2HxEsZ223ttLbHpvQ+Yv9D+ldRpuoWepx+ZYXMU6jrsbkfUdRWTi47mUqU4fEiyRSGPiplWpNoxUkXsZsy8VyniDVDZahHACBuTcfzrs50GK8w8fQ3EuvM1vFI6QQIXZRkKCSeadOKlKzOzDtN6nSuN+mW9x/wA9R/Ss6Stl4wng/Qn53PHk/wDfKf41jSVhsbRlzalnwupbxTpYH/Pyn8696U5J9uK8M8Gpv8W6YPSYH8ua9zTq31r2Mt+B+p4mbfHH0HUUUV6R5AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFTVoxLpt3GRnfC6/+OmvDrU/vRmveZVDLg9DwfxrwlozBfSRtwUcqfwNeRma1i/U9vKJaSXoaKdK2dA+a9RT0ZWH/jprFTpWxoH/ACEIPqf5GvLhuj06/wAD9Dz4QRt4p8RhgGbzMfMOdpyT/SvULVt1tC3qin9K8V8bgp4r1TG4EyDOepygr2XSm3aXZt6wRn/x0V1W/dwfkvyMsTCyUr7llmVVLOwVVGSTwAPWvGvFfiG48SaosNozi0V9lvCBkyHpuI9T/L8a6j4o66ILVdIgk2yTDfOR1Cdl/E/oPevLtavV0rT/ACoT/wATG8jwGHBihPVvZnHA9Fye4ralC3vMdGKpx9rL5FbxBqi2gk0vSJBvYFLy5jOQ/rEh/ujoSPvH2649pahFHHNMsoMAHFbNpbliOK13Iu5PmkNtrQyEYFb+naMXwWFXNKs1GCRW8rxwp2FWokSn2KMOkRqBkCpGsYkHQUy61RUzg1jXWrk5+anoQlJmnPFCo7Vm3BjXpisybUmbvVGa7Zj1qbmiizUeZAe1MNwvtWP5xPc0CQnvSuVymr54zS+aprLDn1p6uaLjsaDFW9KaUQ+lVQxxSGYigVj0L4T3bRajeacWxDLsnUejg7Sfyx+VcTq5W61W9nVAglmdwo7ZYmtz4cSsfEbMv3lt2YfUMtZHilUtPEeowxf6tZmKj0B5x+GcVrJ3po5qcVGvLzsZTxUzyc9qcZs0olrE6xhgz2pjWoPVasCUU4SrQIpNZr/dqvJYoe1apkWopGBoCyZlRW0ls++2lkhf+9GxU/pV7+29aVNkt41ynpcosv6sCf1pXxUZoFyLdF63120lATULAwE8edZsfzMbHn8GFati25TeaHefaRF1ktyyyRf76cMv16e9c9bWv2u5SJR1PJ9BV3xDpj6fdQarZl4vmCs8R2tG3ZgR61pBcz5WV7apTV90ejeHPiDPbskOtL9ohbjz0A3p9R3H6/WvTILiG5t0ntpUlhcZV0OQRXz7b36apiPUPLi1En5bgAIk59Hxwrf7XQ98Hmt7wj4gn8P6kYLtnFjIxWaNgcxt03Y7Ed6yr4aUOlhuEK8eelv2PXLhq4nXb2K31DVDJKqukSMEJwWGwjA9ef512LsHjV1YMrDKsDkEHvXk/j458ST5/wCeS/8AoNctJXnYKNNT91noepL5Xhbw8nf7OT/46g/pXPuK6LxBhdJ0NBjAte31/wDrVzz9K5n09F+RrR+H5v8AM2vh+m7xhZcZxvP/AI6a9oj6H615H8M49/ipGx9yF2/kP6166BXtZcv3bfmeHmr/AHyXl/mLRRRXoHmBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAB5rxTxJH5PiW/XGP37Efic17XXkXj6LyvFNyR/EFb9BXm5kv3afmerlMrVWvIpx8rWxoPGo23++BWNB9ytjRf+P62/66L/ADrx4fEj2a3ws808V6dJqPjfUYImCEBXJcYA+RQPzJAr03R5kg8OWc9wdiRWqO5PYBef5V57r99Dp/jzUpLjeYnjjBKjJB2qa0/GGqPF4E063iyJb6NQQOoQAFv6CummnKnBeS/ImrGVRxj00/4JxF9e/wBrave6nqC7bc7p5Dj7kaj7o98YUe5rgpbibU9RnvLk5lmcscdB6AewGAPpW/4nuWttFhtgSJr5t7g9RDGcKPxfJ/4AKxrOPYgOK632JrPmnyrZFy2QcCtywQDFZNuOa2LY7VBpoiRsR3HlLxVa7viR1qlLPgcGs+ecnvTuSokl1dFs81nySkmklfNQnmpNEhSxNJRRQMBUi0xRzUyigGAFPAoUVKBxQSC9KY4p+MU1ulAHV/DJQmp31w33Y4AD+eT/AOg1x9/cveXs9zIcvNI0h/E5rvPhtbebaX2BgzuYQf8AgH/168+ZCjFGGGU4I9xWktIowpNOrN+ggBpcU4LS4rI6RnNGTUgWlKe1AEWTQTTytHl924FAEYBY8UEMziKEFpG4AFPhjmvLhbaxjaSRvQdPrXqHgrwKIEW4vQGkIyW/oKpIlswfDXh8xpmQfMeXb+grrRolrf2E9lOPkmQoT6eh/A1t3lqkCbIlCqOmKpWrbJaNmbqKcbHk6acrCW0l4urdjE4Pcg4q1HIb6Bo7rP2+2TIc9Z4h1z/tKO/dR7czfExH0jxdFfRZWG+jDNjpuXg/0pkjP5MGp2ZAnjYN6jPofY9D9a9vlVekrnlRnLD1brod38OtXa50+XTp2Be2G+I55MZPT8D/ADqh4z0uCd768LSfaEjDDB+UAAcY9+awtLuU0rxJaXludtlKFdRnpE/BX8DkfVa0fGV9cxazeWUbDyZQmeOfujOD74r56VNwqnr8rclKm9Hqd14o+WHSVznFoPw+Y1zz9K3/ABccXVmg/gtUH6tWCelef0XovyJo/Adh8KUB1y7c9Vt8D8WH+Fep15r8Jo832oSekaL+ZP8AhXpVe9gFaij5/M3fEP5BRRRXacAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXAeN/EN1pHxK8BWQvltdLv8A7f8AbFcqEk2QqUyx6YY9iOtAHf0V5Vqnjq50jV/GV5bw/a9P0u603zi1wzqLeaJS7xr0XG4Hjg8k1Sv/AIq6u1ho0mm6TbGTWZrxrJpS5VreFgEJUYJd8564A55oA9iorzjw54313XvElnpkGk2Fuv8AZ8F9eGe5bfFvdldU2qQxBXjJHvXb6zf3NhFG1ppF9qbMcFLR4VKe582RBj6E0AaFeX/EyLbr0Un9+EfzIrq/+Ej1T/oS/EH/AH+sP/kmuD+I2r6hNe2csvhfWbf92VAlltDnBzxtnPrXFj481E78tly118ypbn5K2NI5vbcesi/zrjrfVr3YMeH9UP0ktv8A49WxpOs34vbcjw1q7EODgSWvPPvPXiRg7r/NHuVai5X/AJM4X4hk/wDCX6jk8/IP/HBSeLLtrm40m0jP/HtZRIoH99wD/UCovELz6n4x1IS6PqcYABMYe33rwoGf3u3GfQmsefVZYtRnvJNMvAbNPMOWiwuxQq5+fpu29P1rvoQ/dw8kvyNfbRST7LsznPEciT+JLiOE7obbbbKc9dgwT+Lbj+NPQYAFY+nPL9428zseSQU5P4tWktxLn/jzuD/wJP8A4qtLM46ctLv8madsuTWlnZHWTaXEwI/0C5P/AAKP/wCLrRuGwKdrFc1yCeWqLuSafK2c1EBk1JaQnWgLUgWlxSuMj20u2pMUUXAaoqRabT1oQhwqRelRipB0piCmSdKeajk6UwPRfByvZ+CLm6QYkCTTqfQjOD+grzUAk5JyTyTXqunSRad8PfOuSFiezKY7lnUgAfUmvLo1wBWlXRJHNhXdzl5iBKesdSBafisDrIwmKQrUhqKWURj3oAa5SJST96reiaDfa/OohVkt84MhHH4etbnhDwZc63Mk94GWEnKx92HqfQV7Xpei2+l26pGi5AxwMAfStYw6mM6iWhzPhPwjbaRCAYxnqSeSx9Sa6wAAYAwKkamGqtYV7mPqqcE1z4JWaul1LlTXOTACWs3uddLY5/4saf8AbfCCXSjMlnKHz/stwf6VxPg6f7RZy20hzlSBn2r1vVbYX3hrUrYjPmW7gfUDI/lXhHh64Ns7vnpXrYCV6bj2POxkbTv3OlJLaSse0lraZo8/7LjcB+at+db2qWc189rqhkQq6QKyc5/hUn061z2lzm5h1SIAgmJJ1+qOB/J2rd07UgbSy09o38wyRqGzwB5gJ49a4MfHlqNo7sLOTpR5ejt8j0LxiSdXUHtBGP0zWC3St7xhzrLe0UY/8cFYLDivCNaPwI9E+Eqf6NqT+rov5A/416BnmuJ+FEeNDupP79wR+Siu1HU19Dg1ajE+bx7viJC0UUV1HGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVm6zoGj655P9taTp+o+Tnyvtdsk2zOM7dwOM4GcegrSooAzYdB0eC3uYIdK0+OC5iWGeNLZAssapsVGAGGUL8oB4A46UXegaPe6bDp15pOn3GnwgCK2ltkeKMAYAVCMDA6YFaVFAFGy0jTbCUS2On2dtKIlgDwwqhEanITIH3QScDpzV6iigArhviin7jT5PR3X9B/hXc1x/wATUzo1u+PuzgfmDXLjVehI68A7YiJwVr901uaGM39v/vCsW1GErc0Mf6ZDn1P8jXz0fiR9FW+Fnmes3osvHWoysrPGziMqCMkkLg/mK4vxJdBNAvip/e3lykR91BZ2/wDQUrpfFxC+MNQYscicHnr92uM8XECy0eILhnMsxA9MqgP5o1ejRVqUfRFV7Knfq7GfYrthFW46gtxiMCrMYrQxWiNG1OBTbhs5p0PC1FPzTJ6lVuaAKcRzT1WpbLGAU7bUgWnBam4yLbSFamwKMCgRCEp6rT8UtNCGYp4pKKpCF7VDP90/Sps8VER5kioBncQv5nFAbaneeOBJD4Q0K3wQmRv+ojGP5muIRa9S+J4VfC2nquObkfojV5rbxNK4VBkmtK6tOxzYKV6SfqMVc8Yq0lmxjMjnYgHU1rQQ2WnRiS8Ikl6iMdPxrGvLu41O5KW6ZHYDgKKysdN77FKaQK22PLMeAPWu38BeCZdSuFub5MgEEK3Rfr71Z8F+DSZ0muBubu57ewr2nSLKOztFSJQqj0rWnC7Mq9T2a8yGx06DT7cRwIAcct3NLP0q3J1qlcmtnojkg23qVG600041G5wDWbOpGXqLcGufm5kra1Bsg1iEZkNZM7aexq2K74ZFPQqR+lfPGgqv290ccB8V9F6f8sLsegUn9K+btMkxqMje5P616WX/AGvkcGN3R2VpB5WrmHtLBNH+cbEfqBUmiDdq+lA9fOQHHP8Ay0FVdMvVl1/Ti7jJnRD9Ccf1rq9OsYkXw80cahxcQgsBy2SSQT35FY5o+VX8ma4GpyxcWdn4sG7WZs8EKg/8cFYE3C10fibB1m6x/eA/8dFc7cjg189Lc66P8OPoj1T4XLt8LKf707n+Q/pXWjqa5/wBB5HhKwBHLqZD+LE/yroa+kw6tSivI+WxTvWm/NhRRXBz/EaBvFl7oWmaXcX01jIkVyVuIY3BYZykbsGkAHUgfTNbGB3lFcZo/wAS/DOp2er3S3ptoNMuWtZmuFxuIbarKBnIY/dHU+gq5P498LwaVBqU2tWqWc7vFG7ZBLr95NuMhh/dIzQB09Fcvpvj/wAK6mbkWGt2lwbe1N7LsJO2EDJbp27jqOhANPt/HfhmfTb6/TV4FtrJlW4MoaNoi33QVYBst2457UAdLRXn9/8AFfw3ZavaW890qafcW0s5vW3LsaNgpjMZXdnnP0Fd1Y3cF/ZwXdnMk9tOiyRSocq6kZBB9CKAJqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArlviQufDefSZD/Mf1rqa5r4hjPhmb2kQ/wDj1YYn+DL0OjCfx4eqPO7Y5iX2rd0Pi7jPpuP/AI6awbMfJiuh0MHz8r1COf8Ax0183Hc+kr/CzzowRTeLtfaSMOwkEZ3DICkc/wAq8t8XndrVrD1EFnEv4sDIf/Q67DxNPIviXV/Id4y88ifKcZHTBri/EDiXxbqZH3UmMS/RPkH/AKDXo0laC9F+Qq8WrXe9vwQ2MYUVPGOaiFTR1oSXUOFqOTk0BsCm5zQ2JCAc1Iq0ijmpBUMoMUhpetWIbGaVS4Xag/iNCC9itRUkixxkhnGfaoHngX+KnYLjgMninBG/un8qW3voozkR7se1X11+RQBHZof+AU0iWyktvM33Y2P4VKunXTf8smA9+KuDXdVkXEFrtB9EqMx6/fNgRvz+FVYV2yhd2726/OVz6A0/w5F9q8R6bARndcJkewOT/KtWHwTrM/zXJKKfQZNb+i+HE0aUTR70uMY82Tlh64PQUrqLuxTjKUWkdX8SNKebwXd3iMBDZzRy4PqTtIH/AH1mvIbSaYtttYZHY9wK9Zm1C+m0k6fNOJLVmDMCBlsdMmqFnpkaNu3Lyc7VXNVWqqcrxRhhaU6UOSXc4m10G+vnDXIZR/dH+Ndh4f8AD0YkRduI4zkgDgn+tdBFYyTAKgMadz3P+FdBpmnrEqoi8VEIyb1Om/IryLOkWgUqAMAV0YG2MCo7K1WJATUs52rXbCPKjzK1X2kipJ1NZ9w3NW5nwDWfI2TUSZrSiMqC4bCVMTgVnX0uAeaybOuCuzKvpeTWJdaTp+pSo2oWFpdMowpnhVyo9BkVcupCzmpbJNzioudfKramfqnhzw7YeHdQu30LScxW7sCbOPrjjt64rw7QNNtri+RXtoWB4wUBFex/GDUxY+F4tPjbE17IAR32Lyf1xXlmhPHby+YzYIr1sFH3G2eTieXnskX9R0fTbXVLcJZWpQSoWBiXBG4ZB4rc0fR9Nm8UWlg+l6e1ut6Vx9ljyw3Hhjjkcd6wp7gXOoWyg7jJMi/mwrsdFw/xCTaAV+3SEZ6Y3P1rnzV8tO67M3wMIvmujqdf8K+Ho9UuVi0HSURWwFWzjAHA9qwbjw5ogBxo2mj6Wqf4V2viE51a8/66EVz843Hb6nFfPynLmep20qcORaLY9P0XwF4SOj2Jl8LaE8hgQsz6fCSTtGSTtq7/AMID4O/6FPw//wCC2H/4muht0EcEcY6KoX8hUgPNfTRVkkfJyd22Zmk6DpOiRyroml2GnLKQZBaW6QhyOmdoGcZNcR4p+GB8Ta8t7qWp2ogW4SdDHpqLeIEIIjW5DA7eO6k+9elUUyTziX4aTNDqsKa5sSfWhr1l/ogJtrnfvO/58SJnjGF+pqXS/hubPUNLv5dWM95b6rcavdN9n2rPLNHsIVd37tQMd26e9ehUUAeWad8JpLHS9PtIPEU8UtnpFxpa3EFv5b5lk3+YDvOMdMd/UVBp3weNrFqLvrcf224uLG7glgsdiQzW2/azI0jbw2/kEj6161RQBwn/AAg+oXetDVdY1yK7u/7OudPby7ERLiUqQQN5+6Fxgkk56jpXSeENG/4R3wvpWj+f9o+w26W/nbNm/aMZ25OPpk1r0UAFFFFABRRRQAUUUUAeIfFjVDYeOLl/Egnk0aHSxLplqb6Wzt7m43/vA0iA/vQv3VPt0zmsXxZ8TtX0PSNKfRZ5bExaTbXhstR2ymXexyolceZKQMA4C4wSSScD6JooA8BvJ5f+EnlAlfH/AAsG2TG4/d+zHj6e1b3xf1ZtH8feHbj+249GVdNviLmSMSDcPLwAp4JJ46H25r2CigDwGHxbq1peax4g1SO4tNRHhaynljhh3mN2mYFhGxAHXJz90ZznFJp/xL8Qy6LcLc6rYpFHrUFlJrSxLKlvbyRl95wAh5AUNjbz9DXv9FAHzjoHivUNP0K0tF1qOx07UNT1QzarLAH8xkbMcag8KXyT+GBVPSfHniXRvC/hyysbuz0+3XSoriCa+A2Xkhdt6l29AANq/NznnivpqigZwXgbWtd17xP4hNze2qaVpt61qlqtt+8bMaMCZNw4BY8befWus1nULmwjia00i+1QuSCto8ClPc+bIg/LNaNFAjmv+Ej1T/oS/EH/AH+sP/kmuf8AHXiK9k8PTRz+F9ctiXQhpDbMPveqTNXotc38Qh/xTM3++n/oVY4j+FL0N8L/ABoeqPJbLWJ9o/4keqn6LF/8XW7peu3CNJjw/rDfu2HCw+mP+elLpQygroNN+Vbg4/5ZY/MgV865KzdujPoK17bngFxfvceKZHOnXmHvCxTCZx5nT72M8Vw0V4Zry4naKYmWRpDhc9ST/WvQYJc6xNOc7V86b8g7f0rgNLHy/hXpqySVi8Qpc8Vcsi6/6YT/APfFTJd/9O9x/wB8U8VMh4ouuxDUu5Ab3HWC4A/655py3yf88bj/AL8t/hUxNANF12C0u4wXyf8APG5/78t/hTxfKTxDdf8Aflv8KkTJGTwKa9wc+XCCzn0qdH0C0u5at9ZsbJd8kNw83YNbvgfpVa41u61B8Kl2UPZLaQj9FqOSBl+aXJI610Oga1aWKHzYgWxWFSsovlSPAzDM6lGo6MFquv8AkYkdrui8xxKvOMSRsh/JgDVUxhptqdO9amuauL+f9wuAewrf+H3hVtXvhJchltIjukbH3j/dFYQUqk7XPLw8a2MqqMpNrrrsjs/h74BiutMgvNWGI3G5U7ke9d4vh/w/aJtisoifUjNVtWvLiLTRDpU1vbTLgK00JlUAdtodT+tc0o8UTHI1XSf/AAWyf/H69ZcsVZH1apVH3SR0c9pYxA+XbxKPZRRZxR8kIo9MCuXuIvEq/f1TSf8AwWyf/H6s2ieI9uBq2jj66ZIf/bio0b3OhqSjs/w/zOoaMMKha1DdgayVt/ErdNX0b/wVS/8AyRUyWvifP/IX0X/wVS//ACTVcqfUy9pKPQtHToyf9Wv5VNFYY6LVZbTxMf8AmMaJ/wCCmX/5JqzFaeJ/+g1oX46RL/8AJNUqa7kSxUl0L9vYHI4rYtLQR4JFYKweKF6a3oP/AIJ5f/kqkceK8ca3oX/gnl/+Sq0jGMTkqVZ1Oh1MrgCqFzNXNyJ4qPXWtE/8FEv/AMk1Uli8UHrrGi/+CqX/AOSaJSCnTfY3ppMk1XY1gtb+Jv8AoL6N/wCCqX/5IqKSLxKBzq+jf+CuX/5IrJ+p2RT2SNyeQKp5rC1CfJIBrOvG8Qgc6rpB+mmyD/24rGmTXnY51LTD9NPk/wDj1Zu3c6qaa+z+X+ZqgbnzWxpsGOTXM2dlr7sMajpY+unyH/2vVbxbfa/pttFYR6lpklzegrtisJEZE6Fs+cfp0pJeZc5va35f5mdremw+MdeurmWV0s4P3MDp1OOuPqc02P4e6aifNLeOfXcB/StPRdC1uysYgmoaagA+61g7Y/8AIwrTh/tx3MQ1TSAf+wbJ/wDJFae0ktFIj2cd3C/3f5nKW3gFV1iwlsLxyEuI2eOYDO0MCcEUvgwmbxnZuMkvM7c854Y10slpr8N3HIup6Vnk5GnSY4Gf+e9cX4Eg1aXxPZC1vbCObDMrSWjso+Q9hKM9fWssTOU6MuZ9GXCKpqTjHdeXn5np+uPu1S7PX96386z7CLz9Ws4gM75kX/x4VT1WDXzfXJfU9LLGRskadIBnPp59J4dttffxHp6xalpayecCrNp0jAH3HnjP5ivPjBOaV+vmTzuNK9tl5f5n0HSDqa5v7F4w/wCg74f/APBLN/8AJdILPxhz/wAT3w//AOCWb/5Lr6U+UOklkSJC8rqiDqzHAFEUiSoHidXQ9GU5Brz3466dqOpfB7WbK0t5b/UXW3Hl2kDM0jCeMsVQbjjgnGTgd+9cReWGuWg8Y6r8P9H1PR9Le3tBb2aWhtnmnWZTK8UBAI/dBlPA3Z4zQB73SMwVSzEAAZJPavFtT1jxfqd3r9zZ2niOz0VtS0/Ef2Ro7lLMxHzzCuMlt4XO3LAE9+KqzTeMZNO0iPVB4mGiPc34DWsDG9eIf8eouAo3KCN2eB23UAe32tzBd28dxaTRzwSDckkThlYeoI4NS183w2/jnT/DfhiytxrmmWUWkKIzaWcsjR3XmNuEsaKW+7twGG3BPeui1YeNpbvWNThuvECS2epWItLSKEiGWJ1j847NpLKCWzyQMH3oA9uorxvTdZ8X/wBu6dplzZa+Gi8RT/ablrU/Z3siHMY8wDBX7vPbHJrBs7Tx5dadYy3OpeLIprvTtSkuI1j2+VLFI32dR+7ypYAf7TDgHHFAH0FRWR4Omvrjwjoc2rrIupSWMD3SypscSmNS4ZeMHdnI7Vr0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXNfEM48NSe8qD9a6WuV+JDAeH1Unlp0x+RrDFaUZeh0YRXrw9TjdIH7utqA7LK7frhB/PP9KyNLXEQ+lad2/keHtSm7qmR+Csa+bavF+h9BVevzR4ErlLXUpB1FnN+qFf/Zq5HT02qTXdaXCJrTUlcZVoRER/vSIP5Ka5250i809jiIyRdmH9a9Zo2rxbnzFSlXPanb3Xg27Z/wB01NbpdTA/Z7VzjvjgUWM7jEjdu1DMkZwTlvQVuaZ4V1TUuZMRp6A812OkeC7XT0ElwQX/ADP50rDUZM4fSdA1LWJFWKJo4z3PBNd5ovgSCz4vU+fjIBzn8a6rSLf7KP8AR1CL/dHQ/WtOTEigEHjk+q/4irSTWgP3Ja6o5TVPAtlfW2bQtbzDo33gfqK4e78D6lFMV8mGQZ+8smP0NeyKz24G7lD0YdKy7sfaJyF6d6ynTjL4kYVcFQxUuarG/n/wx5RouhxLrE1tqpEAh7Kfv8/3q9c0m5tbezjt7RUSFRwFqCbS5JofniV09GGRWNLpRtpC9g/kSf3Cco3+FVGKholY2pYajSjy0kkjorhhJKAOQa5fxNqN3PqTaZp0728cKgyuhwzMe2fQVd0zUg935FyDFcKcMjf0rHjt5rjxHqbwJvYzsOD2pTfKrl1PdRpeFtQuJnm03UpWluEHmQyMeWXuPcituKRon2muV1HTbuGSO6tnVLmIhkI9fSui0y+g1i3LJiO7jGJoT1U+3qPelCXMgpzTVmbEF1z1rQinBFc22+M1PDdY6nFaKVhTpJnSCT3p4k96wo73HerCXoPerUzB0Ga/mn1ppm96zfta+tMa7HrRziVFmg0vvULSD1rPkuwO9VJr0etS5GsaJpS3AXvWXeXvUA1RnvM5wapNIXNTc2jTSJJZmkbrT7eAuRxTrW2Z2BxxVvUb+y0S0E19Jgtwka8vIfQD+tBTdiLVdQg0HS3u7gbiPljjHV27AVh+EdKudSvpNY1f57mU5VT0QdgPaorOxu9e1Manq67UXiC3HKxr/j6mutglFvgJwB2o8iUnv1LV5GEjIHGBXE6pcvZapZzqSEdjG4/ka7G7m3xlj3rhfGLBLSAH75mXFBcdFqdLc3G+NnB6QSt+SNXI/DRc+LLXjO2Nz/46K2oWP9mXTN/DaTdf+ubVlfC5S3i2EZH+qf8A9lrHEfwZejG9Iy9DrtT5vJye8jfzp/hEbvFenD0lz+hpNTP+lTf9dG/man8DjPi+xB7Fz/44a5aWtVev6mFV2oSfk/yPYqQUopBwea+kPkxaKKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAIOpriPidL8mmwA/ed3I+gA/rXbjvXnPxDm83xBbQD/llCM/Vj/gBXHjpctF+Z3ZdHmrp9inYLhAPajxXJ5HgvUG/vI4H5Af1qW0X5azfiNL5Pg5k4G8qPc5f/AOxrwkr2XmvzR7W9SK8zy/RlJs5iOr3ES/kJG/wrtLG1ga3CzgHPqK5LQ45HsrdYgNzXEh56DCIP/ZjXX22lXLKGkuceyrXpyO17tlLUNCtjCzRxDnPIFcjE0mj6g0qoZICcSR46j1HuK9hgtI206NAMkLj8e9cfr2jrLI3l/KV64HWrasjnhPmk0Lp18jxJNbOJIXGQVrSN35rID0HNcBc2d7pLm402TaScyREfK/4evvW/oGsw6xA2xDFdwgebGe3uPaosb37nf6WyDbu6VevYVCCSI4IrmrG7AABODV6W9Ij5fiqUtLGE6bcrpmraMk6bWAHOCO1Urqy+zTM0anaTnHXFV9LedpmdDhTxtI61tvdHH+kRZ7ZFXdSWpi1KnP3digt8UiKnGKxbucTSkRrk+tdOEtbhDtVXI6qetZkunpCS0OCh5x3WplF2NKVSN7Wszm9Q0s37xPueKaPpJGOcehqbTtKaxkklBkklkOWZ/WulsGiRxvArUke2ZOAtLkUlqKrUs7ONzjdgVmLhvm4IPSsS/wBPnivFvLBzHOn3WUdfY+ors71I2c4AxWXOhEoSLv8ApWfIlsaKEZK60Kuma7FeMbfU4vsl2O5/1b/Q9voa0ZbUjlentTJNIjvIGjm5Vhzmsg6Xq+jn/iVXfmW45+zzjcv4dx+FWlpqC00uXpA6HoaiNyy1WPiZIMJq+nT27d3iHmJ/jU8Gr6FecRahbhj/AAudh/XFFi+ZdQN8wpjX7+9XltLaUZimif8A3XBp39lA9KVh3RlNduxpu+R+ma2TpsUYzI6KP9o4qvcX+jaeM3F9bqf7qvuP5CnYXOkU4rSSQ81pW+nqg3PgAckntWNP4qEmV0bTZ7k9pZRsT/E1WXSNY11h/bN2y25OfIi+VfyHX8adu5PM3sWtU8Uw28htdDhF/d9C4/1UZ9z3+grOsNKmnvvt2sym4vH9ei+wHYV1VholtpsAS3iVR64qpegLKccEcilcqKRu2kUKW4PGcVl6icFscZFT2ku6Ec1QvZFZ3y2FUEk0hxjZkYu91sm49uTXCatevquqoYVLW0DYUj+I+tTarqzX0o0/TWJhHEsy/wAXsPb3rrfDWjQw2oZ0HA6U0gbWyKUcudKvgQQfscv/AKAao/CzP/CXR/eyIpOn1WtfV40SHUNgx/osvA/3DWT8K93/AAl8ZHJET/zWsa/8GQT+CXodZqoxdS/77fzqz4I/5G+xx/t/+gGq+rg/aJD6uf51P4Lbb4tsD6sw/wDHTXLS/ix9V+ZhV/gS9H+R7FQaKD0r6U+UCigUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFct4a8b6XrfgW38VsJbLTZQ5xMuXXbIY+i5ySw4Az1FdTXlOifC/XNL8EyeFl8Zf8AEtWMrAYNO8qRGMwkJZhLllPzqV4yG68cgHXDx/4V/s0ag+t2kVmZ2tjJKTHtlC7ijBgCpxzg4p0nj3wxHfxWbazbfaJREVUbiP3uPLBIGAWBBAJzzXKaD8KP7KuLSZtXhcwayNXKRWXlIf3Xl+Wo8w4HfPP071jeJfBHiO58b3MWkQOuhXmsWmqXE03k7Q0YQuVYSeZ2I2mPqPvYoA9MtPGHh+815tFttUt5NTDOnkrn5mQZdQ2MFlHUAkjvW9Xm3h/4XR6J4oj1K31CGWziu5buKGa03TRtJuyqy78Yyx/gzjjNek0AFFFFABQeBRSP0oAAeK8m1ub7Z4rvnzkLJsH0Xj+leryOIoGkPRVLH8BXjOmOZruWZursWP4nNeZmUvdjE9bK46zmdDbrhRXL/FyfZodjBk5eQYH0Vjj82rq4ulcJ8ZZdt5p9sM/KrMQfX5V/oa82CvKK8/0Z6VLWsjL8MxAW9jnGD5jfm+P/AGSvRI44hbAgjOK88srhbWz06MKWlFsrbV6/MS3/ALNWvb3+oMoAtiE92r0L6nVKDlqjr9P3bXxyM8Vn3MCvJLu67q3NIhVLNCDuyBz6k1ga00qXs32fDLnnPrWklaKOWm+apJI5vXLZY0YivPtHa9t9anv7EBjC2HjPR1PUV3Gs3T4IlXGao+BdCF+Li7uSRamZtqj+Mjj8qzR0yVkrnQafcWupx+ZYyjeBlom4dD7j+tTTK8e3fn1rQu/DVldRqYojbSqPkliO1l/GubvZdX0KdV1djf6YePtCp+8i9zjqKHEUaqbOs026VUBQ1cubwtGa5eCQbFltpFkhcZV1OQRVlrl2jIPpST6DdNN3NTTwZZd4JDt39K2HVgv75d2P4h1rnNMuhwAcMK2vt7mPaQDVRdjKrByehMtvDcfcYE/kajewcHCuR9eay5bh4pgyMVOe1aFqZ5utxJj0zVcyfQh05w1T0HHTJ26SKaUaKy5kMuX9CvFPmimiG4Sk/Wqv9reR8rxBmPcGi0VuK9Vr3WTCznBwGj/76xQbO4bg7D/wKli1R26Rrz71dgluJVzlEHsKEovYUpVI6uxntozyj5whB7YJ/pWfc+CdPuubiDJP91MfzrduTcqCfOP5VnPdXC5/etmh8seg4urNaNGI3wx0h23IsyH2eon8E6Pany/tV0zD+FJD/jWrc6rdsojaTCZwcDBNTW5UbTQ5LoVGlNazZg/8INpknPkyN/10ctVm28OafYn93bID9K6kXESqKo3c4lbgYFJjg23sY96iQqhjULg54rSt5AFVqydUlBO0dqsw3KLCMnkVB0NXRoTS7hWDffPccValvNwworL1W+j02wnvpwWCDCIOrseiigEuUsJKyxgDjjk1xXirVhqEg0zT5NyE/wCkSKeD/sg/zqwx1vW7fN0BbWx58iEYyPc9TWTYaY1l4ia3K4SQCRR6VSREp32Ol0DR/JtozEg9eRW8bm5txhk+Uf3a1NOt9sSoo6Cn3NuCpBHNJji1sc1qMwmtL8jGfskv/oJrN+Ff/I4RYz/q5Me3K1e1CLbHqAH/AD6Tf+gmsHwDqcGneK7eS4ju5B5bgC3tZZz1HaNWNZVk3SkkOo0oSv2PQNZ/4+Zf98/zqPw03l+JdNbOB5yj8+KzNW8RWTzyEQaqPmPXSrod/eOqNr4ks4L21m8nU/3cqsf+Jbc9iP8ApnXJGMlNO3U5+eMqbjdbH0VRXNDxrpZHFr4gx/2AL/8A+M0f8Jppf/Pr4g/8EF//APGa+lPlTpRRWc+s2cegzaxKZobGGF53NxA8LqiAkko4Vh0PUCvFdH+Letal4K8YT3D6fBrFjZx6jYm2w6+TIBgMCTlkJAbPdqAPe6K8zf4omyW7s9Q0S5TWopLOG3tVmRhdNc5EfzjhOVOc9O2apeHfiNqzS31lfaabzW59eutPsrFJUjWOOGFJGDS4wdoJ5xk5oA9Zory27+L0H9k2V7pmhXl75+nXGpSIZo4vJSBykoYk84IbpnOBxUWpfFJpvD+uzrp99pU9jHY3MTlopXkguZVVGxyoJBOQc4B9aAPV6K85f4nbdc+yHQbo6eut/wBgvfefHtW4ONuEzuIO4ZPb36Vn3fxXEt7qemW9h5UwtL6SzvYp1njZ7dCxzgbewOAWx0OKAPVqKxPA9/car4L0DUb1g91d6fb3EzAAAu8asxwOByTW3QAUUUUAFFFFAEGoNssLlgAcRMcH6GvCNG8WeJJtA0q00W+s9MSPwrLrLYsxKC8cu3YoLfKCO/Pfj09+rhJPiPZxeGpdcksLlrOa/On6YkJDy6g+4oCi8BQzK2MnoM+gIB55YeM/Eqa1qepjUPPurnw3aanZaO0TGOaRoGZ/KXd/C2SdvLdKba/EjxM3hjVLhNa0Wd0ktfLuHKI8Qfd5iNgeWrfL8u/GOQcnFeqQ+NIbPTDdeK7C48PSed5CQ3LLM0x27gY/KLbuM5x0waSLx3pc3iKOxilhfT30d9Y/tETDyhGsgQj9c5zxjFAHmei+LNa1LxV4DvbzXruzsL9bmBkubZY47mRZVAXCNscsCFVh6Egc4qHwt4p8RXXhrw3ZaLe2elCbQ7zUXZbMSjfFMQAoLcA/j34r1eLx/wCFpdNn1BdatVtIJEileTKbGflMhgCA3Y4warX/AI/0seFrjxDorLq2m2c4jvWhYq8CAgO20jJKghtpxkcg+oM8rv8A4peK2/suVZtO00SabaXkQuUCxX7uMygMcng/KFT5snvXvOqyX8doW0m2tbm6yMR3Nw0CY7ncqOc/8Bq1G6yIrowZGAII6EetOoEc19s8Y/8AQC8P/wDg6m/+RKa954w6f2F4f/8AB1N/8iV09Nb7woGcT4l1XxbaaFeSS6LoSIYym5NYmYjdxwDajPX1rzfR5tf6ppmlH66jIP8A2ga9P+J9yI9Ehgz800w/JRk/0rjdIG2MV42PqJ1VG2x7mX02qDle12PtrjxM7qq6RoxLEDnVJf8A5Hrzv4n32sT+Jf8AS7HT4pI4wdsN68gAJY9TEvP4V7Lpf/H1CcZwwbH05rxzx6/2jxhedDyqcdM7V/xrCi05rTv+n+Z14eDdV69PL/I0NIh1n7YAumaWzpHHH82oSD7qAf8APE+ldjYw33ludStLO3YY2C3uWm3eud0aY/WsC2vli1G5YZJaVtoAyeprYF9cyEZgkC+pxXY2ux0ckrp3Op04kWkWOg/oTWOkfmsc9Scmty1UxwQj0QZ/GsA3KwSMG4Kkg1U9kc9F3lJo5jxhAIbeVsdFJrV8BxKnhfSwo++m4/UkmsrxdcC4s5iD/Cau/DmfzfCFiQeYi8f5MamJtUvZHbz7Y4xisDUN924towvzDLlhnA+lak83mR/hWfow8y4uHPJ3Y/CqerMKa5U2zBuvCM1q5l0O8a1ZuWiYbo2P07fhVG5vL/TTjVNMkZB1mtvmH/fJ5r0pIB95zxUgt4peMinyXEsRynlunavYX9yYrCc+eBu8p0Ktjv1rZju5F4fNbXiTwRbanGssQ8i6Q7kmi4ZTXNSwa7pn7u+sF1CNek0LBHP1B4qJQaN6eIhMtTzhuR1FXLO/wAQ2K5+fWDAuW0TUM+h2/wCNZ6+If3x+2aVd2dsRxN/rAD7gDgUrM1vFo79r1pE5bIrKvDltwPQ5rNtZxcRCS0mSaM/xIc//AKqnUv3BzSuOMUti9b3IUgE1rW+oYXg1zchjggaW5dIYV6s7BQPxNQ2d9Z3QzZahbTA9llGfy60J22FKMZbnVy325cZrPmuF9cmqAjlYckY+tV7q5tbRSbu7hiH+04z+XWhu4owjHYnlbfuxViO52oAa5jUfEMhgMfh+wnvp2H+tZCsa/wBT+lSWmvySIF1XSL21l7tGm9P8RRZj5lsdKb5aikvCwwtZYvbCQEqbkn08h8/ypd9/cAppGmybj/y2uvkUf8B6miwNxRZ8l5ZBlSe5qWSEqPmwg9ScVlxeBtSunabUdcullkOWWJyqj2AHFXIPh3pqOHvLm5uSO0jk5quUh1kVptTs7d/LhLXtyekNv8x/E9BUcOl317eRX2t2xMMfMNpGcrH7n1PvXY6fp2n6bHss4UjHsOtWiYm6EZppWIdVszrW4tZU2xKqkcFcYIrmtft4f+Ev04RKA/kZbHu3FdVeWKT4YHZKPuuOorkLNp7r4iXEd1Hsa3gjXHUHvkexzTRDta6OslmFrdFCQAVB/So5blHBO4H8ad4gtfOvogCVxEAcfjWJc6ZKgLRuamW5tSs4pla+G9rwD+K1n/8ARbVh/DBiPF9sT1MUnbnoK1rZmNw8Uv3milQfijCsb4YnHi603AHMT98fwjmsK/8ABl6M0l8MvT/M9B1ePM8vrvP86xJxhfpXRapzNKf9o/zrBuV61wS3M6T0PatKm+06ZaTd5IUY/iBVgEk1heBJxP4XsucmMGM/gT/TFb9fTUpc0FLyPlK0eSpKPZlDXtIste0i50vVYmmsbldksYkZNwznG5SCOnY1i6n8PvC2pTPLc6PCHe1azfyHeENCTkqQhAPIByeRWl4w0p9b8LarpkMjRTXVs8cUisVKOR8rZHo2DXkWi+EvH13rej3OueZFbahcw3Wrxi7VhbfZtwjQYY5Eg2Z256c1oZnoVz4F8I6doOpx3On7bGXbdXc0lxM8p8oZVvNLGQbQDjB45x1rO0fw74B1O3Gk6ZEZfN2a4u25uBL++UKJhKW3jcqgEBh7iuCtvBfjJvEd7dy6U9sLq21OC68m7i8iYyI3kbQZC7ZJHL4weygV2nw38Maxo/iGzudStPJgj8M2Gns3mo2J4870wCTx69D2JoA6dvA3hswRwDTI0hjsJdMVI5HQC3k++mAR1/vfe96bceAvDdxb3ME2m7ormC3tpV8+Ubo4CGiX73G0gcjk98109FAHPnwboJ35sPv6oNZP76Tm7GMSfe/2R8v3eOlZ9v8ADbwpb3Jnh0tkfbOgUXU2xFnBEoVN+1QwJ4AGO2K7CigCtpljb6Xptpp9jH5VpaQpBDHuLbUUBVGTknAA5PNWaKKACiiigAooooAK8u03wFeXvgG18M6k8unXWhX4m0vUoikgby3ZoZdmf7rbSrY5z9a9RooA4G68E65evpl/e+KUm13TbmSa1ujpyrCiPH5bIYQ/ORzndkGsy1+D9lDaCzbVJ3tTok2kOPLActLP57TBs4HzZwmMY716jRQB5k3wunumludS14XGoyXNjK0yWYjQR2pyqBA55bJy2foB0qbX/CGpWnh/xhaaKftt14ou2zlVjSzjlRY3ZiWywVQx+UZJIGO9ej0UAQWFslnY29rGSUgjWJSeuFAA/lU9FFABSEDIpaP4qAPMvibcedrVtbA8RRZI92P+AFZ2nrhAKi8TT/a/E99JnIEmwf8AAeP6VasV4Wvm68uerKXmfUUo8lGMfI29PGHZum2Nj+h/xrxjXf8ASvHNwpHLXipgdsOB/SvarLhLhsZxHjHrlgK8QspDN4vErHIN2z5+hdv6VeHX7z5fm/8AgF4beTOt8KWollZzyzMSSa6meHyq5jwrOI41OQDiupt2+2XKIDkZyfYV2LU2qNp36GzG6pCof7oUZPpgVy+ow/bLmSYZTec4FbeosVtmA/jfH4VTSHK5NaTd9Dmw6UU59zhvEdm8VtIS2VwetVPhhqYtLCa2nOIXnYo3YHjitzxwyxaPcN3CmpPA/hu3svDlobyPfczL5rhui7uQMfTFZxN5yWlzea6XaQCKh0CX/SblP9oN+BFPk0mBgTFuibsUPT8OlULdZdM1NTOQYpfkEgGOe2aetybRkmkdjKcxqRWSupMl8LZ02SYLA54YD0q/G++Mc8VR1G0FxGNp2TId0Un90/4VbZzQSWjNuy1IEBWq5JHDdIcYDVyFhdiUmOXEV2nDxk8/UeorUtr1onAY1cZ9GZVMPZ3joxbm1UMysornjbrZ33kuoNvLnaCOh7iusuGWVQwOTWLrdv51oxT76fMp9xUSRvRm9mZd54V024bzUiaCU/xwsUP6VQk8NzgMsOsX68cAsD+tdNpNwLmzVu+OaS5Uo2aktSadmclZeD9PvdsuoTXN444InkJwfStJvA+hMMfYI/rVm4mFpciTcFjl656bv/ritO2vkdBkg/jQmOalujA/4QXRR/y7sB6bzU8PhjSbNw0NnFn1YZNbwukY4GCabONyg0yE31MzS0S31G6iRVVThgAPatS6KBMYGaxLudbXVFdiQGj7D0NQ3GpyyvstImkc98Urmrg5NMlx52qKMDZEuT9TWvEwU8Vg2sGoW8hl+zq4b767xk1YbUFGAA6yngRsMEmkhyjfY1Lq9SADJJZuFUckmqjpeXA+eVYQf4UGT+dS2Nmd3mS/NO3VvT2Fbdpp+4ZIq0mzGU40znBpMTcyPM59S5oOj245VpkPqshrrJLaGIfMRVKWNCTtpuNiI1+bY58Q3tqC0U32pB/A4w34GuZsdThufiRceXkH7MkbA8EMBkg13LKUfNcj40sI7DULLxFaRhZEkEV0V/iU8Kx+h4/EVJre51GoEG+hY9CuP1ouolC5HekmUXdqssX3iodfyqqk4kQfMKUi6eqVuhiXcAGq2vH3pAv58f1rlfhx8ni6yBIA2yA5H+wf8K7G+cf2jae0q/zFcZ4MYReN7QElQJpEz+DVz1/4M/R/kb7xl6Hp2pjE0v8Avt/OsSccmt7VlxcTD0c/zrCnHNcEtzGk9Ed38L7jfpd3bHrFNuH0Yf8A1jXaV5l8NrsQ67PbMcC4iyB/tKc/yJr02vfwM+aivI+fzCHJXl56hRRRXWcQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFRzyCG3llY8IpY/gKkrH8X3H2XwzqMgOD5RUf8AAuP61M5csXLsXTjzyUe55JblpZ2kblnJYn3Nb1kPu1i2K8Ctyz6ivl0fVVDWgO2yuWP+yP1z/SvCdAb/AIm5lI4CzP8AT925r3OQ7dIvG+nf/ZavCvD/ADeOcZxbzEn/ALZGurC/E35L9Qw20/66HTeHbRrpd0hIXsoNdtoUKWVwwQYEq7D/AErB8HRBoxmumdRHMhXswrrWmppVfNeBa1UF4g46K3NZ7XQRCCwFad1KsdrKzDcGG3b75Nc5JYpKp3bm+pqqm+hhh1eNmc34ynF4sFqp4mnjjJ9iwr0SCLfN5ajCrwB7V5p4rtVs47e4TIEVxHIRnsGFeoWUgFxuHQ8ilAdfTYutaJEnzYzWdqNjFdQNGwypFTX9ziYKWA3fdHrTY5gwwTzWjtsc0FNLmuZmnyS2rfZrkksPuP2Yf41pN8yEinMityRQAFHHSpLcru5h67aiWFLlV+eI4Yjrt/8ArHmpdOuftKGKU/v0Gc/319frVq4ZRDcb/u7Gz+VZNlDI9rHPBxPEMj39jSNlrGzNq3lKnaxqxKN0ZrOSVZ4UnTgN29D3FW7eXcuDTRnKPU56yuv7PvZUkyE3kA9iK32ZLiIOhBFVUgU6jPHIoZJFDgEcHsantbA2rtsY+UeintSSZc3F69Shf2/n2ksWPmxuX6jpWTZwxTXMCkYV85AOOcV0M58uUfWsONPI1jZ/CJePoRn+tJo0g9DpLKyWBPl+YdiRz/8AXp9ycKK1LdF+wg45xWTfcAVo1ZHJCfPJmBrgY3MHljLkFRWpptmIolTqerH1NVZI/MvoCf4VLVsWwATNQkdE5WikEiKqdOaywiy6kSRnyl/U1oXMygdaztNYPcXTesmPyApsmF0mzdsIssCa0Li5EY2oayzMIY+OtY9xqkjuy20bSkdWzhfzqublRh7F1JXZtTTZ5Y1BazrOHK9FYrmsNxqVwMBo4gfQEmr1jFcWsSR7Y2QdxkGpvc1dNRRozLuU1n39quoaXeWT8iaJkH1xx+uK0VJZORiqsTbLj8aBLYpeGZ1Twrbzy8yRpsx6tyKx/sjks+SCecg1ZtiY7Ce2HCx3sg/DJI/nWgkX7rmlN3NqPupvucszOmpWqynJ81cH8RXL+HGCeNLUg4b7YQPxLCuy1OHGp2mB/wAtk/mK4fR2x4qtWY4H21ev/XQ1jUV6cl5M6Vrf0PYdYx9rnx0LZ/SsG4HJrf1jH2uTHQhT/wCOisK67157OWj8KINPujYaxZXYOBHKpP0zg/pmvca8AuzwQO1e56XP9o0i0nByXhR/xKivUyyXxRPOzeHwyLgOaKZEcrmn16p4oUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcl8TpjH4Z2A/62ZF+o5P9K62uH+LJxo9l6faB/wCgmufFO1GR04NXrx9Th7NuK3LHBrnbRsHFbmnNXzqPpahszZ/sa7IHTv8A8AavCvD+Ptj8cm2mH/kI17wBu0q5HYsAfxVq8I8Pj/iZqmeWjlTHrmJwK68N8UvRfqLDbTO28MT+UBg44rpYJ0nuo4w4LFuma4fw4r3BAJwnciu1t7ZYEHlKFxyMV0pm1RIu3xPlOO2/P86ZbKpTJp91+8gLKOSM1hzalsBSPLN6LzVy3uYUleNin4utFu7CeId1OPrWx4Uv/t2hWFzn5/LEcnsy8H+VYN09xLG2Ubn1NZ/hrVV0XU5LC+Pl2l4waJ26JL0IPoDUxZpUheNz0O/jjuIcMfmHIPpWM181rL5U+6Qf3l5ZfrWlsSVWjkYjPcVLbafbRKQqhiepNVuYpqCsyrDfJIMxXKEehOD+RqZrrapMk0ar67hSzaPaSNnZtPtUEmm2dupdyAq+1GoXiypcStf5htQxi6vJjAI9BU+l3CrO0K8KhANEd/8ALtsbd5F9QMD86zJpJ4L43Elu8aMMN3H6Url2urGrOn2C8P8Az63B+b0RvWpQzQS4bpSJdw39i6HB4xWdZXihWt7pjtj4WXqAOwNMlJtanQwSIzq5wWFXJ7lTHgACud2zR8xkMh6EHINK00xGCDTUrGbpJu4+4fzJsDpWTfyqurhwR8roP05q/LJ9nQsQWkI+VR1P/wBaqdvbxy2zlWDyPks3fNSzeKtqdtbSgWIBPOKxr9ssBT7KV/s6hzzjn61VlJkuABVt3RzU4csmyGLJvG/2UArW25hAFYVlOsl/drnoRt9wOK2IZtowalGlRMpXsU2f3ciqPdc1U0/zLS4dbkhllIKyAYGfQ+ldAqJcIw4zWdJEpDwSjKtwaGuoRndcrIdTmaRkt4zhpOp9F71bsrWOOIAKAAOBWZpqu9zcmQ7niKxZ+nNb0IygprUJvlVkZmpXOowyoulWVhcKR85uLt4CD7BYnz+YquLrxKRxpGi4/wCwrL/8j1o6hpyTAE7gw6MpwRWfDPc2UgjnJeInCyf0P+NO9uhnyc2sWI114lCnOkaNj/sKS/8AyPVFbrxG0/GlaRn/ALCcn/yPW5JJI/GDUNxcR6dD5s3MrcRR/wAUjegFF79AUHFb/kcwZPEOy9kGl6Vj7UWP/Exk4PQ4/cdOOtXEvvETRDGlaRj/ALCcn/yPXS6VYsunxxXI+eRWaT6k5P8AOucW8NtK0b5KgkBscGlPToaUVzq19vT/ACMq6uNebULQNpmlhvNXA/tGQgnI7+RXnuly6mddtWjtLPzDcoQDdMBnfnk+X0z7V6lJcI2qWjZ4U7z9Bz/SvP8AwsnneI9KGCxe5jbr75rKckoN2OiMWr+8/wAP8j0rVLrxGbp92k6QpwvA1SQ/wj/p3rGubjX+c6ZpY/7iMn/xiuz1k/6fOB2IH5ACsO55zXnOSWlvz/zOelF8q1/L/I5W4n1zJzp+mj6X7/8AxmvT/Aep+Kp/DNstvo+iSxxFot0mryo3B9BbH19a4a5616L8JJC2jXkZ/guMj8QK7cBP97a25zZlB+xu3ezNCC88YAYGhaB+OtTf/ItTLeeLywD6HoAXPJGszEgf+AtdEB85p1e2eAzzT45vKui6WItbtdMT7WHkivJJYbe7UD/VySxcoO45ANcXpPizXRonh2z0HOhpfLqkrNc775SLdEZWhaQg+WxLYznGT14r2nXNZTS7vSYHWJjf3Qtl3y7CDtLfKMHceOnFYn/Cy/CDmdINbtp5oYJbgxR5LMsYJcDPBIAPGc9+lAjz3S/iJ4ihsL651e8S4SXwxFrcX2SxG62dpDGVClvnHG4lj+QGKx7Pxjq/iG/0e11K+gvFsvFWnCK4tyvzpLBMxUlAFbBHYevXrXrFl8TPCtz4esdYk1IW1vdglI5lJlBVQzAqufugjJGQM9a0J/G/huG9tbRtWgae5SOSMRBpBtk/1ZLKCFDZGMkZzQMw/gg7yeBi0jMzf2hejJOT/wAfD139cHpHxO0XW4oH0hg+/U1011uHETAtv2uvXdnyzgcEjritWx8e+Fr/AFZdMtNbtJb5vMxEGIyUzvGSMZGCcZzjnpQI6eisLw/4u0HxDczW+janDdzQqJGRMglCcB1yBuXPG4ZHvW7QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyfxOtjP4VldRkwSLJ+GcH+ddZmsDxzcpb+GbsMATOvkqD6t/8AWyaxxFnSlfsb4a6rRt3PH7STJU+tdDpzc1ykBMUpjbgg10WnS/dNfNn1E1odXYjdZ3S88bHwO+Dj+teE22LDxTGso/1d3tb6byp/nXuWksJJWiP/AC1Rk/HqP1Arxnx3btaeKLvA2eaRMuO24Zz+YNdVB2qeq/J/8EzwvxSj3NfwuTDlG6oxU/hXbidWhH0rhraZftjTJgJcBbhR/vDJH4NuH4VrR3zTHy4zx3NdW2h0uPNZnZWq7rZR3wMVlPapHPJlQCWJqSx1CRVRLjG3GAwGMfWrd8N+JV6j71W7NaHNG8J69SgbdGGNtcv4v0RLqwlAHIGR7Gu0ikRUOaydUuoQrK5GDUm0W27HJ+BPGDXP/Es1c7biEbUnJ4cDgBvf3r0JZHUAjkV4rqtsLTVnuoADG3DY7Gut8NayXjWFLl427AnI/I07kuB3/nue2KpxRHUbgvLzbRthV/vn1PtVSdr9YS8kyCPHVVAJrb0iEQ2sKnsATTWpnL3FdF62sNygkbVqSawUJ8pB9qLu4woVDhRVO2vQ8CSMwXcSACevNae6tDlXO/euYGq2n2CU3EA2xk4kUdB71f0K3UWRd1BMx3Nkdu1W9SiFxFIjDh1IpmlMWsIvUKB+VZ21OhzbgN/syJCfs7yQZOcI3H5UHT5m+9ePj2Rc/nSfaGF+0R+6FDD86uyTBVznmnoJuSK8FjFb5Iyznq7HJNUr2xIYz2mFlHJUdH/+vWhaTfaVZlB2g4B9aVjtOKAUmmU7W7WS13LwT1HoaguZ/s1tJNjLn5UHqTUEwFtqMu4hYnXzPYetVpZWvJldhtgT7inv71NzRRvr0ITCYIo5hJskXkmtC2a+uIlfyY0VuhYnn8KZYW63ty0kozbwnAU9Gb/61bgYySADoKaQTnbQfpsTq4LHnHOKjvAPtfFXgwijz3rLurhIVknmYBF55qnorGEW5SuUbOZRq2pQ9yVcD6DBrdsJUyN3SuMgW9eZbyG3cuWLEnjcD2rZtb5Wchcow6owwVNJOxrUp8yOluTGY8LWPNGkxeFxlXBU/jS/aiFqnfXX2Sxubx/4EJUerdh+dNu5lCm4nl+gSa/fzywjV71YY3KZ8w9jiu88NaMlrqsFxcyy3NwTjfMxYgfjVbwxpos9Pj3Lh2+Zvcmum0mIveB8fLH/AD7VC1Z0zSjBl3V5jHasFOGf5fwJ/wDrVjS2ytD8wB4rS8TYjsUk3AASAfoayXuw1sWyOBVVNzLDL3Lo5bUj9ma+mX7sNtJj2LDaP1YVjfD61Nx4us1CkiINIffC4B/M1a8T3LLprKvBupsZz/Cg3H9Sv5VrfB60xe3+oSAlYUCAk8ZHzH+Q/Ouav/Ca76ffodM5ctOUjrNTffeXDert/Ose4rRnY4JPU8msu5bmuF6sygrKxn3R5Nei/CNCNHvXPRp+PwArzS7frXp3wolRtEuIM/OkuSPYgV14D+MjlzL+A/kdx3ooor3j5w5/xR4c/t3UfD919q8j+yb4Xu3y93m4Rl25yNv3s556dK5bTfhclpY+GLWTVjIminUMstvtM4uhICB8x27fM9847V6TRQB5PJ8JJ5NM0OGTXYZbvSYHsopJLAmKS3IXCPGJQdwK53BhnPIqZvhO39saVewa0lmLJLdCbK0MErrEANu9ZNu088MrkA4z0r1KigDzi2+Gs8MkCHW1aytvEA16CI2eHU/vC0RffznzBhsDG3oc8Mh+FkX9n6PZXGqNJDY3d7cvtg2mVbkSAoDuO3Ak685x0FelUUAef/Dz4dnwfqK3Dahb3ixWZsomFn5c3l7lI3vvYNjaOAqjvXoFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNY06m4+akxodXAfE653T2FoD0DSsPrwP5Gu/ryTxXdfbfE14w+7G3lL/wHj+ea4swny0rdz0Msp81bm7GFqFmXjE0Y+ZetJp0+MA1tWqZXB6GqF7pzQOZIh8h/SvDR711sbVhclGR1OGUgiuf+MOlidIdTtwdiHD/AO4/I/Jsj8auWExBCtXSPBDq2gzWlwobYhjcZ6xsev4E/rVqTiuZdNfl1/DX5GDfs6imeL6ZOJdJZAcTWhLqD3jY8gfRv/QjW34fBLKT35Nc9NFNoGuSRXcfmeUSkidpEYYOD7jkehre09xaXSqr+ZC4DxSdN6Hof6EdiCK9G6kuZHf6Hew24kgyPSltJcEQt1H3T6j0qvZXo8jg9qoXN95NzG45O4cDvTTsc7g5XTNnULKQ20klny2M7P8ACuaj0n7S++cl2Pr2/CunttR8xOImHpzUq/ZZXzKNpPUkY/UVTSexEJzgrSRgp4fiKcKv4isrUfDsMZ3KnlSdpE/qK702gVMwScHpnkfnWRqYcqY5k2t1Hv8AShxsOFXnZg6TdSyzx6ffsFKYI9GHtXbxjaorz/VI2+zieP8A11sd6kdx3FdtptyLjT4Zv7yg0RFXjtYW/lEcTOTwoJqrodptto5pxumIyM/wg9hUeoObiZLVOS5y/sta8S7ECjsKN2Zv3Y27kdz0FU9F/wCPMHsckfnTtZmMVrJt+8RtXHqeKq2d3HGqwqSGAxtYYNHUIxbgF+3l3cM/8OTG30PT9aS5Zp5I7ZDjfy59FqPVZglhKWGWf5FHqTTtAR5HeSQ7iDsB9hS6mm0b9joLO32xYQYUCqdyMSkVtxAJbmsK6OZ60krI5KUnKTKd3bLNfWvmDcCj8H2waydRhayY7P8AUvnA/un0roiN19AP7kbE/iQKz9di325HowP61DR1QlqkOt08i0t4V67QT9TWnAAiAnrWdIf9JA9KvmIugG4jI7U0RPzIL+6WJSzttUVSs4zqMgmmXEKn92h7/wC0alvLSKKGVyCzhTgsc4qzpSbLWIHsooHdRjoXFRQMVm6naxzsP4ZB0deCK0ycCs+4bdLgUMiDd7nN6z4gXQJoLe6gkuZZlLRmMgAgHHOelVml1HWmjnuFWCBDujtwMjPqT3NRa7Euo+M40xuW0hVT/vHn+orqILbZCMDgVL7HTG1uZkOkpc3UxicIoUZLD0+lb+UtIsgfKvQd2NQaTFtEk2P9ke9MuJA9yVY/KnH496pe6rmFRuc+XoinfO9yWabknt2FclqLNbEpESVc7do9T6V1l7IoViOgFcfqd4LWG4vflLRfLFn/AJ6Hp+XLfhWb1OqGi0OY8UXQk1EQKQYrRRCD2LA5cj/gXH0Feo+FLBtG8GwRSjbcXR3uPqdx/wDZR+dec+A9FOueIYImBeCEiWXP8XPyg/U/1r1bVrgSXG1DmOMbFPr6n8Tk1y4id5cq6fn/AMN+hnXeqpr1Zm3LcVj3T4zWhdPwayZg0jbVHJ4rlHFFZIzPISPur1rrvhpe/ZfEb2znCXUZUf7w5H6ZrHS3Fvb7R16k1WsLs6frFpeDkQyqxHtnn9K0oz9nUUuxFaHtaco9z3qimo6uiupyrDIPtTq+mPkwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooozzigCpq12LHTbm6b/AJZRlh9ccfrXjdtudmdzl2OSfU16J8R7sQaEtuGw9xIFx6qOT/T864GyTgV4uYzvUUex72V0+Wk59/0NC2XCirwQOm1hkVXiXpVuMVwROuozJu7LypNyDirWmXTW06uRkdGX+8p4Iq86h1waz5ojG+RVbO6EpKa5WVfHvhlNXtWkgC/bY1DQSdPNTrt/z0P415ro0+SdPuyYnDnyHc48tyeUPoGP5N9TXtOlXP2i3+xP/rFO6Ak9+6/j2964n4g+F2vA+padEXuI+J0xguPXHqO/qKKNX6vP2cvge3l5GlCrb93MpWVy6KY5Mq6nBU8EGm2rG51XBOVQfrWHpV+L2KO3mk23iAJHI7cSjspPZh0BPUcdRzpaGzJeyBwVYHBB4INek0dR6Fp9sCgyKv8A2NcfdrO027UKOa2RexlPetI2sefVc1LQzJUktiTExA7qehqtczx3duQex5Xuh9RVy9nUqxJFcvcXPkzmReg6j1FS3bQ1pwc9XuQTRt5rxkcsCMVc8P3UjaVHDboWcDG4/dH+NRXbboxNAN7lDsHqccVT8IXq25+zzfK+eQeOaRtL3o3Ot06z8ktJId8zfeY96vE4FNRwygg0rruXHaqOJtt6mWM3uoA9YIT+bf8A1qn1G2SaIK65HZh1U+1W1VIUCoAAOgFRlxIhIIIosXza3Rzflu85W8bLwfdXsR/era0FdlrGT1JLfmazb9XfUAYkLMIuQCB3qxY3iwCKKZHiYAAbhwfxqVozWaconVXEoW3AzWGx3z1NLNuTrmqs0otraSZuoGF+vark7nPShyklnJvuJ5O2di/Qf/XzVPW5MREDqSBU1idkSj0FRS2ktzKzyLiNR8o7n3qehtGyldiysN6SDoQDWzZ7ZYeDzWBCRsEEp2yLwuf4hUkVxLbPjnApp2JqQclZF/ULWWQCMD5WPzH2qxGgRcVSOqsRzVeS/d+FBobQlGbVmXrmcL3qjLcR20E13cHEUSlif6U1iI4WuLuRYoUGWZzgCuXurybxLeLBao8ekxHJZhgysO5Hp6Ck2XGPREvhiKSaW4v7kfvriQyH2z2rq4i0pEad+p9Kg0nSClqD5uEzhRt5xWi+20hAT77dPf3oSe7KnUXwx3Hz3C2kSpGAXA+VT29zXMi5mhu2W4bcrnIfGOfeteRMLuY5Y96w9ZYEqiglm4AHWlJ3KpQURdQuS5EMWCzepwPqfavPtdvjqF2sNqrPbxHbEuOXJxlserED6DArQ8RakYYXsYyDKwxcuGHGP+WYPp/eP4etdF8OPDDRyJrGoq0exS9uGH3R3kP1zwKxq1VSjd79EauSgudm/wCE9IHhnQCWwb+5++47ccj6AcfUmmyNnJq1qV39omLDhB8qL6CqJ+avPd+u5hBN3lLdlaUNI2BVq0tAvJHNTW8HOSKtkbRRYbl0RmXa4WsG6XrXRXQyDWHdrgmgqB634B1A6h4YtWc5khzC5916fpiuirzX4R3hE2oWLHghZlH04P8ASvSu9fRYWfPSiz5rGU/Z1pRX9XCiiiug5QooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkHUmloAxQB5n8R7rz9ehtgflt4hkf7Tc/yxWVaJyKi1e5+3+IL24ByrSkKf9kcD9BVyzSvmq8+epKR9VRh7OlGHkXIlqwo44pkY6VOF6VMTKbGGo5FDDBqZhUZFNkplFlMbZH4Gti2uRqYGcfbYxyP+ew9f94frWfIm4YNUnDwyB0JVlOQR1BqJRUlyy2NGufXqcv438HszS6lpUZbOWmt1X82X19x+Vc5pGur5scWonkcLdDJZR2Dj+Ie/Ue/SvZbG8GoDbvCX/PfAm+no3864vxh4MjvvNu9IjMV1kloeiyHv9G/Q06OJdBqnW26P/P8Ar/M2pVr+7Pcgj1Brdl34KONyOpyrj1B7itBNWBXIb9a82s7+60uRraePdEH+e2lBUA+vqje46981vW7rdRGXTnd1Ay8L/wCtj+o7j/aHH0r07dUdDiup0txqW5Tk1iz3RkkIHOarxxzzEA5xVqRYtOVWYCW7f/VxZ5J9T6Cpsx6RLC6ta2VxBZyyqlyFzh+F56DPrVu6s4NQG+MmG5XkEdR/jVC08MC/R5rpvMnlO52I6mq1xZah4fkVlLz2a9YyeQP9k9vp0q7GSkr2Oj0bUZoJfsl9w38D9mroDMwGSRiuSEkOqWQkRg+RlXHB/EdiK1/D0VvcQYkjBlQ4bJJoTM6kEveL3nPcMUt/mPd+y1ZKLb2ojU9B1qx8kS4ACgdhWTfTm6nFtAeTzIR/Cv8AiarYyXvPTYXTU8+SWYjhjtX6D/6+as3VsrKVddyHsa0tKs1WNRtwo4AqW9gTkL0p8mlzN1lz2Obti8E4t5GLowzG56n2PvUd+ZLx/KgQtFHwTnGW/wDrVZ1OIm0kK53x/OpHXj/61WNPRGhTYMLgECp8jfmt7xRtpygXzBgj5WHoRWxDKJAMEZrP1CxYsZIcB+4PRvrVKG4aB9rhkPo39DRewnFTV0bV3p6zr8y8+tZMsU9sdu8Oo7OM/rWlb37MACwIpdQw1uW703Z7ERcou0jktZ8RR6TeR282nNLJIm9WWUBSPyptvrOsXq5sNJggX/npIxf9OKxvGFv9o1zRgc5IfP0yK7Wzdre0UIAVUdCKVzZRvqY66JeajKsmr3LzkHIjxtRfoOldDa2lvaKofaqD+EVHDqAuV/dL5YHBzyc1OiRtlmOT70tAfNbXQtHUYlGFjZgBwOgrE1DVt+oRhk8tcbRzmrU21c46VzWqv9ouBHAC8nXjt70nJvQcKUI6m1dXvAWMFnPAArj/ABFrZs3e3tZA96QVklU8Qeqqe7ep7duelbXfEPlqbXTJMvjbLcg4z6qnoPVup7Y73fBHg/7eY7/VYmFkCDHCeDL6e+3+dZ1asaMeeZrpFXlsN8BeEzqcsV/exn7GGxHEBzMc+n90frXomq3aqgtoWyq4DsP4iOw9hUt/diyiFrb4EwBViuMRA/wj3x19OlY+M15zcpy5579uy/z7nK5OrLme3QjOWNWLaAsealtrbJyRWlFEFHSqUQnUS0REkYVagnHFXnGBVOfvTZEHdmdN3rJvV61sSjrWbdrwazOmJY+H1x9m8X2oyQsoaI/iMj9QK9oHNeA6bcGz1qyuR/yymVj9MjP6V77nB+te1lsrwcfM8XNYWqRl3QtFFFeieUFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVS1q5FnpF5cZx5cTMD744/Wrtcx8RbkweGZUGMzyLH+Gcn+VZ1pclOUvI1oQ56kY92eZ2C8AnrW9aDisaxHyitu1GBXzJ9TMuRirCjioYhU46VpE4pvUCKjZalpCKqxCdiswqKSMMOatstRstTY1jIyZ4CpytatpqK3SiK8cR3OMJPnAf2b0P8Atfn61G6561SuIO4qZJNOMtUzRpT9RPFHhm01pfKuEeC7iGElVeR9fUe35V5RrWjaj4euUM6MgDZiuYiQp91bqp9jXr9nqRiRYL1XlgXhXU/PGPb1Hsf0rQuLaG5tGYrFc2Ui7MkblJ9CD0PsayhUq4XWPvQ/Ff193oXTrSp+7I8hg8QnUIRbX9w9lOOl5boDu/66JjP/AAJefY1dtdP/ALOSO7lZbmCU8XUb+Yrn3bsfY4NaHiL4fDMs+hyEjg/Z5Dj8Fb+h/OuMtLzU9AvJEQyW8h4lglTIkHoynhq9OhiKdZXgzeymr038j1TS9UtREoDKKW+uor8/ZYsMW+83ZR/jXA219p2pScv/AGRcEdRlrZj7/wAUf6j6Vq2815osiLew7VflJFO5JB6qw4NdBjy8j13L72H9k3TsARBL1I7HsataPcKmpkIwIbGdpyKt2mr2t/H5coH40xraKxmNzbKHiI+ZQeR7ila2pSnzLlZ0Fzb/AGhcF2Ve4U4zTNNsY7SMrgZLFjiqsGqQso/eBT6NwRRPrFtCpLzL9BzTutzLlnaxv/ahHHsWqrT7urCuPuvEc1w5i0+Bnb+9jNVv+JnIP39zHCD2zuaqu2THDnV3MkRDKXXkY61S0q4WO2iDMOOPyrm/7P3HMmoSk+y//XqP+ztvCahN/wB8ip5Wbqk7WO/SZJBwRTJrdJFIIBB7EVxCR3sP+ov1Y+jrip01vVrLm4gE0Y6tGd36daZDoyjqjov7LSOYPGq7e6n+lTXxCW+wcE8AVm6f4khu144b0qn4h16HT1XkSXkvEMIPT/aPoP51Iveb94x7xftfi1VXlLSIJ/wI8n+ldYxVbIjviuc0C0+zxmSZt00h3Ox6kmtDUr5IbYjPJqbnRy7IZo7/AOt/3jV+e5SBTubFczaXzKQkCNJK5+VVGST9Koazqkdm5WdlurwHBgRspH/vsOp/2V/EihK5T3sbGq6ovkmRpVgt920yNzk+igcsfYfjiuM1LVpL4m0tFdLZzt2jl5j23Y6+yjge55pLO11TxNqG2MGV1GCx+WOJfTjhR7DrXqfhXwha6IwCKLq+cFTOf4fXaOwrmr4qFDRay7ClKNPWW5z/AIP8EGOZLvWIw0q4aO0ODz2Lep9hXbahei1QxwMGuMYeRTkJxjAPr7/lTb/UUhV4rV90rDa8w9O4X+prHwZOBXElKUvaVfi/I5W5VXeWxGMs3FaFpasSGen2lsAAW61fUACtEhTnbRBHGAKlpuaXtVnOyOQ8VSm6Vck6GqUtRI2plR+tUbteDV9+tVLkcGszqRz92MdOua9502f7RpdlPnPmRI2fqteFXY5/GvZPB8nm+E9Mb0jC/kSP6V6eWv3pI83NY+5F+ZvUUDpRXsHhBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcD8Vp8R6dAD1Z5CPoAB/M131eYfFCbzNdtIh/wAs4cn8Sf8ACuTHStRZ3ZdG+IXlcxdPXgVswjArKsBxWvEOK8A9+Zai6VMtRR1MtaxOKe44DFLjNFLV2MxhWmMualNIRSaGmVXWoWHrVx1qB1qWjWMijNAGBxVeGa4sZjJayNGx4OOQw9COhrRZcVFIgPWp21RsmmrMt2V/bXeEZVtbvoOf3bn2/un68fSodX0i01JDb6pbLKQDgOpDKf8AZI5rOmg7ip7PU57RRFIBPbg8RuT8vup6qa550IyfND3X5f1+X3C5GtYnEa78P7mHfLo0huUAz5LnDqPZu9VPCX9qWl09hcRSiyY/vbaePKfXDdPqK9WgubW7+W1kCyMc+XMQrj2B6N/ninSoGJSeMYX5dpBBPvWlPH1cO0q0bruFSrKpBw6nFXGhWcp32Ur2Mx/hbLxn+o/Ws7UV1XTIgLmNngyCJojvQ/iOn44ruZdNRjtQ7GI5B6VSktp7Zt0bMMfxI3SvVpYzDYjSMuV9mcCrYih8a5kcfJ4hDRZKKx9xmpbOJ75BPekxwHlEXgt/9atHU7DT7kPLf2qKw+YzwnymHucfKfxFYwvbANi216CULwEu4yh+gZQR+grolScXqduGxVOt3+43I9qII7dBGnoopTaSyetV7C4mYBorZLhfW2nST9M5/StAaxHBxcW11CR13wOP6U7Lqdiqx2gyuulSnk5pG0yUdM1oJ4h0/ODNg+hU/wCFP/4SDTtufO/8cb/CjliDqy7HPXNpcR5wDVZLmaFvnBrpTrNjcfLEs8h/2IHP9KoXqNIf3Vhd893j2D82xUuC6M0VeH29DLnto9QjZraQW15/DIBwT7j+tcnEktnq8i6kGN2Dks5zu9we4rrhFJHLzLY2v+1LcBv0XNTzaPaX7wzajcSX7R8oI8RRj8RliPxFCpyl0OSti6FN35jJi1aaRhFbozyHoqjJP4Cr6aNe3jB9Sm+zRf8APNfmkP4dB+PPtXQWsYiTybWFIUP8ESBc/XufxzV+DTixBnPlg9u5FRVlRwyvWl8jhlj6tbShH5nE+IbG+hjSHQopFt3TZNsIMjknueuMdQMD2pND8ATzFZtXk8iIYzBE2XPsT0H4V6Tb2yJhIoiWc4UgZJpLu7t7HcJyJ7gdIkbp/vN2+g5+leRVx88Q+XDxsu7/AK/zOilUqwjyyd35b/19wzTNNtdPszFaRxW1ihyxcYGfUnqT+ZrO1DVQ4MFmClvjaT0aT6+g9qq395c6jKpnbIXhEUYVR6AU62siTlqzp0ow1Wr7mij9qZFDG0jdK07aDbyRUsUSoOBUwFbJClMVeKcKVUp4WqRi2NAp1OxSGnYi5FJ3qlLV6TpVOXvUSNqbKcg5qrcDircnWq0/3azZ1owrscmvV/h8+/wda/7Jcf8Aj5ryq8HWvT/hsP8AikY/eV/516GXfxH6HBmn8Jep1q9KWkXoKWvbPnwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvI/iC+/wAWSj+4iL+mf61653rxvxe3meLL8+kgX8gK8/MXaml5np5Ur1W/IdYDoK14xxWVYDFasfavFPYkWY6mXrUMfSpl61tE45jxS0gp2K1SMmIaaaeaaaTQ0NIzUbrUtNaoaKTK7JUDpV0iomSpaNYyKLrxVaVAa0HSq0iVm0dEZXMyWHOfSrNtq93aqscm25gHAjm5wPZuopzpVeSIEcUr2LcVLRm3aanY3ZO6YW0xGNs/3fwcf1Aq5JC8SxOVDJz84AZD/wACHBrjJoCKLO8vLBibSeSLPUKeD9R0NYzw1Ofk/L/Ih0WvhZ0N/pMF5AyONomUq3PBBrgNR+Hd1FuexuFkjBwA46fl1rtLPxGOFv7RX/6aQnY35fdP6VpxX2mzgeTebDnlLhSmfbIyP1rSFTFUlZNSS6P+kzFKVJtx0v22PFrvwxq1m5JtScd4zz+XWi3vtfsSFjl1CMD+EqzKPzr3IQPLygjmBHUOr/lg0j2BTG+zOTxjyz+ddCzGUfiptf16FOu5aT5Zf18zzzw1rWr36S/bxKipjbJll3H0x/WrOv6pqtnZB7Dz5ZScH5mOwY64ruls5EUYtXBz2jOT+lOazlYnfas3tsP+FX/bMtvZv7/+AcTw0XU9pdW7dPzPEJtT8SXjEGfUGJPRNyiof7F1u7OXgnfPeWTH8zXuZ03ONtmWbqTs609bJ4gD5KQ4OdzFV/nU/wBouS0pyf8AXozsVdx+BRX9fI8e07wFqFwQbhkhB7Ku4/rxXoGieHotOsorcSN5cZ5x1J61uySW0YLXN/axvn+GXcR+C5qlda5p0ChYElu5AMZx5Sf1J/SsZYnFz0glBfj/AJ/ciJ81fSfvfLT+vVl2CFIVMaxAluBgc0XDxWfN5KqN2j+8+Pp2/Eiudl1y/mDLG6WyHjbAu04/3uv61WihZzk5/GuaOGje9R8z/r5v8DaNF9dEaV3rErAxWK/Z4yMMwOXYe7dh7D9aqW9uW69KsQWwGMirsUXtXSlpZbFe7BaEcNuqDpzVpExTlSplWrSMZTGKlSBakC07FWkYuRGBTgKdikPFVYm4UxvanGo2NSNDHPFVJcVZc8VWlrORvAqS1Un+7VuUVVlHy1mzriY14Oten/DkY8JRf9dH/nXmV4OtepfDgf8AFKW/++/869DLv4r9DgzT+CvU6degooFFe2fPhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeM+JOfFOpf8AXc17NXjPiH/kaNS/67tXm5l8C9T1cp/iS9Cez7Vpx9qzLPgitJK8c9aRbjqZetQIamU1rE45koqTtUa1KK2iYyGsOKYRUpqPFMExmKa1PprVDLQ2kIpaKkoYy1XkjzVuo2XIqWioysZzx4qB4zWk6VBItQ0dEZmeVB6ioJIR2q+6VCwxU2NVIzJIuelMVRnmr8qDGaoy/LzQaJjSnNAmlQ/JI6/RiKQSgjrSZBNC0G9dx/2y8HS6uB/21b/GmPc3TD5rmYj3kNGRTT0quZk8sewx5JGHzSOfqxNIBk+tNdsVNbruPSpKWg9U4qVLcnmpooqvRRdKLEuViCC2HpzV6KHHapYovarKR4GTVKJhOoRxx1YROKFXmpRVpHPKVxAMU9RTR1qQVaRm2FPUUAUoqkZtjaQ0ppppsaGnpUMlTHpUMlZs0iRMeKgl61M3SoJKzZvArSVWlHymrT1Wl6Gs2dKMW/4Jr1L4b/8AIp2v+8//AKEa8v1Ada9W8ARiPwnYY/iUt+ZNejlv8R+h5+aP90vU6EUUCivaPBCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooARe9eM+If+Rn1L/r4avZx3rxfxFx4n1L/r4b+debmXwR9T1sp/iS9Czadq0UNZtoelaCnpXjnrSRbQ8VKhqvH0qZK0RyyRYU1OKrpU69K3ic8hxqM9aeaaaZKGGmNUh6GmN0qGWhlFFFIsKaadTTSYDGFRMKnI4qNhUtFRZUkXFVpF5q9IvFVJFwaho6IyKzDtVK5jrQZahkTK1Jsmc/cq0TblPy06KTcARVy4jzkEcVlEGGX2poovFqC4C5PFQiQY4NROxkkCCgZNEplfJ6Z4rVt4toqG0i6cVpRR9KRLdh8EdXYo8Y9aSGPHarUairSOecwjTFS4oxg0tXY527gKdSLS00IctPpop1UiGPFApKcOlUSNPSmGpD0qOhjQ09KhepmqF+lZs0iQt0qGSpm6VDJWbN4leQVWk6GrT1WlFZs6ImPfc5r1vwYuzwvpoxj90DXkt8Mbq9l0FPL0WxQdBCo/SvSyxe/J+R52bP3IrzL9FA6UV7J4YUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAK8Z8UDb4q1EH/ntn9BXs1eP+NkMfi69/2irfmorzsyX7tPzPUyl/vZLy/yG2p6VoIeBWZangVox/dFeKeyy1GeBU6Hmq8VTpWkTmmiwlWF6VXSrCdK3icsxT0prU89KYaolDfWmmnd6aahlIjooPWikaBSGlpppMAFManZ4prGkNEbjiqso5q23SoJRk1LNYspsOajYVNIKiaoOiOqKVylY97HkE+lb0q7lrMu4+DxSNEZCvgGrNgm5yx+lVJBhyK1LCPaqimxmrar0rQhXmqtuvStG3HGaaRhNkiDBqdeBTAOaUVaOd6kgPzU+oV+8ampozYCnDrSU5aYmKKcOtIKcOtUiWLTu1N7041ZIh+7UdSN0qOpY4jW7VE9StUL1DNIkLd6hepm6VA9Zs3iQvVebpVl6rTd6hm8THvPmfHqcV7daIIrWBAOAgH6V4psM19BEvV5FUfia9wxjGOgr1MsXxP0PMzZ/AvUWiiivWPGCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8t+JMQj8Rxyf89IVP5EivUq87+KcWLvTpf7yOn5EH+tcePV6LO/LZWrpd7nN2h4Facf3aybM8CtWLpXgHvyLMVWEqvHU6VpE5plmPrVhKqxnpVhTW0TlmiQ0hpaSrIQzvTT1p56009ahlIjPWkpW60lIsKQ0tI1JjG1G3WpDTGpDRGajkqVqjepZqirJULCrD+lQOKlm0GQmqV0vBq8RzVe4XINSaLc5y5TEw9zWvZr0rNuxi4Ue9atoOlBTNOCr8XAFUoRxVxOlWjmmWFp1NXgU4c1RiOTvT6atKTTJY4U8UxakFNEscKcBSLTx0rRGbYg60tAopiGueKYac/WmGpZSGtUT9KlaonqGaRIG6VC/SpXqBzWTOiIx6qzd6stVabvUs2iV9EiM3iXTkAz+/Un6A5/pXsp7V5Z4Hg83xXC2MiJHf9Mf1r1OvZy2NqbfmeNmkr1UuyCiiivRPMCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4v4oQb9Msp/wDnnNtP/Ah/9au0rB8c2/2jwzd8ZKbZB+BH9M1hio81KS8jpwk+SvF+Z5daHBxWxAcisW2PzCti25FfNs+mkW0qcVClTCric0iVDzVlDxVVKsR1rE55osdqSgdKK1MRDTG6080w1LKRG3WkpzU2pLQUjUtIaTGRsajLZp0lRd6kpDiajY07NMbFItMhc5NQydKmbqahepZrEiIqKUZFSk80yT7tSanP364vE+tatqOlUNRH+kxt71etiaY2acXSrSniqUJOKlUk1aOeReU8CpARiqisdtPDZpmdi0Gpc5NQpUq0ySValFRLUoqkZsetOpq07vVohhRRSMeKBDDyaTvRSGpZY16hepXqGSoZpEgkqButTPUBrNnTEa1Vpehq03SqsowhqWaRN34bxFtTvpscLEFz9Tn+legVyPw5tylhdznpLKFH/AR/9euuHSvfwMeWjE+fx8uavIKKKK6zjCiiigAooooAKKKKACiiigAooooAKKKKACkJpDTaTY7Dt1LnI4qOlXIOaVx2JAc1V1SIT6bdREZ3RMP0qyBjPpQwBBB78U2rqwk7O6PHUs2V1wDgCtO3tWx0rqW0HDknGM8YqzHpYUAba8T6nLqj3JY6LOYW3YHpUqwN710v9mj0p66avpVLByMZYyLOcWAjtUixMB0roBp49BTvsAq1hJGbxSZgqpxQVNb39nj0pp0+q+rSI+sRMIqaZtPpW6dP9qDp3tUvDTKWIic+yn0pNpreOme1KNM9qn6rMr6zEwNhpChrov7LFJ/ZQo+qTD61E5mVDUOw11R0gGmnSB6Uvqk+xSxUDlihpjIa6s6MDSHRAetH1Op2KWLgcgyHNQuhrsm0FTUbaADUPB1OxpHGUzjQlJJGcV2H/CPLml/4R9TS+p1OxbxtPuebajCfMQ471etYDjpXaz+F45tueMHNSp4eROlP6nU7A8dTtucvFAdtSCA5rrI9EAFKdHAqlhJ9jF4uLZywhOKekJ9K6T+yhQumAHGKf1aQvrMTn1jIp6oQa6H+zFx0pP7LHpR9Vn2F9ZiYirUgWtldMHpUi6aB2prDTIeIiY4U+lG01tiwA7U77AvpVrDSI9ujCCmmspPaug+wJ6Uv2BPSn9WkH1iJzuw+lL5ZxW//AGeuelL/AGevpS+qSD6yjnGiNQPEc9K6r+zk9KjfS1JpPCSLjioo5KSI1EYiTXWto4NINFX1rN4OfY2WMgjkzAcdKgmtWMZ4rtho6ilGjxkgEcZpfUpsax0UWfD9p9i0W1hxhtm5vqeT/OtKgDAAHQUV7UIqMVFdDxpycpOT6hRRRVEhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACEU3aafRSsFxu00badRRYLgOBRRRTAZtNLg+lOooHcZtPpRtPpT6KVguNApaWinYQfhSY9qWigBMe1GKWiiwCYoxS0UAJijFLRQAmKMHFLRQAmDSbadRQAmPakI9qdRQBHtPpRtPpUlFKw7jNp9KTafSpKKLBcZtNIUNSUUWC5XMbelKsRzyKnopcqDmGBOOlGyn0U7BcaFo206iiwrjdtG2nUUWC43bRtp1FFguJijFLRTsAYpMUtFKwCYowaWiiwCYPtQBzS0U7AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_62_38884=[""].join("\n");
var outline_f37_62_38884=null;
var title_f37_62_38885="Nizatidine: Pediatric drug information";
var content_f37_62_38885=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"20\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nizatidine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?29/16/29958?source=see_link\">",
"    see \"Nizatidine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/58/31652?source=see_link\">",
"    see \"Nizatidine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Axid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F202317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Nizatidine&reg;;",
"     </li>",
"     <li>",
"      Axid&reg;;",
"     </li>",
"     <li>",
"      Gen-Nizatidine;",
"     </li>",
"     <li>",
"      Novo-Nizatidine;",
"     </li>",
"     <li>",
"      Nu-Nizatidine;",
"     </li>",
"     <li>",
"      PMS-Nizatidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Histamine H",
"       <sub>",
"        2",
"       </sub>",
"       Antagonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/16/29958?source=see_link\">",
"      see \"Nizatidine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants 6 months to Children 11 years: Limited information available: 5-10 mg/kg/day divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     GERD, esophagitis: Children &ge;12 years and Adults: 150 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Active duodenal and gastric ulcers: Adults: 300 mg once daily at bedtime or 150 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maintenance of healed duodenal ulcer: Adults: 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     -associated duodenal ulcer (limited information): Adults: 150 mg twice daily for 4 weeks (combined with clarithromycin and bismuth formulation; followed by 300 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Active treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-50 mL/minute: 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: 150 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-50 mL/minute: 150 every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: 150 mg every 3 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F202292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 15 mg/mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Axid&reg;: 15 mg/mL (480 mL) [bubblegum flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F202278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with or without food; do not administer or mix with apple juice",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1060588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nizatidine is stable for 48 hours at room temperature when the contents of a capsule are mixed in Gatorade&reg; lemon-lime, Cran-Grape&reg; grape-cranberry drink, V8&reg;, or aluminum- and magnesium hydroxide suspension (approximate concentration 2.5 mg/mL)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and maintenance therapy of duodenal ulcer; treatment of active benign gastric ulcer; esophagitis; gastroesophageal reflux disease (GERD); adjunctive therapy in the treatment of",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     -associated duodenal ulcer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F202366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Axid&reg; may be confused with Ansaid&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tazac [Australia] may be confused with Tazact brand name for piperacillin/tazobactam [India]; Tiazac brand name for diltiazem [U.S., Canada]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F202364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, fever (reported in children), headache, insomnia, irritability (reported in children), nervousness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dry mouth, flatulence, heartburn, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Reported in children: Cough, nasal congestion, nasopharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alkaline phosphatase increased, ALT increased, anaphylaxis, anemia, AST increased, bronchospasm, confusion, eosinophilia, exfoliative dermatitis, gynecomastia, hepatitis, jaundice, laryngeal edema, serum-sickness like reactions, thrombocytopenia, thrombocytopenic purpura, vasculitis, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nizatidine, H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and modify dosage in patients with impaired renal function",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3268342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of gastric acid inhibitors including proton pump inhibitors and H",
"     <sub>",
"      2",
"     </sub>",
"     blockers has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia (Canani, 2006). A large epidemiological study has suggested an increased risk for developing pneumonia in patients receiving H",
"     <sub>",
"      2",
"     </sub>",
"     receptor antagonists; however, a causal relationship with nizatidine has not been demonstrated.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F202352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F202287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: H2-Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: H2-Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: H2-Antagonists may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with H2-antagonists and antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: H2-Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: H2-Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: H2-Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: H2-Antagonists may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with H2-antagonists should be avoided in patients who are being treated with delavirdine.  The clinical significance of short-term H2-antagonist therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: H2-Antagonists may increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: H2-Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: H2-Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: H2-Antagonists may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: H2-Antagonists may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: H2-Antagonists may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: H2-Antagonists may decrease the serum concentration of Itraconazole.  Management: When this combination is used, the itraconazole should be administered with a cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): H2-Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: H2-Antagonists may diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: H2-Antagonists may increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): H2-Antagonists may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be impaired by H2-antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: H2-Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: H2-Antagonists may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and the H2 receptor antagonist by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: H2-Antagonists may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: H2-Antagonists may decrease the serum concentration of Posaconazole.  Management: Avoid concurrent use whenever possible.  Monitor patients closely for decreased antifungal effects if this combination is used.  Consider using a noninteracting antifungal as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: H2-Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: H2-Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: H2-Antagonists may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: H2-Antagonists may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: H2-Antagonists may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1060601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit xanthine-containing foods and beverages; administration with apple juice decreases absorption by 27%",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F202289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F202301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies; therefore, the nizatidine is classified as pregnancy category B. Nizatidine crosses the placenta. An increased risk of congenital malformations or adverse events in the newborn has generally not been observed following maternal use of nizatidine during pregnancy. Histamine H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists have been evaluated for the treatment of gastroesophageal reflux disease (GERD), as well as gastric and duodenal ulcers during pregnancy. Although if needed, nizatidine is not the agent of choice. Histamine H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists may be used for aspiration prophylaxis prior to cesarean delivery.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibition of histamine at H",
"     <sub>",
"      2",
"     </sub>",
"     -receptors of the gastric parietal cells, which inhibits gastric acid secretion",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1060597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maximum effect: Duodenal ulcer: 4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 0.8-1.5 L/kg; breast milk: 0.1% excreted into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 35%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination: Adults: 1-2 hours; anuric: 3.5-11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 0.5-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 60% excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/58/31652?source=see_link\">",
"      see \"Nizatidine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid excessive amounts of caffeinated beverages and aspirin; do not take with apple juice.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11430199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 2.5 mg/mL oral solution may be made with capsules and one of three different vehicles (lemon-lime Gatorade&reg;, Ocean Spray&reg; Cran-Grape&reg; juice or V8&reg; 100% vegetable juice). Empty the contents of one 300 mg capsule in a mortar. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label \"shake well\". Stable for 2 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Canani RB, Cirillo P, Roggero P, et al, \"Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(5):e817-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/62/38885/abstract-text/16651285/pubmed\" id=\"16651285\" target=\"_blank\">",
"        16651285",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mikawa K, Nishina K, Maekawa N, et al, &ldquo;Effects of Oral Nizatidine on Preoperative Gastric Fluid pH and Volume in Children,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1994, 73(5):600-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/62/38885/abstract-text/7826786/pubmed\" id=\"7826786\" target=\"_blank\">",
"        7826786",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simeone D, Caria MC, Miele E, et al, &ldquo;Treatment of Childhood Peptic Esophagitis: A Double-Blind Placebo-Controlled Trial of Nizatidine,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nur",
"      </i>",
"      , 1997, 25(1):51-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/62/38885/abstract-text/9226527/pubmed\" id=\"9226527\" target=\"_blank\">",
"        9226527",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12649 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-284481FE57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_62_38885=[""].join("\n");
var outline_f37_62_38885=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202316\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202317\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060591\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060584\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202292\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202278\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060594\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060588\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060593\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202366\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202364\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060599\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060583\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3268342\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202352\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202287\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060601\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202289\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202301\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060582\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060597\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060598\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060590\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11430199\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12649\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12649|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/16/29958?source=related_link\">",
"      Nizatidine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/58/31652?source=related_link\">",
"      Nizatidine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_62_38886="Cyclophosphamide: Pediatric drug information";
var content_f37_62_38886=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyclophosphamide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"    see \"Cyclophosphamide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/25/6550?source=see_link\">",
"    see \"Cyclophosphamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F155456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Procytox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Alkylating Agent (Nitrogen Mustard)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"      see \"Cyclophosphamide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adults with no hematologic problems:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Induction:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral, I.V.: Children: 2-8 mg/kg or 60-250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 40-50 mg/kg (1.5-1.8 g/m",
"     <sup>",
"      2",
"     </sup>",
"     ) in divided doses over 2-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Children: 2-5 mg/kg or 50-150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Adults: 1-5 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 10-15 mg/kg (350-550 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) every 7-10 days or 3-5 mg/kg (110-185 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SLE: I.V.: 500-750 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every month; maximum dose: 1 g/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     JRA/vasculitis: I.V.: 10 mg/kg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BMT conditioning regimen: I.V.: 50 mg/kg/day once daily for 3-4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nephrotic syndrome: Oral: 2-3 mg/kg/day every day for up to 12 weeks when corticosteroids are unsuccessful",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;10 mL/minute: Administer 100% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;10 mL/minute: Administer 75% of normal dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 500 mg, 1 g, 2 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F155411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food only if GI distress occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: May administer IVP, I.V. intermittent, or continuous infusion at a final maximum concentration for administration of 20-25 mg/mL; usually administered as a single bolus dose or in fractionated doses over 2-3 days. Most protocols use a 30-60 minute infusion time; doses &gt;1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     need to be infused over a longer period (ie, 4- or 6-hour infusions)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F155516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amikacin, ampicillin, anidulafungin, aztreonam, bleomycin, cefazolin, cefepime, cefotaxime, cefoxitin, cefuroxime, chloramphenicol, chlorpromazine, cimetidine, cisplatin, cladribine, clindamycin, dexamethasone sodium phosphate, diphenhydramine, doripenem, doxorubicin, doxorubicin liposome, doxycycline, droperidol, erythromycin lactobionate, etoposide phosphate, famotidine, filgrastim, fludarabine, fluorouracil, furosemide, gallium nitrate, ganciclovir, gemcitabine, gentamicin, granisetron, heparin, hydromorphone, idarubicin, kanamycin, leucovorin calcium, linezolid, lorazepam, melphalan, methotrexate, methylprednisolone sodium succinate, metoclopramide, metronidazole, minocycline, mitomycin, morphine, nafcillin, ondansetron, oxacillin, oxaliplatin, paclitaxel, palonosetron, pemetrexed, penicillin G potassium, piperacillin, piperacillin/tazobactam, prochlorperazine edisylate, promethazine, propofol, ranitidine, sargramostim, sodium bicarbonate, sulfamethoxazole/trimethoprim, teniposide, thiotepa, ticarcillin/clavulanate, tobramycin, topotecan, vancomycin, vinblastine, vincristine, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstituted I.V. solution is stable for 24 hours at room temperature or 6 days if refrigerated",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Oncology:",
"     </b>",
"     Treatment of Hodgkin's lymphoma, non-Hodgkin's lymphoma (including Burkitt's lymphoma), chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), acute myelocytic leukemia (AML), acute lymphocytic leukemia (ALL), mycosis fungoides, multiple myeloma, neuroblastoma, retinoblastoma, breast cancer, ovarian adenocarcinoma [FDA approved in pediatrics (age not specified) and adults]; has also been used for Ewing's sarcoma, rhabdomyosarcoma, Wilms tumor, ovarian germ cell tumors, small cell lung cancer, testicular cancer, pheochromocytoma, bone marrow transplantation conditioning regimen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Nononcology:",
"     </b>",
"     Treatment of nephrotic syndrome in children [FDA approved in pediatrics (age not specified) and adults]; has also been used for severe rheumatoid disorders, Wegener's granulomatosis, myasthenia gravis, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, autoimmune hemolytic anemia, idiopathic thrombocytic purpura (ITP), and antibody-induced pure red cell aplasia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F155519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cyclophosphamide may be confused with cycloSPORINE, ifosfamide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cytoxan may be confused with cefOXitin, Ciloxan&reg;, cytarabine, CytoGam&reg;, Cytosar&reg;, Cytosar-U, Cytotec&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F155515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia (reversible; onset: 3-6 weeks after start of treatment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, azoospermia, gonadal suppression, oligospermia, oogenesis impaired, sterility",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, mucositis, nausea/vomiting (dose-related), stomatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Hemorrhagic cystitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia (dose-related; recovery: 7-10 days after cessation), myelosuppression, neutropenia, neutropenic fever, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute respiratory distress syndrome, anaphylactic reactions, anaphylaxis, arrhythmias (with high-dose [HSCT] therapy), bladder/urinary fibrosis, blurred vision, cardiac tamponade (with high-dose [HSCT] therapy), cardiotoxicity, confusion, dyspnea, ejection fraction decreased, erythema multiforme, gastrointestinal hemorrhage, hearing disorders, heart block, heart failure (with high-dose [HSCT] therapy), hematuria, hemopericardium, hemorrhagic colitis, hemorrhagic myocarditis (with high-dose [HSCT] therapy), hemorrhagic ureteritis, hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive liver disease), hepatitis, hepatotoxicity, hypersensitivity reactions, hyperuricemia, hypokalemia, hyponatremia, interstitial pneumonitis, interstitial pulmonary fibrosis (with high doses), jaundice, latent infection reactivation, mesenteric ischemia (acute), methemoglobinemia (with high-dose [HSCT] therapy), multiorgan failure, myocardial necrosis (with high-dose [HSCT] therapy), neurotoxicity, neutrophilic eccrine hidradenitis, ovarian fibrosis, pancreatitis, pericarditis, pigmentation changes (skin/fingernails), pneumonia, pulmonary hypertension, pulmonary infiltrates, pulmonary veno-occlusive disease, pyelonephritis, radiation recall, renal tubular necrosis, reversible posterior leukoencephalopathy syndrome (RPLS), rhabdomyolysis, secondary malignancy, septic shock, sepsis, SIADH, Stevens-Johnson syndrome, testicular atrophy, thrombocytopenia (immune mediated), thrombotic disorders (arterial and venous), toxic epidermal necrolysis, toxic megacolon, tumor lysis syndrome, wound healing impaired",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cyclophosphamide or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with bone marrow suppression and impaired renal or hepatic function; modify dosage in patients with renal impairment or compromised bone marrow function. Patients with compromised bone marrow function may require a 33% to 50% reduction in initial dose.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Cardiotoxicity has been reported, usually with high doses associated with transplant conditioning regimens, although may rarely occur with lower doses. Cardiac abnormalities do not appear to persist. Cardiotoxicities reported include arrhythmia, congestive heart failure, heart block, hemorrhagic myocarditis, hemopericardium (secondary to hemorrhagic myocarditis and myocardial necrosis), pericarditis, and tachyarrhythmias. Cardiotoxicity is related to endothelial capillary damage; symptoms may be managed with diuretics, ACE inhibitors, beta-blockers, or inotropics (Floyd, 2005). Use with caution in patients with pre-existing cardiovascular disease. For patients with multiple cardiac risk factors, consider monitoring during treatment (Floyd, 2005). Cyclophosphamide is associated with the development of hemorrhagic cystitis; may rarely be severe and even fatal. Discontinue cyclophosphamide with severe hemorrhagic cystitis. Bladder injury is due to excretion of cyclophosphamide metabolites in the urine and appears to be dose- and treatment duration-dependent. Bladder fibrosis may also occur, either with or without cystitis. Increased hydration and frequent voiding is recommended to help prevent cystitis; some protocols utilize mesna to protect against hemorrhagic cystitis. Monitor urinalysis for hematuria. Severe or prolonged hemorrhagic cystitis may require medical or surgical treatment. Hematuria generally resolves within a few days after treatment is withheld, although it may persist. Secondary malignancies (bladder cancer and myeloproliferative and lymphoproliferative malignancies) have been reported with both single-agent and combination chemotherapy regimens; onset may be delayed (up to several years after treatment). Bladder malignancy usually occurs in patients previously experiencing hemorrhagic cystitis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May impair fertility; interferes with oogenesis and spermatogenesis. Effect on fertility is generally dependent on dose and duration of treatment and may be irreversible. The age at treatment initiation and cumulative dose were determined to be risk factors for ovarian failure in cyclophosphamide use for the treatment of systemic lupus erythematosus (SLE) (Mok, 1998).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Nausea and vomiting commonly occur; premedication with antiemetics is recommended. Stomatitis/mucositis may also occur.  Anaphylactic reactions have been reported. Cross-sensitivity with other alkylating agents may occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Dose-related neutropenia is common; thrombocytopenia and anemia may also occur; immunosuppression and serious infections may occur; infections may require dose reduction or interruption or discontinuation of treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pulmonary toxicities, including pneumonitis and acute respiratory distress syndrome, have been reported. Consider pulmonary function testing to assess the severity of pneumonitis (Morgan, 2011). Cyclophosphamide-induced pneumonitis is rare and may present as early (within 1-6 months) or late onset (several months to years); early onset has been reversible with discontinuation; late onset is associated with pleural thickening and may persist chronically (Malik, 1996).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F155504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2A6 (minor), CYP2B6 (major), CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2B6 (weak/moderate), CYP2C9 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May enhance the adverse/toxic effect of Cyclophosphamide. Specifically, bone marrow suppression.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May enhance the adverse/toxic effect of Cyclophosphamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inducers (Strong): May increase the metabolism of CYP2B6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etanercept: May enhance the adverse/toxic effect of Cyclophosphamide. An increased risk of solid cancer development may be present.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentostatin: May enhance the cardiotoxic effect of Cyclophosphamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: Cyclophosphamide may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to succinylcholine in patients who have received cyclophosphamide in the past 10 days, or reduced succinylcholine doses (a serum pseudocholinesterase assay may help inform this reduction) with close monitoring.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F155422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13494887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Studies in pregnant women have demonstrated a risk to the fetus. Women of childbearing potential should avoid pregnancy while receiving cyclophosphamide treatment. Cyclophosphamide may also cause sterility in males and females (reversible in some cases). According to the National Comprehensive Cancer Network (NCCN) breast cancer guidelines (v.3.2012), chemotherapy, if indicated, may be administered to pregnant women with breast cancer as part of a combination chemotherapy regimen (common regimens administered during pregnancy include doxorubicin, cyclophosphamide, and fluorouracil); chemotherapy should not be administered during the first trimester, after 35 weeks gestation, or within 3 weeks of planned delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, ESR, BUN, urinalysis, serum electrolytes, serum creatinine, urine specific gravity, urine output",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with the normal function of DNA by alkylation and cross-linking the strands of DNA, and by possible protein modification",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 75% to 95% with low doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the placenta; appears in breast milk; distributes throughout the body including the brain and CSF, but not in concentrations high enough to treat meningeal leukemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 20%; metabolite: 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Inactive prodrug must undergo hydroxylation to form active alkylating mustards; further oxidation leads to formation of inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Range 3-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine as unchanged drug (&lt;20%) and as metabolites (85% to 90%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Moderately dialyzable (20% to 50%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/25/6550?source=see_link\">",
"      see \"Cyclophosphamide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintain high fluid intake and urine output. Report any difficulty or pain with urination, unusual bleeding or bruising, persistent fever or sore throat, blood in urine or stool, skin rash, or yellowing of skin or eyes. You may be more susceptible to infection; avoid crowds and unnecessary exposure to infection.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1046695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aggressive hydration using fluid containing at least 0.45% sodium chloride at 125 mL/m",
"     <sup>",
"      2",
"     </sup>",
"     /hour, frequent emptying of the bladder, and concurrent administration of mesna are used to reduce the potential of hemorrhagic cystitis (use mesna with cyclophosphamide doses &gt;1 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day; doses &le;1 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day may not require use of mesna)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Myelosuppressive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WBC: Moderate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Platelets: Moderate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset (days): 7",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nadir (days): 8-14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recovery (days): 21",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F155432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Liquid solutions or oral administration may be prepared by dissolving cyclophosphamide injection in Aromatic Elixir, N.F. Store refrigerated (in glass container) for up to 14 days.",
"    </p>",
"    <div class=\"reference\">",
"     Cyclophosphamide Prescribing Information, Baxter Healthcare Corporation, Deerfield, Il, April, 2012.",
"     <span class=\"pubmed-id\">",
"      20103616",
"     </span>",
"    </div>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 10 mg/mL oral suspension may be prepared by reconstituting one 2 g vial for injection with 100 mL of NaCl 0.9%, providing an initial concentration of 20 mg/mL. Mix this solution in a 1:1 ratio with either Simple Syrup, NF or Ora-Plus&reg; to obtain a final concentration of 10 mg/mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;.  Stable for 56 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Kennedy R, Groepper D, Tagen M, et al, \"Stability of Cyclophosphamide in Extemporaneous Oral Suspensions,\"",
"     <i>",
"      Ann Pharmacother",
"     </i>",
"     , 2010, 44(2):295-301.",
"     <span class=\"pubmed-id\">",
"      20103616",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bostrom BC, Weisdorf DJ, Kim TH, et al, &ldquo;Bone Marrow Transplantation for Advanced Acute Leukemia: A Pilot Study of High-Energy Total Body Irradiation, Cyclophosphamide and Continuous Infusion Etoposide,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 1990, 5(2):83-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/62/38886/abstract-text/2107007/pubmed\" id=\"2107007\" target=\"_blank\">",
"        2107007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCune WJ, Golbus J, Zeldes W, et al, &ldquo;Clinical and Immunologic Effects of Monthly Administration of Intravenous Cyclophosphamide in Severe Systemic Lupus Erythematosus,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(22):1423-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/62/38886/abstract-text/3259286 /pubmed\" id=\"3259286 \" target=\"_blank\">",
"        3259286",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13191 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_62_38886=[""].join("\n");
var outline_f37_62_38886=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155456\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046686\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046677\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155426\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155411\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046690\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155516\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046681\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046689\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155519\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155515\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046694\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046676\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046675\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155504\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155420\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155422\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13494887\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046685\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046674\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046693\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046683\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046695\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155432\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13191\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13191|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=related_link\">",
"      Cyclophosphamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/25/6550?source=related_link\">",
"      Cyclophosphamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_62_38887="Alcoholic steatohepatitis - medium power";
var content_f37_62_38887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Alcoholic steatohepatitis (medium power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In addition to fat-filled hepatocytes, some swollen hepatocytes contain Mallory's alcoholic hyaline. Scarring (blue) in areas of liver cell necrosis is prominent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_62_38887=[""].join("\n");
var outline_f37_62_38887=null;
var title_f37_62_38888="Differential diagnosis of anaphylaxis in children and adults";
var content_f37_62_38888=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Differential diagnosis of anaphylaxis in children and adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/62/38888/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/62/38888/contributors\">",
"     F Estelle R Simons, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/62/38888/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/62/38888/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/62/38888/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/62/38888/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/62/38888/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24666085\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death. The diagnosis of anaphylaxis may be readily apparent in patients with a clear history of exposure to a known or likely allergen in the minutes or few hours preceding onset of characteristic symptoms in several body systems. However, the symptoms and signs of anaphylaxis overlap with those of many other disorders, and diagnosis is not always easy to make [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disorders that may present with some similar symptoms and signs to anaphylaxis in children and adults will be reviewed here. The differential diagnosis of anaphylaxis in infants (ie, children under two years of age) and in pregnant women during labor and delivery is reviewed elsewhere. The rapid recognition and acute treatment of anaphylaxis are also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33625?source=see_link\">",
"     \"Unique aspects of anaphylaxis in infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/27/7610?source=see_link\">",
"     \"Anaphylaxis in pregnant and breastfeeding women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24666092\">",
"    <span class=\"h1\">",
"     CLINICAL DIAGNOSIS OF ANAPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of anaphylaxis is based on recognition of characteristic symptoms and signs occurring within minutes to a few hours after exposure to potential triggering agents or events. These symptoms potentially include itching, flushing, urticaria, angioedema, hoarseness, throat tightness, stridor, wheezing, coughing, shortness of breath, abdominal pain, vomiting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dizziness, collapse, or hypotension (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"mobipreview.htm?20/36/21068\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Involvement of body organ systems varies among patients and even in the same patient from one episode to another. However, review of anaphylaxis case series reveals some general patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin involvement is reported in up to 90 percent of episodes",
"     </li>",
"     <li>",
"      Respiratory tract involvement (up to 70 percent)",
"     </li>",
"     <li>",
"      Gastrointestinal tract involvement (up to 45 percent)",
"     </li>",
"     <li>",
"      Cardiovascular system involvement (up to 45 percent)",
"     </li>",
"     <li>",
"      Central nervous system (CNS) involvement (up to 15 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the patient is seen after resolution of the acute anaphylactic episode (eg, in the clinician's office weeks or months later) the relevant emergency medical services and emergency department records should be obtained and reviewed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24666099\">",
"    <span class=\"h1\">",
"     LABORATORY TESTS TO CONFIRM THE DIAGNOSIS OF ANAPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical history is the most important element in the evaluation. Sometimes, the diagnosis of anaphylaxis can be confirmed, or anaphylaxis can be distinguished from other disorders with similar symptoms, by demonstration of an elevated plasma histamine level or an elevated serum or plasma total tryptase level. Typically, elevations in plasma histamine occur within 5 to 15 minutes of the onset of anaphylaxis symptoms and then decline to baseline by 60 minutes due to rapid metabolism. Elevations in serum tryptase are somewhat slower and more prolonged. Serum for tryptase measurement should be obtained from 15 minutes to 3 hours of symptom onset. Tryptase elevations are more likely to be detected in anaphylaxis from stinging insect venoms or injected medications, and following anaphylaxis with hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Proper collection of samples for the measurement of plasma histamine and serum tryptase is described in the table (",
"    <a class=\"graphic graphic_table graphicRef72041 \" href=\"mobipreview.htm?21/8/21644\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Elevations of histamine or tryptase levels is not specific for anaphylaxis; for example, elevated histamine levels are found in scombroid poisoning, and elevated tryptase levels are found in myocardial infarction, mastocytosis and other clonal mast cell disorders, other hematologic disorders, and other diseases, but for some of these disorders, levels are chronically elevated whereas in anaphylaxis, follow-up testing days later will reveal normal levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histamine or tryptase levels that are within normal limits cannot be used to exclude or refute the clinical diagnosis of anaphylaxis. Tryptase levels are seldom elevated in patients with food-induced anaphylaxis, or in patients who remain normotensive during an anaphylactic episode. The interpretation of serum tryptase levels is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link\">",
"     \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24666106\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS OF ANAPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common disorders that mimic anaphylaxis include acute generalized urticaria, acute angioedema, acute asthma exacerbations, syncope (faint), and panic attacks or acute anxiety attacks (",
"    <a class=\"graphic graphic_table graphicRef65677 \" href=\"mobipreview.htm?40/61/41948\">",
"     table 3",
"    </a>",
"    ). Additionally, anaphylaxis may present as sudden collapse without cutaneous symptoms, and may be misdiagnosed as myocardial infarction or stroke in adults. Age-related entities in the differential diagnosis, including choking and foreign body aspiration, are important considerations particularly in infants and young children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33625?source=see_link\">",
"     \"Unique aspects of anaphylaxis in infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28982731\">",
"    <span class=\"h2\">",
"     Common disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24666113\">",
"    <span class=\"h3\">",
"     Acute generalized urticaria and/or angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden onset of generalized urticaria may be a symptom of anaphylaxis, or it may occur as an isolated problem. Urticaria, with or without angioedema, is limited to the skin and subcutaneous tissues. Anaphylaxis is typically characterized by involvement of one or more body system in addition to the skin. Therefore, the clinician should determine if symptoms and signs are present in the respiratory, gastrointestinal, or cardiovascular systems, as well as ascertaining the time elapsed between exposure to a likely or known trigger and the onset of initial symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21898?source=see_link\">",
"     \"New onset urticaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The various allergic and nonallergic disorders associated with angioedema are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38391?source=see_link\">",
"     \"An overview of angioedema: Pathogenesis and causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Typically, patients with nonallergic hereditary or acquired angioedema have intermittent episodes of swelling that are unilateral, not associated with itching or urticaria, and located in the deep cutaneous or mucosal tissues of the face, extremities, and genitalia. Patients with nonallergic angioedema can also present with edema of the tongue and larynx, leading to life-threatening asphyxia, or with edema of the bowel wall, leading to recurrent abdominal pain that varies in severity from mild discomfort to severe intractable pain accompanied by vomiting, diarrhea, and hypovolemic shock. In hereditary angioedema, complement (C4 and C2) levels are reduced during acute attacks, and C4 is persistently low. C1-esterase inhibitor is deficient or functionally absent in most patients with hereditary angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33864?source=see_link\">",
"     \"Hereditary angioedema: Pathogenesis and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=see_link\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24666127\">",
"    <span class=\"h3\">",
"     Asthma exacerbation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden onset of wheeze, cough, and shortness of breath may occur during anaphylaxis; or these symptoms may occur as an isolated problem. The diagnosis of anaphylaxis should be considered in any patient presenting with wheeze, cough, or shortness of breath within minutes or a few hours after exposure to a likely or known trigger for anaphylaxis; for example, food, medication, or insect sting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such patients should be asked about sudden onset of concurrent symptoms such as itching, flushing, urticaria, angioedema, hoarseness, throat tightness, abdominal pain, vomiting, diarrhea, dizziness, collapse, or hypotension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24666134\">",
"    <span class=\"h3\">",
"     Vasovagal syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasovagal syncope (faint) may be a symptom of anaphylaxis or may occur as an isolated problem. Typically, vasovagal syncope is associated with pallor, diaphoresis, weakness, nausea, vomiting, bradycardia, and if severe, by loss of consciousness, and is relieved by recumbency.",
"   </p>",
"   <p>",
"    Anaphylaxis, in contrast, is usually characterized by sudden onset of flushing rather than pallor, and other symptoms and signs that are not typically seen with vasovagal syncope, including sudden onset of itching, urticaria, angioedema, hoarseness, throat tightness, stridor, wheeze, cough, shortness of breath, crampy abdominal pain, or diarrhea. In anaphylaxis, tachycardia is more common than bradycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Information about the patient's propensity to syncope may be available. Patients with recurrent syncope require further evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36007?source=see_link\">",
"     \"Causes of syncope in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/52/9034?source=see_link\">",
"     \"Approach to the adult patient with syncope in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/9/5272?source=see_link\">",
"     \"Pathogenesis and etiology of syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24666141\">",
"    <span class=\"h3\">",
"     Panic attack/acute anxiety attack",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a panic attack or an acute anxiety attack, symptoms can include a sense of impending doom, breathlessness, flushing, sweating, trembling, palpitations, globus sensation (feeling of choking), gastrointestinal symptoms, \"feeling faint\", chest pain, and numbness or tingling of the extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In anaphylaxis, associated symptoms can include itching, urticaria, angioedema, hoarseness, throat tightness, stridor, wheezing, coughing, collapse,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypotension. These symptoms are unlikely during a panic attack or an acute anxiety attack [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/19/21814?source=see_link\">",
"     \"Globus sensation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28983746\">",
"    <span class=\"h3\">",
"     Other causes of sudden collapse",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28983754\">",
"    <span class=\"h4\">",
"     Myocardial infarction or stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis can also present as sudden collapse, without skin symptoms or signs, especially in middle-aged and older adults, hence the possibility for diagnostic confusion. To make this situation more complicated, elevated tryptase levels can be found in myocardial infarction as well as in anaphylaxis, making it difficult to distinguish these two diagnostic entities in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/2,4,8\">",
"     2,4,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28983761\">",
"    <span class=\"h3\">",
"     Other causes of acute respiratory distress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of sudden onset of respiratory distress include vocal cord dysfunction,",
"    <span class=\"nowrap\">",
"     choking/foreign",
"    </span>",
"    body aspiration, and epiglottitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4344978\">",
"    <span class=\"h4\">",
"     Vocal cord dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vocal cord dysfunction involves the involuntary, paradoxical adduction of the vocal cords during inspiration. Symptoms and signs include dyspnea, cough, inspiratory stridor, or expiratory wheezing. This disorder is most common in young women, although it has been reported in adults and children of both sexes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In a symptomatic patient, direct observation of the adducted vocal cords by laryngoscopy is diagnostic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16567?source=see_link\">",
"     \"Paradoxical vocal cord motion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Useful clues to the diagnosis of vocal cord dysfunction are obstruction to airflow that is present during both inspiration and expiration, characteristically abnormal inspiratory portions of flow volume loops on pulmonary function testing suggestive of variable extrathoracic obstruction, and absence of uvular edema. In anaphylaxis, laryngeal edema is characterized by inspiratory stridor and is often associated with uvular edema. In asthma, expiratory noises are prominent and are more audible over the chest than over the neck.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Choking/foreign",
"    </span>",
"    body aspiration and epiglottitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33625?source=see_link\">",
"     \"Unique aspects of anaphylaxis in infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/36/35399?source=see_link\">",
"     \"Airway foreign bodies in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4345088\">",
"    <span class=\"h3\">",
"     Other forms of shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shock is characterized by a significant systemic reduction in tissue perfusion, resulting in decreased tissue oxygen delivery. There are four broad mechanisms associated with shock: hypovolemic, cardiogenic, distributive (which can be due to anaphylaxis or spinal cord injury), and septic (which involves hypovolemic, cardiogenic, and distributive mechanisms). The approach to a patient presenting with apparent shock is reviewed elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14104?source=see_link\">",
"     \"Initial evaluation of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284797902\">",
"    <span class=\"h2\">",
"     Flushing disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flushing is defined as a sensation of warmth, accompanied by a visible reddening of the skin. Typically, it is prominent in the classic blush area that includes the face, neck, upper portion of the chest, and upper limbs. Pathologic flushing is a common symptom of anaphylaxis. It may also be a prominent symptom during menopause and may occur after the administration of certain medications, after the ingestion of alcohol (ethanol), and in association with several uncommon tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284797909\">",
"    <span class=\"h3\">",
"     Menopause",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peri-menopausal state is commonly associated with brief episodes of flushing that last less than five minutes. Perimenopausal flushing is not associated with urticaria, angioedema, itching, or significant hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284797916\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications associated with flushing are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12857?source=see_link&amp;anchor=H12#H12\">",
"     \"Approach to flushing in adults\", section on 'Medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284797923\">",
"    <span class=\"h3\">",
"     Alcohol (ethanol)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some people are susceptible to flushing after ingestion of alcoholic beverages, because of genetic variations in the enzyme alcohol dehydrogenase, Hodgkin's disease or other malignancies, hypereosinophilic syndromes, or adverse reactions to other ingredients in alcoholic beverages (eg, histamine or metabisulfites). In addition, ethanol can also amplify food-induced anaphylaxis by increasing the rate of intestinal absorption of food allergens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/11-15\">",
"     11-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ethanol-induced flushing can be potentiated by certain medications. These include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    , cephalosporins,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/17/5397?source=see_link\">",
"     disulfiram",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/61/6102?source=see_link\">",
"     griseofulvin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/43/34485?source=see_link\">",
"     phentolamine",
"    </a>",
"    , niacin, and topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/11,16\">",
"     11,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284797930\">",
"    <span class=\"h3\">",
"     Tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid tumors, gastrointestinal tumors, medullary carcinoma of the thyroid, renal cell carcinoma, and pancreatic carcinoma can present with flushing. Some of these tumors will be described in more detail below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Carcinoid tumors",
"      </strong>",
"      - Carcinoid syndrome refers to a constellation of symptoms mediated by the serotonin, substance P, and other vasoactive substances released by some carcinoid tumors (eg, those in the small bowel, appendix, and colon). Episodic flushing occurs in most patients, typically affecting the face, neck, and upper chest. The areas become red to violaceous or purple, and there may be a mild burning sensation in the discolored skin (",
"      <a class=\"graphic graphic_picture graphicRef55493 \" href=\"mobipreview.htm?15/40/16000\">",
"       picture 1",
"      </a>",
"      ). Flushing episodes begin suddenly and last 20 to 30 seconds, although they may become more prolonged over time. Diarrhea is also a common symptom. Wheezing can occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/11,17\">",
"       11,17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If carcinoid syndrome is suspected, plasma serotonin or 24-hour urinary excretion of the serotonin metabolite 5-hydroxyindoleacetic acid (HIAA) should be measured while the patient avoids foods that have high levels of serotonin and tryptophan. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=see_link\">",
"       \"Clinical features of the carcinoid syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis of the carcinoid syndrome and tumor localization\", section on 'Biochemical testing for the carcinoid syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Gastrointestinal tumors",
"      </strong>",
"      - Gastrointestinal tumors producing vasoactive intestinal polypeptide (VIPomas) or substance P are extremely rare. Most patients have watery diarrhea, hypokalemia, and hypochlorhydria, and a minority (20 percent) experience associated flushing episodes. Measurement of serum VIP or substance P is helpful in diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16311?source=see_link\">",
"       \"The VIPoma syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Medullary carcinoma of the thyroid",
"      </strong>",
"      - This carcinoma usually presents as a solitary thyroid nodule in a middle-aged adult. Facial flushing and diarrhea can occur in advanced disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9560?source=see_link\">",
"       \"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28983407\">",
"    <span class=\"h2\">",
"     Post-prandial syndromes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28983415\">",
"    <span class=\"h3\">",
"     Scombroidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scombroid syndrome, also called histamine fish poisoning, occurs within 15 to 90 minutes of eating spoiled fish such as tuna, mackerel, saury, mahi mahi, sardines, anchovies, herring, and others. It is characterized by acute onset of flushing, headache, nausea, vomiting, diarrhea, abdominal pain, dysphagia, palpitations, dizziness, and hypotension after ingestion. Urticaria and itching are uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms are due, at least in part, to elevated levels of histamine in the fish. The histamine production occurs under conditions of inadequate refrigeration or preservation, when bacterial decomposition in the musculature of the fish leads to decarboxylation of the amino acid L-histidine to histamine. Additional compounds might be responsible for the symptoms, because ingestion of large oral doses of histamine does not reproduce the syndrome. Cooking the fish does not reduce the histamine content. Clustering of cases (ie, several people developing similar symptoms after eating the same fish meal) is consistent with the diagnosis of scombroidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasma histamine levels are acutely elevated in scombroidosis but serum tryptase levels are not. Either plasma histamine or serum tryptase levels, or both, are elevated in some patients with anaphylaxis triggered by fish. These two disorders can be further distinguished by skin tests and measurement of serum specific IgE levels to the fish implicated by the history. In fish allergy, these tests are positive, whereas in scombroidosis, sensitization to fish is not typical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/61/16346?source=see_link\">",
"     \"Seafood allergies: Fish and shellfish\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28983429\">",
"    <span class=\"h3\">",
"     Anisakiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, anisakiasis has been included in the differential diagnosis of anaphylaxis; however, anaphylaxis can be triggered by an immediate hypersensitivity reaction to the fish parasite Anisakis simplex. Such patients have typically ingested raw or undercooked saltwater fish, for example, marinated anchovies, a few hours before symptom onset; however, the delay between ingestion and symptoms may be as long as 24 hours. They have positive skin tests and elevated serum IgE levels to the fish parasite Anisakis simplex. The major allergen in this parasite was identified as Ani s 7 in 2007. Skin prick tests and specific IgE antibody levels to the ingested fish are typically negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/61/16346?source=see_link\">",
"     \"Seafood allergies: Fish and shellfish\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/8/44168?source=see_link&amp;anchor=H8121222#H8121222\">",
"     \"Miscellaneous nematodes\", section on 'Anisakiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4345207\">",
"    <span class=\"h3\">",
"     Pollen-food allergy syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pollen food syndrome, also known as oral allergy syndrome, is elicited by fresh fruits and vegetables containing various plant proteins that cross-react with airborne allergens, such as birch tree and ragweed pollen. Typical symptoms include itching, tingling, and angioedema of the lips, tongue, palate, throat, and ears after eating raw, but not cooked, fruits and vegetables [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11082?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28983436\">",
"    <span class=\"h3\">",
"     Sulfites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ingestion or food or beverages containing sulfites can cause significant asthmatic reactions in patients with asthma, and there are rare reports of anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40681?source=see_link&amp;anchor=H15#H15\">",
"     \"Allergic and asthmatic reactions to food additives\", section on 'Sulfites'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28983443\">",
"    <span class=\"h3\">",
"     Food poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, anaphylaxis was often diagnosed as \"food poisoning\", for example \"egg poisoning.\" However, modern use of the term food poisoning refers to a nonallergic acute illness caused by microorganisms or microbial toxins in food. Food poisoning may present with vomiting, crampy abdominal pain, and diarrhea within a few hours of ingesting a meal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16426?source=see_link\">",
"     \"Food poisoning in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/44/24265?source=see_link\">",
"     \"Differential diagnosis of microbial foodborne disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Signs and symptoms of food poisoning are usually limited to the gastrointestinal tract. In contrast, the gastrointestinal symptoms of anaphylaxis are typically accompanied by symptoms in at least one other body organ system such as itching, flushing, urticaria, angioedema, hoarseness, throat tightness, stridor, wheeze, cough, shortness of breath, dizziness, collapse, or hypotension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28983450\">",
"    <span class=\"h2\">",
"     Excess histamine syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syndromes characterized by excessive endogenous overproduction of histamine include mast cell disorders, other clonal disorders of mast cells, certain forms of leukemia, and hydatid cysts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28983458\">",
"    <span class=\"h3\">",
"     Mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastocytosis refers to a group of disorders characterized by excessive mast cell proliferation and accumulation of these cells in one or multiple tissues. In these disorders, anaphylaxis can result from IgE-dependent mechanisms (eg, insect stings), other immunologic mechanisms that do not involve IgE, or nonimmunologic mechanisms (eg, direct mast cell stimulation after exposure to extremely cold air or water) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with mastocytosis may have both transient elevations and baseline elevations of serum total tryptase, in addition to histamine elevations. Mast cell disorders are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28983465\">",
"    <span class=\"h3\">",
"     Other clonal disorders of mast cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients who do not fully meet diagnostic criteria for mastocytosis may have an aberrant mast cell population with clonal markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=see_link&amp;anchor=H31#H31\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\", section on 'Disorders with similar clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28983472\">",
"    <span class=\"h3\">",
"     Certain forms of leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be an overproduction of histamine-containing cells in basophilic leukemia and acute promyelocytic leukemia in patients receiving treatment with tretinoin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28983479\">",
"    <span class=\"h3\">",
"     Hydatid cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial infection with the cestode",
"    <em>",
"     Echinococcus multilocularis",
"    </em>",
"    is asymptomatic. Typically, infections are latent for decades before symptoms develop due to the mass of cystic lesions within lung, liver, or other organs, leading to obstruction of blood flow or lymphatic flow, or to other complications. Cyst rupture, either spontaneously or during a surgical procedure to reduce the cystic mass, can result in fever and symptoms resembling those of an anaphylactic episode; these symptoms are due to the release of cyst contents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/3\">",
"     3",
"    </a>",
"    ]. New case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/27,28\">",
"     27,28",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28025?source=see_link\">",
"     \"Clinical manifestations and diagnosis of echinococcosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24666320\">",
"    <span class=\"h2\">",
"     Rare disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24666328\">",
"    <span class=\"h3\">",
"     Pheochromocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pheochromocytomas are catecholamine-secreting tumors arising from the adrenal medulla, and associated with the classic symptom triad of episodic headache, sweating, and tachycardia. Hypertension is characteristic, although paradoxical hypotension has been reported. Pallor during attacks is more common than flushing. Initial testing in patients with suggestive symptoms includes 24-hour urine assays for total and fractionated metanephrines, vanillylmandelic acid, and catecholamines, plasma levels of catecholamines and free metanephrines, and CT and MRI imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/11,29\">",
"     11,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24666335\">",
"    <span class=\"h3\">",
"     Capillary leak syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic systemic capillary leak syndrome is a rare, often fatal disease, characterized by recurrent episodes of angioedema, gastrointestinal symptoms, and shock with hemoconcentration, usually associated with a monoclonal gammopathy. The diagnosis is suggested by an elevated hematocrit during an episode of hypotension and treatment involves aggressive fluid resuscitation and supportive care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/426?source=see_link\">",
"     \"Idiopathic systemic capillary leak syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4345430\">",
"    <span class=\"h2\">",
"     Other nonorganic disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4345437\">",
"    <span class=\"h3\">",
"     Munchausen stridor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some individuals with Munchausen syndrome (in which the patient consciously and voluntarily produces physical symptoms of illness for secondary gain) have a similar presentation to those with vocal cord dysfunction; however, they are usually able to adduct their vocal cords voluntarily and they can be distracted by requests to perform maneuvers such as coughing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16567?source=see_link&amp;anchor=H10#H10\">",
"     \"Paradoxical vocal cord motion\", section on 'Presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Munchausen anaphylaxis is induced when the patient consciously self-triggers anaphylaxis; for example, by knowingly ingesting a food or medication to which he or she is sensitized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7512?source=see_link\">",
"     \"Factitious disorder and Munchausen syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4345444\">",
"    <span class=\"h3\">",
"     Undifferentiated somatiform anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with this disorder present with symptoms, such as throat closure, shortness of breath, and syncope; however, there are no objective signs of anaphylaxis; for example, no evidence of upper or lower airway obstruction or hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38888/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24666342\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaphylaxis can potentially present with different permutations and combinations of more than 40 symptoms and signs. The presentation can vary from patient to patient, and in the same patient from one episode to another (",
"      <a class=\"graphic graphic_table graphicRef66333 \" href=\"mobipreview.htm?20/36/21068\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24666092\">",
"       'Clinical diagnosis of anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical diagnosis of anaphylaxis is sometimes supported by the demonstration of typically transiently elevated levels of mast cell mediators such as histamine or tryptase. These elevated levels are not specific for anaphylaxis, and test results that are within normal limits cannot be used to exclude or refute the clinical diagnosis of anaphylaxis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link\">",
"       \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The symptoms and signs of anaphylaxis overlap with those of many other disorders (",
"      <a class=\"graphic graphic_table graphicRef65677 \" href=\"mobipreview.htm?40/61/41948\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24666106\">",
"       'Differential diagnosis of anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common disorders that mimic anaphylaxis include acute generalized urticaria, acute angioedema, acute asthma, syncope (faint), and panic attacks or acute anxiety attacks. (See",
"      <a class=\"local\" href=\"#H28982731\">",
"       'Common disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Age-related disorders that are important in the differential diagnosis include myocardial infarction or stroke, especially in middle-aged or elderly adults, and choking from aspiration of a foreign body, especially in children. (See",
"      <a class=\"local\" href=\"#H28983746\">",
"       'Other causes of sudden collapse'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28983761\">",
"       'Other causes of acute respiratory distress'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the patient presenting with hypotension and shock, anaphylaxis must be differentiated from other forms of shock (hypovolemic, cardiogenic, distributive, and septic). (See",
"      <a class=\"local\" href=\"#H4345088\">",
"       'Other forms of shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Flushing can be seen with a variety of medications, as well as in response to alcohol ingestion or the combination of alcohol and certain medications. Several uncommon tumors are also associated with flushing. (See",
"      <a class=\"local\" href=\"#H284797902\">",
"       'Flushing disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Post-prandial reactions include scombroidosis, anisakiasis, pollen-food allergy syndrome, reactions to sulfites, and microbial food poisoning. (See",
"      <a class=\"local\" href=\"#H28983407\">",
"       'Post-prandial syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with disorders that involve excessive production of endogenous histamine can experience episodic symptoms that resemble allergic reactions and anaphylaxis. Such disorders include mastocytosis and other mast cell disorders, certain forms of leukemia, and rupture of hydatid cysts. (See",
"      <a class=\"local\" href=\"#H28983450\">",
"       'Excess histamine syndromes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/1\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/2\">",
"      Simons FE. Anaphylaxis. J Allergy Clin Immunol 2010; 125:S161.",
"     </a>",
"    </li>",
"    <li>",
"     Lieberman PL. Anaphylaxis. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF Jr, Bochner BS, Busse WW, et al (Eds), Mosby, St. Louis 2009. p.1027.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/4\">",
"      Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 2007; 120:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/5\">",
"      Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 2008; 359:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/6\">",
"      Levy JH, Freiberger DJ, Roback J. Hereditary angioedema: current and emerging treatment options. Anesth Analg 2010; 110:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/7\">",
"      Harar RP, Kumar S, Saeed MA, Gatland DJ. Management of globus pharyngeus: review of 699 cases. J Laryngol Otol 2004; 118:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/8\">",
"      Triggiani M, Patella V, Staiano RI, et al. Allergy and the cardiovascular system. Clin Exp Immunol 2008; 153 Suppl 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/9\">",
"      Noyes BE, Kemp JS. Vocal cord dysfunction in children. Paediatr Respir Rev 2007; 8:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/10\">",
"      Bahrainwala AH, Simon MR. Wheezing and vocal cord dysfunction mimicking asthma. Curr Opin Pulm Med 2001; 7:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/11\">",
"      Izikson L, English JC 3rd, Zirwas MJ. The flushing patient: differential diagnosis, workup, and treatment. J Am Acad Dermatol 2006; 55:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/12\">",
"      Vally H, Thompson PJ. Allergic and asthmatic reactions to alcoholic drinks. Addict Biol 2003; 8:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/13\">",
"      Knight AK, Boxer M, Chandler MJ. Alcohol-induced rash caused by topical tacrolimus. Ann Allergy Asthma Immunol 2005; 95:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/14\">",
"      L&uuml;bbe J, Milingou M. Images in clinical medicine. Tacrolimus ointment, alcohol, and facial flushing. N Engl J Med 2004; 351:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/15\">",
"      Geha RS, Beiser A, Ren C, et al. Multicenter, double-blind, placebo-controlled, multiple-challenge evaluation of reported reactions to monosodium glutamate. J Allergy Clin Immunol 2000; 106:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/16\">",
"      Mooney E. The flushing patient. Int J Dermatol 1985; 24:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/17\">",
"      Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/18\">",
"      Becker K, Southwick K, Reardon J, et al. Histamine poisoning associated with eating tuna burgers. JAMA 2001; 285:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/19\">",
"      Ricci G, Zannoni M, Cigolini D, et al. Tryptase serum level as a possible indicator of scombroid syndrome. Clin Toxicol (Phila) 2010; 48:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/20\">",
"      AAITO-IFIACI Anisakis Consortium. Anisakis hypersensitivity in Italy: prevalence and clinical features: a multicenter study. Allergy 2011; 66:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/21\">",
"      Rodr&iacute;guez E, Anad&oacute;n AM, Garc&iacute;a-Bodas E, et al. Novel sequences and epitopes of diagnostic value derived from the Anisakis simplex Ani s 7 major allergen. Allergy 2008; 63:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/22\">",
"      Webber CM, England RW. Oral allergy syndrome: a clinical, diagnostic, and therapeutic challenge. Ann Allergy Asthma Immunol 2010; 104:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/23\">",
"      Greenberger PA. Idiopathic anaphylaxis. Immunol Allergy Clin North Am 2007; 27:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/24\">",
"      Brockow K, Ring J. Update on diagnosis and treatment of mastocytosis. Curr Allergy Asthma Rep 2011; 11:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/25\">",
"      Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol 2010; 126:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/26\">",
"      Koike T, Tatewaki W, Aoki A, et al. Brief report: severe symptoms of hyperhistaminemia after the treatment of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1992; 327:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/27\">",
"      De Wispelaere L, Vande Velde S, Schelstraete P, et al. Anaphylactic shock as a single presentation of Echinococcus cyst. Acta Gastroenterol Belg 2011; 74:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/28\">",
"      Castanares-Zapatero D, Laterre PF. Ruptured hydatid cyst in a patient with shock. Hepatobiliary Pancreat Dis Int 2009; 8:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/29\">",
"      Ueda T, Oka N, Matsumoto A, et al. Pheochromocytoma presenting as recurrent hypotension and syncope. Intern Med 2005; 44:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/30\">",
"      Druey KM, Greipp PR. Narrative review: the systemic capillary leak syndrome. Ann Intern Med 2010; 153:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38888/abstract/31\">",
"      Dowden AM, Rullo OJ, Aziz N, et al. Idiopathic systemic capillary leak syndrome: novel therapy for acute attacks. J Allergy Clin Immunol 2009; 124:1111.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 395 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-0E8BE10A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_62_38888=[""].join("\n");
var outline_f37_62_38888=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24666342\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24666085\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24666092\">",
"      CLINICAL DIAGNOSIS OF ANAPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24666099\">",
"      LABORATORY TESTS TO CONFIRM THE DIAGNOSIS OF ANAPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24666106\">",
"      DIFFERENTIAL DIAGNOSIS OF ANAPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28982731\">",
"      Common disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24666113\">",
"      - Acute generalized urticaria and/or angioedema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24666127\">",
"      - Asthma exacerbation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24666134\">",
"      - Vasovagal syncope",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24666141\">",
"      - Panic attack/acute anxiety attack",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28983746\">",
"      - Other causes of sudden collapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28983754\">",
"      Myocardial infarction or stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28983761\">",
"      - Other causes of acute respiratory distress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4344978\">",
"      Vocal cord dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4345088\">",
"      - Other forms of shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H284797902\">",
"      Flushing disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H284797909\">",
"      - Menopause",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H284797916\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H284797923\">",
"      - Alcohol (ethanol)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H284797930\">",
"      - Tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28983407\">",
"      Post-prandial syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28983415\">",
"      - Scombroidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28983429\">",
"      - Anisakiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4345207\">",
"      - Pollen-food allergy syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28983436\">",
"      - Sulfites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28983443\">",
"      - Food poisoning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28983450\">",
"      Excess histamine syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28983458\">",
"      - Mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28983465\">",
"      - Other clonal disorders of mast cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28983472\">",
"      - Certain forms of leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28983479\">",
"      - Hydatid cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24666320\">",
"      Rare disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24666328\">",
"      - Pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24666335\">",
"      - Capillary leak syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4345430\">",
"      Other nonorganic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4345437\">",
"      - Munchausen stridor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4345444\">",
"      - Undifferentiated somatiform anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24666342\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/395\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/395|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/40/16000\" title=\"picture 1\">",
"      Carcinoid flush",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/395|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/36/21068\" title=\"table 1\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/8/21644\" title=\"table 2\">",
"      Tryptase and histamine collection instructions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/61/41948\" title=\"table 3\">",
"      Differential diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/36/35399?source=related_link\">",
"      Airway foreign bodies in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40681?source=related_link\">",
"      Allergic and asthmatic reactions to food additives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/27/7610?source=related_link\">",
"      Anaphylaxis in pregnant and breastfeeding women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12857?source=related_link\">",
"      Approach to flushing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/52/9034?source=related_link\">",
"      Approach to the adult patient with syncope in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36007?source=related_link\">",
"      Causes of syncope in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28025?source=related_link\">",
"      Clinical manifestations and diagnosis of echinococcosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11082?source=related_link\">",
"      Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=related_link\">",
"      Diagnosis of the carcinoid syndrome and tumor localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/44/24265?source=related_link\">",
"      Differential diagnosis of microbial foodborne disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=related_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=related_link\">",
"      Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7512?source=related_link\">",
"      Factitious disorder and Munchausen syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16426?source=related_link\">",
"      Food poisoning in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/19/21814?source=related_link\">",
"      Globus sensation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33864?source=related_link\">",
"      Hereditary angioedema: Pathogenesis and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/426?source=related_link\">",
"      Idiopathic systemic capillary leak syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14104?source=related_link\">",
"      Initial evaluation of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9560?source=related_link\">",
"      Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/8/44168?source=related_link\">",
"      Miscellaneous nematodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/9/5272?source=related_link\">",
"      Pathogenesis and etiology of syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/61/16346?source=related_link\">",
"      Seafood allergies: Fish and shellfish",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16311?source=related_link\">",
"      The VIPoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33625?source=related_link\">",
"      Unique aspects of anaphylaxis in infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_62_38889="Warfarin-induced skin necrosis on thighs";
var content_f37_62_38889=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51999%7EDERM%2F62792%7EHEME%2F80462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51999%7EDERM%2F62792%7EHEME%2F80462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Warfarin-induced skin necrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sharply demarcated, purpuric lesions are present on the thighs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Warfarin-induced skin necrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5mooFKO9SISiijtxTAKKB70opAJRRRTAKKKMUAFFGKCMUAFFFFABRRRQAUUUuaAEpQaDSUAApaKKADvSjikxTsUCFBpwpoFOxzVCFzSUppKAFpG7EdKKUdaAEI4HBpc/WkOQcUUrgHelyKSii4B19RRmiikgDvntQT9aKKoA4ooNFK4BSU48dKbzzTuAUUD1pfxpXASiiihMYUlLQe4ouAh60Z6cUooo3ASig0UgCkJpaKLgID7UtFIaADNIaWjFACCilpKBhQD2NFFACk0UlFACYxSZpeaSkAUd6KKYBRmiigAzQaKDQAUtJS0gEooopgFLikpaQBijFFFABikpaQ9aADNGaXr0pMUwFoozRQAo60vegcUo/WgQtKM96QUtAgJooopsAoBooGM8ikAdWzRSDGTxS00AUUYop6AFFFH1FSAUUUUAFB+lFLx6UIBuaPpRigcUMAooo7U+gwooxRSAKTNLQaAE5ozRjmjFABSYpaMigApM0vHYUlAC0maXj0pKADNApKKAFNIaKKBgaDRRQAUUGigBuaOtLRQAgoxS0UAIaKU0mKAAUHrS0UAJRS0mKACiiigAooooAWikxRikA7rTT1oNHNACjil60lFAAaUdKQU6mAoFKBSCl9KBC4ooHSigQUUGigAooooABRRRmgBaTNHeigAooo7UAFFH5UdeKAD0oNFH5UAHakNO4pKBiUCiigBaSij8aGgCikPWjtQAvekzRS9qAEooooAKKKKACkpT0ptAC0UtIfeiwCUU7FGDzinYY2inBGI6Uoic9BSsK4yipltpSelFFmFyCiiigYUUUUAFFFFABRRiigAooooAKO1FFAB+FFHNFABRRR2oAKMUUUAFA60CloAAKcBSCloAX2pcUlGaBBjmlxjpSe9KG9qADGetHFHWigQUUUe1AABnmjt6UopDQAUUUD1oAUjFJRyetFABR3oooAKCKUUnrQAmKMUvWgn0oGJj2owMUvJpyozcKpP4UAM+lJjrVhLWZiQqGp49MuGPQCgCiAaCK100Sdup4PtVlPD0hIySf0p2Hys540CukXQAGw2cj1qZNAyMlRikPkkcrg54BpVRicBT+VdgNE2feC9fxqwNKULgxhcd6VylSkcUIZCeENOW2lJxtrtUsIgwyAKl+wR9cc07otUG9ziVsZm7VKmlSN1OK7VdPQseOcdBT2sihyqAL3ouh+wZxq6Xzhm/WpV0tAM7SwrrTZKi7mUZoa1DfNsHPvVN6B7E5hNNTj93zUgsFGSIua6IQCP5QuPwzUghGMbPmNJMapGAung/wgH0qUaeNrHaML15xW2tmA5OcEDOKc0K9WjGPVhzT5h+yRhLYE/cXGfWitpoy5yoAAHY0UcwezPMqKKKk5gooooAKAcUUUAGaXNJRQAtFJmlFABRjmiigAoFFFAAaMUUUABooooAKUUlKKAFoBoooELRRRQAZNAopaACigdKKACigd6UUAJS0nenYJ6A/hQAlJip0tp3PyxtVmLSbuRVYRnB74oHysz6MVuL4dueC4wPar1r4XZyNwkOenGBQUqcmcqKUAnsfyruLfwrEuN69e+e/0rRt/DluuAySNjrsA/rQUqLZ50kEr/dRj+FWYtLupCAqY+or0qDR4lJCwt1wMkVcg0gk7WCrt7ZA/WgtUDzWLw/cMcMCufUYrQg8NMfvg575r0qPTFD4JBUc8HNWV00H5VjjA7gt/SixXsEeeQeG4lKh8Z/u9TWknh9AP9TwO+a7P7DEisGClumAeaFskXAVdy+haixoqKORXRkUAhMY689asRaUu7JGMnB711wsFCqGjwTyMnP9KYLNUckpn8MClfUtUkc1/ZaA437fTPQ1INNCjnG4dua6OaNI0DtsKA4yKrh0IGwDnjrzRfUfszFWyAyWHT15pTZAsCFOO2RityKJGyzIuB/eNNaEfMVVR9c4NIORGEbUE438A4qb7EuQylfzrSFsDnztpyOMDg0ihI1ACEE/dFA3G+xjtYqWyGyD3xUkOmxqMghvx/pWrnCnMZUjjoKFOY8mMH0OP60XBRM17NUbACimvZnAyM+mO9X5SndWZvfmmlwiqFQqc4oK5THlszyQoPsO9QNCYiWUAkfwkVsyy4kIGRn1BxVYKvGSORmmJ+RmiLc2XHHoOKcwAJEbEE9sZq+Y855J/ColjeUAiRQuOmKYrXKyfK3zOGI654xRK6FuW4Ix1zmr0tlH1WTOenHQ1Te2BV9/ODgFelIEkROqAKBu247UVMkDBfkw2R2FFUhOKPIqKKKR5wUUUUAFFFFABRRSjnrQAdqSlFGKAAUUUUAFFLSUAFLSUtAABRilooATFLiinBTkYBP4UCGilqaO2mb7qH8asw6XcykAKP1oHZlAc9qMc4zW9F4buWIDhlB7kVZh8NEEB1Yn0z1o0Gqcn0OYGM4p6qWICqSfSuyh8PBX/wBSCw/Ktaz8OxTSxmZ/KBOGcKTtH0o0NFQmedrazN0jIqzFpVxIRwBmvSIdBjjbBXcM9SOtWl0xd3KJx0zz+lTc0WGfU88h8OXDHBP6Veh8MHcd53CvQo9PidQzhRt4IAxVj7DArEhcgjjtRc0WGRwsXhqNMHyxsPc1ej0KBSAqLnH8OK7E2gKbVgU59SKRdPmfGU47bRS5jWOHRzsejxKgIUAj15q5Bp/CqsZ55GK3obFvLJQsCvGzvTltVDAOWRhySTk/hTv1KVJGXHY4ceYqADnp1p0enqmVUkr1JOTWusMSsFG5COcucmn7Uc8yM2ODlOMUrj9mUYtPyy7JHJIz9zH61MliWZvnPXkFeRV3DkrteRkAwo29vzqOctjJZgQOTyCfbimNU7lI2S+aPNKq2MfMCFx6jjrViG2xGMLgHoxTjH5UW80sjZ2ggNhQWx+Rq26Tldsznb1A35UUrl+ytoNWFo2ODEhHqaC4DEOR74TqfrTlGQAGiUKcYI6mkna0QfeLyd9o4ovcFDuhjbScoE83HCheabHFKrgtJEGJwcMePwqORpAoEUSp7kc496kie7DYRmOMANtppmig+hOIBJhY1Z26Hy8jNRNEICfNPTu/J+nWmXMM5IlZpAehduBVadeQzFGwOSvSpuCpDpsycKXfnIWNcYqsUlU4kJGOoJx+NToqunzSSYP90EUJCGQlE69Dyc/nUSlcpQtoMThioUSDGc9jT5Gd4QAsESjrtNIFQkBhIo92x+lPeOOLg4Y47n+lNMHTuxrAy4JmjVR7nBqeS2R0UK8YYHjBpI5lVVC5+XnkcUskzFhu2gdcBaq5k6bexWliK/eZQo6+9R5V1+Q7sHpjFWw6NuDruH0qNkQt8nmDjNFw5GVmVyVG0jPXmmzGRMqwJ+pq2CsYDCPcvcetBUtGMKv4GqIaZkyfL97IznvUKNu4VAoPHIrVe0jkwH+XHOc9KY9nGvSQbRQJJGdujSLa6rg9zQphZcq4Dk49RVmSEZwPmPY7arNFIhLqygnjBWglxJJHWFcFuccHHWod4kIwY1HTJOP50xmuQuGSMj69Krs8o6JCQeCMZpk2sTuBG2BchAeu05oqBZZ05FshHYkAYoouKx49RS7T6UbT6Gg84KQ07a3900bGz904oAbRTtjZ6Gl8tu4NMBlKaUoQaUKTQA0UVKsLt0BNPS0lYgFSPwoCxXpavJp77vm4/GrMWlqSN5b6AZoK5WZGDSgMegJ+grprbSoSPmjlOfTiro0lQMrGo465OaVylSkzkEt5X6Ianj064cZWMjAzzXYwaWuQQ3lkdTtrQt9Jjzl5S3c4WlzGqwzOJi0SdioYhcjdyeMVeg8Pjdy28gZ+U5FdkmkRBxsBOB3/AJVci00MAyhAfRV9KOY2jhO5yNv4eDhWWEHHTAxWlb6H5ZCvHEremcmupS32KF8xyFOdhHepY7YluINxPelzmiwyRhRaQF+XI5/ugCrqaUFeM4jUt7nitqKybODEAD1IbNTrpzg/dCr70uZmiopGQNMKYI8t+eTk4qaDTlaRRvjDdQBWq2nhfukAdMbqelgVb7q7j0Ctii5oqNzOi05i2dxbJ6AVbFiUbBQKDwFK1pC0dFX7yDtu5GaUhlYq0xZj220rlqmUlswob9w4bH8J7Uot9sR+QDHGCOTWvaqRHtMR6d+9Suqk/vkkUjHPWlcrksY/2fjPl4z7/wBKjhg2t+9IKgcZOK15Gj6LG3tx1p62sRi3zTJGMZ285o1HymT5W5lZNoOeOanNpK5DIW3Y/Cp3twqh4p4nHbA5qWIXC7SgBHGRmj1K9npoRwWjoSqRyehye9NureQSqqRJv9j19q1IbS4ljyFkXnJxzSS29xEpwqDH3s8EVVna5ny6mK1sEjyUAf0B5z700kxj9+mCeo5OKnvpJQo8xyUB4CDFQFWJEzu2wjHzNQrFcj3FeSG4ISMlTjqpPFV2TL5SQOo4XLFam+0qUKRrFkdXHWq0g3OWSQo3qV4/OqS1HawSl8Mu3aW53Kcj8KgjWNGJcnHfNNt1WJmCyHzCfvknH0p8gJTGN3cv0zTcC0rFhcuOfMMTHCheOaddWeGC7o1JOSC3JqnAjup2ttB6uQSR9KepSB0Q+Y8h6yHpS5bCvbYmkiRSAzF2HHy9Kd+78tgrSbu3PSnpdxQEqxAJ6cZqWK4t2DEjknoOM0rDWpWFuHTc5f2G3IqOe3RiCFd1HYcDNakaoWG9ZEx6c4HtVfUUt5JA5kyF9Wxio5Rq1yGCZYjyqBWXABJ5pzmPJbgZHAHSqqtbrny90rZGPkO2tAXE7AiKMKq4wNmcU+UbiuhCicbhEeOgUcn86YI5FYOYWB7HvU9zNMuCT8xH8JxUPmOqAnzGJ67qkTRXeOV2LEsvXrSlZFIbJK+xFMnMasWJfJ6L6UBY3iJTczD2qlG42iVZ4nkIHmOeuM4zVhSpj3FWXB7GqkUUghCiBAzcgnO6p5AW2qmVI+9uHP4VSMpQtoEkgDALGzIehqOS43IFEaxc8NV5LcfZy3mKSp+6zYz9KqmOMMSSuG657UzPlRWJDEqzID6gdauQWxmwqzJGwHHPWoUskKlt7Fv7uecelSNaInARuncc00zOUewsmnOMATxkE+tUJ7ORFI3q6ZwRmppCoUZiGM4zu71HIyBjvQD2FDsSoPqU5bZYQGURn1FQ+R8hYhRnoAOR9KuOIipLBVzwAxqP7PA3LSjH+yaQ3GxTSwdlBaTr2NFWJY4cZSRyR2opi5TxwGJWPFIZ0H3VFPSybjkHPT5qmWy2gbk49zmndHlcsn0KTzZ6LTdzOflBNa8enMxGwAZ9KtQ6aw/1gYfhRzopUmzn1t5G5AAJPepksWZhuIzXRxWBY4RGyatQ6eucbmBHbFT7Q0jh2zm49MJGSvHvVqDTFPRPxFdMunoEzyxHvU62LFAIuCenTik5s1jh/I5pNMBfo7Y7AVbi03I5jcEfpW8tk0XXcT1JB70C1mLD5mxnnI6iocjeOHMqPTlJwUY/iBn8atQ2Cqfuba01UlhtG4Dg7lq1BCZMZwT+eKVzb2FjKNsqAAKxHU/NUtpa78hY3x3wf5VqiCMHbg+vTrSqixlgwKbumBQ9S40iFIvKBX5wx45Xmp1jVQS5bJ9B0qylqgj3kjr0zzUnlqQMOV/nTRooJFfYjnoQF681YgjhZg3zqPWkDog+ckk9QV4qaGSIvl2IA9B0p2ZXIrDzNGjgxTZCnPK96sG/JQKznnuVA/lVQNHOxAAAB/iGKtRKCAkcCOx6YbOKaTGoolF1uOyRvlYcnbViNoivzOGbAx2qGC2mY5MOP9k81bhsnB2m2kfJ4+XijlY3CKIHigLk+aQe460o8vGDdMST0C9Kvvp0jAKtqFOOapPbtDuDWxyT1PTNDTKST2JQYWkCeYyoOTlupqxi3VsCRgc5JIqotv8AvPMaEFunHH6VeL28V0FZH5UEqw5B9vai1xtIZKs7svl3I2dh0JoMkkR27Nzf3t+cU6SVWbCbznuFqqYHMh+Vuf71LlLUCzJNKyDIXaKhlmWVAT6fwUsNntKmUS884HNWUit5vlVJioOMnpRZlWSK1s/mJhYlIJ59RUiGeaQCMlcccipGgAG2GN3Of4MjNIyXQVEjjkjz0Jbk1SKsmrlknYf3900eOgU5xUMxgeRT9q3En7zg1JHZrIT514u7+IZzipXhsFQKLp3ccH5elUk5GLilqZ1zNBko0YlC8Fh8oP0qrJJalgJYQnHAJOKuyRxiTyltXfHO/P8ASo2sbqdHaRGEYHG4gHFS4A0kZ8DRK7iGFl3cnnFNuskEjJI67n4P4VbXT4tvM8rP6HtUU1hKp/dOm4jGSORTWhLSb0Ksgug67FUIeygH/wDVTlttiuvykDk7j3p7Wl0XPmz8gcYGD+dVrqL7PJh5Szt684qmxpIkkgHloWYqmeNpqBlEcgZCZDg4DHNSC68shHiZ0A6ioVkEuN7RW4JOCRziquramdve0JTLJKgOAAOuFzirMMX2jG7cCOpyAKbAIlQrHOu7vgGlt4bWcnzrl1cHjsKlu5Si0XJ7iJJFiZpenVWrPnaLzGDkMp5VmHB9q0JmhiVVMbOB1dSCDWfcW0F2zNCWMZ6Lnbik4jjoypOzREC3kIz0HTFTWlwyt/pVwSrD5uaiuLf7PGu0u38JUqD+VQyMvl7XiCqOD1BpJO5XMjVmt7R4BLbTZIPIbjIqJpFVCVcqvUqxyD9Kit2HkPH8jBgNueelMk3WygWyjLdUcg7qqSVrmMXrYIt1y7GZwcDIXGM/jSeXIGBSVRzjbu5AqDEwJICqV42g5/WnRRGYujoH3c7s4YVO6NG0t2XH3DYz7nA69zSiWMZfc2M/cA5/WooVFsSIomc9iSaJZQobzI8H/Z5osTZE8VxHJIFXGOgDDpU8jw8qu4Y4JC5zWal3LJjy1II4yE5qdbgOx80hs9R0IpWE4j5SAUKqfX3phuWbrKWVuo7iqlxIUBMILHORz0psN88isssUe7GFOMEU7CcUXEa0U7ZQzk+gxVaZovN+UED3OaRkdpEaUjHtVyWyTy8+YhJ5+9mp1IskZ8ogJ/jI9cVJ5UXkrthct0zmrCxY2opTHcmpUiMaAeYjH0U0tNxtFJER4SPJfcO+OKK0VfEbLgg98HminczdzySO2i2ZPfjGKspbxDghTgdAKvJAuRiFs/nUyJhs8K3oVqWzNUkR2tnGV++UJ6ArV4WY3bRMG9TjpVi0UMDlonA/2cVbW1jQZWNfdlalcPZalVbFtgwQcc9KmjtgFPyBj3wMVewwXKZVcelSqVRT87gj260ro0VIqw2SGLLqRnoKabZHwqg8dulXYyZG4cY9xg0SR7C2CQcfWlcuNMzJbfBOCMdxTGlMUhRwhUD5cd6l3SpK5RQx9xVGSaSSXDxgAdeKaR0RplnzXCblVV9t3erNmyOAFO1+5XpXKXc6xTk42rnoTV6x1SJFO6QA/XOapIJRila50skDBh5cgH1FT+W4UGR1Yj0I4rPjvjPApjkTb3JqlJqhQlcI5Ht1q1Ai/Y0rrUPIJ3qjAd8dKig1hTE0rBcD0rkLzVImkkVTKJAeQo4ojkmlaP8AdtsIyA3f8K0UEjD2qbsjqmv1ky3PIxxzT4JGkVVSQxqpxkiqFrM8CorLGDjoO9aUc7TxAGDaBk53cikomzlZXJUJVyrXADk8ArnNTQvHG2fOXzG6nnNYt3MIlPn28w5zvB7VFBKouEMSTFSvRuSKvkRmq1mkdlai7YAx5EP98tirUt1Im3/S3LdAoaqmmy27Jubex2/dPABrUjtLW4UdAw5+lZSstjdPXVEf2q+3R+U77cdM1bee7nVVYOMfxDpUunxrBJgSoV7Z61rvJOIxtC7exxUrzLlZbIyybl0EbRbgoyGFUkCxOJbiVAc9DzWu8l5tIlBK9MAYzXJ+IzcoQR3P3cZwPrV20Fexs3VzaQlZJJm5/hj70sTwTuSgmCjkMT19hXLaZaMsyvOsrk8109rCZGO1ypbjbu6UNDTTRYjyihordnB6Bm6UsV1N8ypujJPPYCpPscyRFDKS3Yk9KrtER1uCWPU4qWWmjQjNyg/1oRcf3sZqjO0cRJnmBVuy8mmJGFkEio7sOhfnFSTzL8jS4DH0WmgW4kF1bJEdkTP6U4F5OkRUZ/hI5/GlUq8bCLbkj1py2jd2Cr145qk+4WQpZ93yxjIHG7mny3M5GydIo1A4IGaelmW3MLgyoo4xTRBFI5DjYByMjOaq3UjlTFmuc2yrD5Yz0bZg1nMtyGBM5LnqQARWjsQNsEcoXufWqs1vIrkwgD/Z9KiVxqCMu6sZ7mXeJGITq3SoLq08pGLKZMdMmtB7S7lChmCKT0B5pJ9JSOImScqf4jnrUpXKaS0OamzJKqxs6hT35xU62UbLvuZY8dBgc1pPYxRqCrNIvcjvSWkCS/IyqozkEc/hV26Gdmnd7EVjBEUUxMVA6nHNR+ZJDOQiqBnO4jNazReVnZhiPfpU0NtHJzKqMT0IpNME1cypIfNO7cjbhn5T/OqRQ+Z5cjsnbjtXQSQRyM1t5ZQNwrZwM1k38XkEQM+GAILbulKzC5Wlt127knYhT64OapXbKMkM/PXdyR9abeGMMN7swJ5Ze1PKrMGZPm4xu9a0jE56k0inFNKsylWOBwfcVfDIzbv4W/vdaZaWk7HCtjvzWmsbrEqSlQucZHBq4w7mE6tvhKcdtHHCZXkYjPQDp71bcQRlWSUuv8RUUTLZqu0u7j+LHWqflRyxM6sy7ehFW6ehl7WVywLyEZHDKvAOaR5oyQcDHUsOo+tQRWdoqg3O45PDH+tMu7aK0fzd4BC8DPDD3qOSxca99GTS3KKzSIWAX+4azhdrJKpKAtnljSLf2zL+7UrJ3x0NLczMkRCQhJOz5GDS5U1cJVnF2LhnijJKbN5HYcCq0sk8kodAoLd9vFZsd68Dhp4lKMeTnoa2bWWK6IzwDxUSXU1pVG9GSW9sXTN2cY/u45q9NBbpbfu3XIHAJ5NV1jhhyCxJB5B707b84TeAn8Oazehso3ZJbPEhAljAz1OaZNNFvAiDE5+6B/KpEt389YgEkdyETnqSa0TFYw6qtrJM2yM4e5ROFcdsegPepsErJmfGUaUrLHIjrwVPBH1FFGqpcw6xcJdfPOrndJnJb3z9MUUAop6nIMCDtHln8MVXUKHZyp47A1Zmiwu5iS/86zpAVnDgZXuoNSFOGhdt2GDzjJ5yauwyLsAZk2npmsgTkuMce3pWjEElA3KAe3FSb+y6mlE8Rwxzg8Bc1aBY7AEyM9zVa0t28z5scYIxWmsUm3KoC3vU7k8tmUgkiTHCF88gZoxhh5qsH+vArQlhfYCiqJDVO8t5DAdw+b1FCL0ZQu7iOEAZwW6HNZOp6gkEDN5oLdKz9aMsC7HdgR1Nc/Okk/zsSFP8Oa2irmNesqWiK+oX6vKQwAHPQ5zUKTozLsRjxzk4NTm1Teo3ZJ7077Oqg7cDng+tbKNjxqk5yd7kRu3UFdzrznhsUWmpXEMoEJJx/e5o+yFs8jcfWrVtalDhVUseOatIlSn0LDX93KkrhYUL9WVOadbyzMOZNrH+LH6VftrGURbXjwMZ6U8R+XnKc+pFPXqaRiyC2iumc+Wwk7AZrV0+310y+VFDuzyap2/nxuDb44Oc1safqV5HJuJfPcg9KaUblc1VaIjnsL4t/psbMg+8N+Bn6VNaJslU+Zz0CkZrVl8y/IZpgEP8I71Z8iIW4hKjzV5Vh2qpx0siaUpRndl/TFAG1Y0OOST1rQuJIMohAV/7o/rWFaSfLmWQqE9KvrdQswKx7geAe4rna6HtqzXMzUtU3SjAXaO4PFa4mtUATzC7AdAcYrl4det4W8pxt2jnjNQPqvmSmW1j2J2Zh1oUL9AlOK3Ol1S7MNs0iyNuHGCelcfPd3V7IwiMjxgZyBUM1/JfuFySR94npU1t5cJwbgKT1GelaxgcVbEW0iRw6vFAv+kCUSZxnHSrZ8QQx4aziILcGR6xruRFlZbYrIR3POTSxadqmoLz5aIOmOKbjrYzjXny3OvtNTi1BVieXLEdu5rattMtkceZcDd3BrzuGyvLKRQ5TKsOR3ruNNgnuo28y4SPgYxyaHTSNaVZz3NeSGCFS0JUe2az442lcySZaPpjFXVs/KtzsYynvnqamKvFCdkbAgevSko9ztVoopm3gyESMoW554pYJTbzAbGZh14qKS7cyAh9zjjmrH2rcpLhFfsRSsUD4iDFA6lznHYVaWNPsqSDDHHPfFUpZ5/LEmFdAecmoRr9nCzCP7x4KgdKtR6mU6sYuxZXcwYqMj1PWlhtt5IlZt2c5rEufEsURZo0k64+7mpLTXPtfbDAdOlQ4h7eL2NC+VbdcqjNjoSayzNkbZwgDdjU63hnDIygDPGTVO5hV5MMpYjkYOaapNmc8TGJYiliaALFExUHsKhlsnMwVPk7nIxTEZlULAHBP4Yq5BNPsJdtzj2yaapu+pnPExlHQfFZxMW+Zl4596v2tnBbRbhcN83IBGa5TUdYuYLo74WGT1q9DqMn2ZXc4VvXnFP2bbMvrCjGxr3UwaJlYAtzjK9K5u7EU0WwFS6kksRUZDy3xP2lyXHAFV3thFK4LHPoTVypNK4liU9DI1COWVhbxR/u84L9Me9WdNtJbaBYnm3KG5+lWoPtZdsRoy9x3FPuZ5FX5bfK55xVwSSOWd3LmuPkyf3aBgAPvA1AGiUL5hLsDnB605nD7QA6Lt6+hpqRfNg4OOSx4zVcpHNckPlKGlSMxvjoahkDPIiq6rIwyRjgipFsriZt/wB5CO54p4twmUcZIHLIOVp2JUmRqUcyxONvTg9CahuolKGN13r6mrbEGIBLglWGCXTkVDdaXOwQRSmUAZJU1Mo6FplK5sbOO2VrdWSVRuI7VlreXLYR7bepPArdmsxJYsr7lYeprJjuI/LMMrMky/dfHBrCWjsaRXUpXJlDMk1u2w8gip9HuUe5WMjBxxVie/G1En+UD7rAdar+Wn2qOa2bEitnPY1Mo6FUp8stTo1kW4YkIuR0PripXVpnVHUKexHeqcBMcwMYO5uSD0rUdlkw2z5lHY1i0z0rpbAkcttcRvGM+WQ4yO46GuujiaVjNP4ffz2/eFRKAjN7jqPpXL27Na3VtJJOoj8xWzJ0HI6+1aep2NjPqM841q0YOzMMu2eam1jGdmzM1Ced9RujfwYn3neBztPp/KioJN0V1NGkscyKcCRckP7iijUtRRzc1q7Dc3QDpWa9sI2y0WQTxg10c1s8anHKkdKyZoWQDG/rwDyKxubwM1LVmuSAvBFa+m2TblDNkn9Kls4WeUc8nrW1awqZOV2sO/tSZcqnQctiVC4GQBnirEKngsAOe9WolwpOTt7VEy72ZgQNv5UrGcfe3GyuolGEz9KilYGUbwQoHpVuGAbsOy7m560+9hAif5x8q5+tXFFtLY4XxJHbO7glWIHU1wWpDy5QqjGOcj1rsNUZ33lk7kmuVk33MzYjO3PetYK5y49qMVFmeYZgcgk96Yom2452g10wsfOQF8IxXAI6ZqhLA0LEPgkHGR0NbWa3PKcU9jOzKeQvNW7eK6dsiI4Her0ATfHkdeq119gbaTTzEI8SKcnb1NVFN6Jj5bK5y0U17gBUPpxVyzt9QuZNrxgKOpatGW0t3I3Jcxbf4hVOeGW3TIeSRWOMHg0+VlKa6ItGwltiGXax785q9atvP+k2xUDgsvpWN5F2q7ySqE4w3UVftPMyRNK7AdgcUm2i1HmNJVtw+YXdQD6fyrVs0hMTuqMzY5L96wcszKIi8fPfnNW2S5HDsTEuCSO9Wpj9k0xWs7mEGRWDtLnao/hFTW1peS20ir8q+3XNWLOdJWDRfuwB0fvWmbhUtyCwWQ9AOpqoU03cJVZpWZkLo0MUAaWcbjywPXNSR20ZChvMkTpjoKsRgSHlMt1JNWmPljAXc3ota8ltDByb1ZC9pZJFk/KfQCqMtqjLhI1yfUVameSRvkiVTjnNFtL86ozDzM4GBVciJcnfQzWsEUea8RUr1I700FplKwiVPU766TULNTCJM7m6lfWorOCEKWeE4HasnDllZG6l7upzogjZdslzIze56Vt+EtW/s/UxHLIhixgFxxU7xWbNsWMR++KyrrRoZZx+9zzxjtSaaego1LO56GuuI8u2PaUPO4Dis281R0Mx81XQ/pXLxaVeW5CxXY2/3c1VutCuZxIDfFA33sGpbkdX1mLViy2txNOCgZpM5+XvV8Xl40G8WjbSc5qrpOiQQGOKNt7Y5Y12X2QR2iwjJPoT1qoUXPUxnipLRM5CG41GdmRo9kZPetqw03hiFUMRljjNaVvYAzAMPlPatcWjwxnYnymt40bLUw9q3qYdnp0ce7zNrKexFU7jS4EctGSG5OK2jAVkLOdvtVW8CSA5GFB6qetE6aaHGTRRgCqhDLwOtNRoQT0WRjxmm3CpEwTLbyMjJ61SmeNiSME9PoaSQpM0JpLSAOJdpfsVNZn2q5jmMkUJOR17UsVpK8hLAZ69K0YYcuNzYwOgquS+pHPYyruaS+gKtDtkByQazJrpVIjYBZB1B71s65ePZwGRQrZ4xXH3mpGS4W4EQZwOUxUN2eoO7V0bEdwVBeKPDdiO1U7j7fJNHhwQx64qzp1/azH96DGrDkehqZlh2kx3IODke1KbTWhUHZktr5qLudcORg471IQixM/zAdMVJakyFWDh8DsKS5LrtXggnpVQ2Jm3fQhQWbRlXdlJHBNRvBCgZ4p3bIx61blWPYoKKW7YqndhfL3R/Kx45FU2SkLBNHBGRLLOqgdMUWV1DdT/ADTMj9MsMA1U86V3COx45ytWrSIhvMeRSeoBXtQmDVjQit7cmRjMgMZyR/eFVb92imItnZWI4IGQa1ZLWNmJRI5xKoJC8YNLFCqQyBYzg8YPUUON9BxZmW6+ZAMkI7DG0iqN9pts0QAI8wDkH1rWy7ArIoIT7rY5FVL5CpEjKc9mrKcE0aRlZnHT2D5K+YVAOArjtVVIrgHYrb1ByMdq3tSnMqukkYDFSVJqjZskwVIFKuMbv/rVzNWdkaXdgs72bbl8lh/Fmug0F5pFY3YHTIA7iue+zSC5Ee1hzzxXR2DNCygncmMAdxSSfU1U7G1a38VtbyCSytrhWbJ85d2PpU0erQSMuNL07Hb9zWNLMwjxweamsJklcL0wecjjFZS3OnkVrsnQtcTXUjwxxKWyEjGFH0FFWLyCG2mH2e6MwJI+5t7dRRSK0Zg3IboATjrWbPG6AttYoepNb0ksSwsNnIHXrWYH3Rnf09657nTTuiGGNy64UhTW1ap+9KNwMdaqWkpVgHjGB3zU81wBIxUkNTG07k91vT5YznHvio7InawfPXv0pkSPIcyMc9aesUm1m3EIBiixcUrWGTTeXKHyWLdzVS6uZpZNgIGOSasMnmR/M/A6VQn+TIB3nucVReiRSvY1licrt3HOcisKay8qNjENzY7dq3bTZIWSU5GeuOlOnRVhcKmFbhcVpFtbHPVpqesjlY4ZZhtJ6ds1q22nk6e6yoSeecdKSFIhcgZ2Feox1reikSGIZPydSKtPuQqcdkjiJdKmty0kYYqOQSKsaRqb29ynmrhTw3tXXX7QzyCOLAjIyc1zmsJBDGQijd6+tUn1RzVKCSubj3qD9+jGS37+xp8A+0xySzjKryv/ANasHRtsOnzSyucPwqdjWrFcQyWsEMMnzY5xWyldXkcMaalPlQtrHNc3JZyCo4Fa0Gl+dcCRl+ZRgVVsWKSMYwOOuR0rqtMDShGHfrxWW568Y8sUkjGNrGkojC5k7selX009EYYYnI5OO9a+oW0SlSnL4rA1vUTp1s0kp2hRwB3NNMJJJXZQ1kxQ6naRrkFOT2BqQeXJOHkByT0zXErqk97qRnuGYbuFHoK6rTIGkVJYnLH3ropSseNXfNI6eGBWU+WnPqe1QoXiDKQPrnmrFqQkOzcxbGce9OigST5nT5vc102bIb0MxBK07DyxgjqTVuztjG6sdq81ZdEUsXwgH8VZsmo2zFh5oXb0OetPRbmdnujZkCSykbl3KMZFCTmNzFGoOfvGsOLUEaQeXuY/3sYFb1iI47cyPKvzdc9aaabBt2sxIniZ2MqK/PTFV57Bbh8xq0ZJ4x0AqzMkj248hBlvbnFS2kdwFCSKvynqOtU4xYveCDQbcON/mM5HXNXo9IggfGwOfQ1pwyiPYSu5u+O1K7K8u6RSv0o5EVG5XfTYLWJpG25AyAOKjtGFx84yo6DitIwwSx4yT60trGirs+6q+3Jpq17DktCERRK6GRsU7UA4RZIpyFHarEsMLpltzEHpVW7mjGI0hJHqwp2BbGRJPczbnfBUEgH1rPdLifIEioSeBWhPcG3Plyldmc4HYUz7Ol9LugXaAPvCplG5F3cw7uGUlleXfLjAxUNlYscIQQw5Oa3n08QgEOS7Hn1pkkT4yGORxkisuRopX6iRJ5QHJA9TRbyKZD5yoVOeaiuHKIolJb6U2FY2dWmJUN2HatES3Yp+IreF4kCsuCeMVQtLSAwv5iKrddxHJrevNN3uPIUMo5GahTTvlD3HOP4elZSj7w91Y5qO3jCyeXb71LcsR0FTf2XZrF5i7l55Fdc1tE1sUEYiU8571jyQtHlHUMvY4rOdOxUHdGSbeOJ/9DlY+oFaNmmIy04fB7kZxSWMaG+AVPlHJrZJhJ28BMYzTpRdipuxgkNbvvRgw602d/tWFjAzjP1q5c2qGNl8wNzwDVQ2wRcjjt16Vry2M2yt86xkRIA3TNWYlmOxn2gqKsQW8YRG+X3BPWpxGPMDfKFYYPelaw73CzE43MigOBlcHillaeRRII9rAfNinySFCI4mUhR1xUZucK6MxU4496CkQl9gO5sEjNYmoTSOHWOT9yvXJ6VZ1a4lldFULuVcA1gywy3Mczh9rqcFP71cs5dEapJasz9UuHEed4ZDkAjrUGgbYbjzJX+Q8AZ5zVO+V4kB35cH7lVLZ3z9pTJKt9ys15lXR6CZxIDlTu/gaqN3cyQ3atuwV6js1WrG4BKRmI5wOSKnXTUkuWlmIIx8vtWUm9j0qcIWuWtNkF1c2wmG2KRlDgcYBOM11bK2nrcSw6bGLma4FtawMhbKL1PPr61z2nW7XN3CkKqsmQgLdPSt+7gsooVkEt65hufIeUyc4xztHapbIqWuY+rhRrF3HAv7mF8ADkD1AoqZ7KS0vLq2bBEb4Dj+IdQfrRSNItJIzhEr78fhVRVRAylcjOeR0rSYqjYAG360yUh0JQAdvrXOkaRkzHljc8LLgHnFSoox+8JzjkkVa5+46rx3A60lw8MshQ7V7AVcUauY+KVSgIkXIHApsc7SEkoSDxxUFtFG0rZGENaNvaZCFG24PUGizGpKO5XuIk2LgAYqs8Ocv8uccA1pT2zl2Gdw9aqXNmVKg54/WguLRmRwNMAGQBc/w1PPbx+WBuIx61diwkZARsD2p8kUbo5Yc9VFaRIbuc/NZSGYyGP5BznFOCK0WXXI9RW5IZI0TKcNxzUT6cpgaWP5c9VzVrczk7I4ae6cXRECkBPXvVO8Se5/eSvx0wOgruzpsMvKKBtGcYqIaYjxyfu1ZO/ufQVpZHJKEmcxof2dX8q5bdGeAD2rV1izgsWiubTBG4A4PQVZ1HQrUWokjHkv6ZzWGwuLeWSEsJY8fMD/AEqr8qszjlCXNdHU20sUcy7sYdefQ10+nXKiSJIgNpGK8/gfMUYlfaF6L7Vs2N5IF81QdqHG4Cpk+x3UKya5XuddqUY27owd2Oea868TzBpWWTJjYjk12kusKbNQVG8jrXK6xZPeusiYAJyB61SFXk2rIytJ0+3eUGRjs7V1ltBHbxKY2+Udea5y3huEyrALjii4N1Db74X37vvc9BWsZJI890ZbnQ3WrNAhMRTgZLGsyPxE7fLH87etc7cRyyxF3fKn+dFmJEdUiBOOvFHtJMfs0tzp57+aeBVcMcnpTrHTG3Btijd60y1hkZV3hq04rAvt33OAOozV76snRbF+O3hig+Y5PoOKjsLdZb5VXATPrT7axV5AisxJ9TxXR6ZplpbOrNJlsc1tFNmbtc0rGPysIFDADr61bjMa7/3QHqSKzptRs7QkCTBHaqz+KbQoY4lLP34rVyitAtpc1Y5dgfAHzcZNCwO43q+R39qz7XV4byLylKR45O6q2o67baeoRJ9+euKOeKV2HK3sbCRu9wFWcLn8qutbPApLybn+tcE3jRt4MVsXAOBxWbqHiPVL2XkNGvTAqPax3RThI9Am1HyUcHap9+1VX1NpbfCshbPYda85e4vnbcVlk9c09bi+RDJCNuOuan23kDp6WO9SI3cowqBVGWJqdFC/6hCFHHHFcLZ65eW4ffl/XFatn4nWX5JV8sdMiq9rF2uSqcl0OjmEgcthQTwDUcgcxBJGVVPWo4VidFaO4yp5xmpmhRsGToB1J61puTYrTRKLf76sw4xVe1hUbXdc8960YbBSpbGFPTNRLaSR3Gcny/5UdROxOQQ20kDd2HYVEEPmsVcNt9e9R3ah7oyJnAXbgHrUIleNQnlsRn72O1TLTUFY07axilh3TsAGbrnpWdqFsis8RAO1uD6ir1yIxpavbyZY9V96pidZ7VEumSMJnnvQ49AUktTIEXksxTg5ximXUa/MwLdc59K0NkOGljlV+euawdfvTFGFi+Yv/d71GsBOSY+4ulSEs0ygIOcdaxv7btmuHUFmAxzjrVN7aeaINMBHzjJ71TXTZzKAlwiAdwKmU5diU0+pty+IrQJ5RAQg0+LXrV4wI5Mtnp7Vyd7ZXRwyvGw5JyvNZsF5PFMf3IBA/u1m6rW40r7Hd3mtWyKzox808YqgNbzGQkbfUjpXKnUHlBLRDOasf2s8UHl+WCfpUOozZQsb39sh3VdzE47iobi8CICzfvT0HvXOS387OroFHtjpTnnM0pZn5P6Vk3ctX6lkxPcSEsT5rHmtjSNEIuEmkXCJyQO9YELOsuMlecq3vXcaDdlrAq4/eZwfelHzLaNGZE8gCNVD9R6gVBt8tcs2c1ZKNcEEoVPTmmXEMY4VuFGCM1lLVnfTklGxZtDIZIfK3Akgqw9c8c128UN00eLrS7d59/mn94MM+Pvbc1w+nX6xJETD5kUbAsp7gHpXSPFb3Mv21NViETv5m5iRIoznG326VL0IqXkyPULa9jk864jO6ZiS4IIJ9OKKnvb22Nncskv/AB83AkWID/Vgdz7mipuaRTa1OXkP7gNtHA5NVXKlQFOT1pnnBYvmA57A0xFB3MuUbGMHvWVjeKG75IcuzZB/GnyxC4kEighOhxRaQs25WAyfep0iZXKquCB1FUx3sya0tU8pjDJlAfxq3HE6uSCCgHAPWqRJjt2ZowTnjnBFWrScmJmfeEHTIzTaE31JmjYxmVML7U2QyFcrg5/hx0pbibdBlWBxzx1rPW83MzNKsbDg9c0JWBaq5ZjU8q+Np61JPCZoy0O0qg6d6zbqdhBud95PQrUdrK4i2mbax5ye4q/QVramigWWJTIGD9qPNE0bRomCB1FVI71TKIw+cDPSo7a7ELSfN8xJ/Ki9h2uTmARxKS4wRT1hjSDajdslqGnhNthWUADOGFVIb8NOUz8vt0quYqMG0MugemQExnJFYE4gupQPMCknt3rqZDHLL5bggdBxxXO6lo8UVxmLPllske9aJ3OSvF9ERyxpgtG4BXjBH8qs2t99kVcDeDncO1VII8xuC/zdADTZI2C4wwHY9qcXbY4p056aGqNSWeXIRVOMH0qO7uQrokB+f+VQ28ZiZXMQVWHX196tx6cXHmq447Hriqc9LG1OhK93sQSXAOxht981k6ldSRl441wjdTV/V0EPCjLEcVSgHG64ySAOMcVCRpWm/hRTMJiiVhkg9QatWEqwYbkZ9e1OZjPMBGvArVtLQMMOmR64rZLscbbFSdpVGyRat2kdwz9VI+tSwWUSqCFXFWjDFHgIOT3rVJvcnmJ4L17THm25c+oNTahqSTKnk7lAHIqp9mkZCxnKfSqdzEFEaqzMxPJNVd2siNNySa+g2ZY5bGB3qoNQuN4EEKnPGcV1dtolobJbgqm4jkDvTvsdstkzoqoQOTWdnc6o0fdu2cybieBP3iDLnGRVS5n4wUA9yc0/VbiLd5UMmee1Z0TAEq2W56mlJa6EJ2Rs6dcgIFEYZieMCtiCF533ugHtise0xHgAjHrWtaThCMyYrpgc82ayxIqABB7nFQT6cXyqLgHnip4LhZlwz/N/OphJuk2M4Vscc1rymVzm5bbYWTbgnrkVkXNtHGxywHqK7K8RcsCu7j7wrm76zj3kvnH86wlE1jMo2t7JaXC+U7bfQmu8sbmO8s4yzAt6A159LG7ucRkKOhqxZ3cloQUZkPv3qIycXqaaSR6U0gWCNVB3VWuZ5fLYCRcdK52w1S7uRtZgB605ZTFM4dwwbqWrojJS2MJuzN+KSKPDqS5XrmszUdQ3uFAIXd26U5bjbFhdhX0zWDfCeabKvsTd07VUtDJzLOu3H2WzjNu5+YEk56GuOlubu6fK3ZAfjArrrqEyWiLKi5I4A71h3ugNCUlMbxg8jvms6ifQSkim2m6gkKtHcupB5Ias+6GpQKIxPv54zWneXexiLdmGOuawru+LMfMLbu2KylZaD5pblyWee6gSK6LKVxyp60y5u1tSCoIZeCDzms6OO5u3CweeST0q3Fol5NcLFOGDZ+uBWUpvdmsKUpaITShPfXgG7hsnHYV1tnp0UJzOiMu0jkVY0jSI9L2F0y56HFTXdu7J8owCTmsJye561DDxSs0ch4isoREZIFChT0FZltGLi4jjVd+7AOO1dHq1iTAjIWYE8gUzQrAQySSSqQB93ilz3REsP7+hS/sq2trlnVSzIMhW6Gsq7twsPmomZJuSg7V2ly6oFkJXJ/hxWPLbpPJ59tF+9BIIB61UZJmdei4O8TnoGeKNVIBUnnI5FbWi6hJ/aMgIxFGOPeoxZou5pHAbjg9qWOFoyqKR8xzuFWcqunqdsHaa1Vm++ehqneQFCoEnXqR61BY6kHUpIypsGBnvTdSaWQCSPqOcetZysdNPm2LGm3EUt/BaynCGRVcHuM13h1CZY7lY7CBWtblYzD5QyYznB/Qc+9eW2Qa5v4UVgsszqhJ/hycV1sV7Z2epSpFdawbiMmFpQyjO3jv2471nNm3K2zU1NY4tVuVZw7+Zk8YA/D9KKqFofNdo2kZWyQZfvH6n1orMtOxyfnNJuUIAF64pjyvnG5uRnBFC3G4FyvzEfSoRK6gs3U/dzUqJupaF1WkZNyMM98Hmprafaf35dGPc9Ky7e47Mm8DuGwasmSNgvlyyj1VxkU7AzVu2TbGEO85zxzR5xZVTcYW7/LxWbO0X2cGI/P8A3lPSoxeTGREMoIHIJ702CsbEznBKBXwMnFU5ZI5R+6fGR8wYZ5qBLnKEXC7Se69xVRyEPybfKzkkUJFIWQkxOZFIZTnch4/Kq8N6Ym3GVGiAPDjkVHd3CMmEQq4POD2rNV5Jsx+USD0JxWijcxqVPZ7mmdaEkgaMKARjNWY7hJihZSrHoR0PvWMLGSFQ7YUAHI/+tVc7lGYGlC55wabp9UZ08Vd8tjob6dliZkfcwGAvrVG1vSqYaLErfpVC3i84mNmy4OeCRmtb+zJY9rspVTyADk1cKakRWxjg7RNCwusxbnfJHf0qrd30j3JhIXaRw2etUmysmTuCd8DqKnGkmPMrSMWxlDnIpxotCqY1SWm5X85IpVwuMdQetOk1CDzNoBC+p70iKqykyLubPU1BfwwuyqqgOTkYPaqdPTQxp41p2kaUV75iAoMgDABq0sssyK0SMAvBIqPR9gygKK6jkEda3tNSKBiEZNj9QDnFCpX3Zr9eVtjitcvHkuY0wdy9aVZCqbWA6c8V0Fxp9u925lAZQ33h1qpJaokhRJFLH7u7vSVNoynXUtShaCMfODhutXbfUZImAWPd2q1pqus37yKF8deM4rWhUw3Hl/ZY2Vvm3AZrdU3uc7q30Rii4mKEhWXnoBSi5u1IIhdj6kV1kM/lHJji47YFSXMq3EKmNFB6EDirVO/UTk10OUt726wd6Ooz3FS3moo7YOR+FaE6pb7izkDrVOe6tpSPkVyBycUmuXqP4i3oOrtITbgEhehPNaNzM1zDNCoZNwwTSeHBbxRebHEGlJwAB0rQil8t5C8ajuQayctdz1KMHKFpHm91by21wySL8w6NjtUSo5JJkA55rstYs1vpEPmBGPQDvXOahYtaybHOAP4gOtQu5zVoODsyOKeJEw8x9hmp49SQMBjeOxrNAjAAWLfz1NEYbfgBFFaqoc7idJBqEg64IPIx1FX4rtmdWYZNc9AwjyQ+SR27Vcjm8zaitlzx1rZVLmTiblxdERkM3X0rKnvF3YCkjvmnx2qrIftt0q+nPSpZW0y1Xck6yswwcmm2LQxLnUQoZET73eqYmklK/ITg9avXkto5wvU9MUyKORlzECSOnHArCSbdi4ySNvTLdiFkeQL7VJqoSIEpIjMfQ1hJb3X3WY+1K1hK6M8pPy981tCTSskZTSk7tkzXE8KBiw2ngDNX7DXLIDy7mL5v0qtHpJa3EjHeMZwTTptGVHhjfGZenPSq95GT5TRvtY01mUoTuA6VUm8Q2jpskMnHTHSm6rocVmYzIVPGcg1mT3GnW+7CgsPWnKUo7itF7D5ruynWTZE3rkisaWSydW2R/MP0p2pavCyN5QAKjGAaxbeOYhpipVSc81zTlfU2hFbM7Hwwz+R5rRBVHAwvOK6K2KNuPl7XbvWJpkkjWcYgX5CBu+tbdsrrJ+8I2EDr2rmlO+h7tKkoRXctS3BiCoQufU96q3jvLFjA69qusitOwIVj2NMubdIlJEmScZqWrl3SdjATf9qVJV+Xpirs0cIRRGDnPIFRTwyPeMQ4AHSlCtESHYFc+tQW7PVEMlpFkFkz3Gaghs1KkxLsccketbK7JFQtjI6VFJGoV2UAnHB9KcXYzm77nGeIrb5/Nhf94oxg96oWUrSAno69Vro720Sc5fjac/Ws0QRC4eaHhs4xVqTZx1qS+JFWHMk/lTA7RyDW1aXB2+SOicg561kXNxcJLvKr5eMYHWnWQmkYjbjjhjQwpXehoWD2zanG0ysYnlAYL1OTziu9kudUW+uFGiQbA21GNsWLJ2Oe/HrXHaVY2G1nvr77K64Me2Ivn3yOlbSSWcaGRvE9zsPGDE/X86h6mktdCWeV5L2RrmMRMCd0artC+2KKyZ7+3W4njjn+07mys2CC4980VA2jCNyrRfw5A7NRE++PBdlx6jNVwE8gPF90DBLLxmpImRgQ6qu7pgmpbaNItFlAoIJWMgDpjGaRZIkjV4t4OeVzUbqotxt3/wDAuRWc9wyJiSBCCfvKSPzp8xSVzUnu0aF/LVmRjjjqKqlSwDeawIB6jGKrRtGEPms4GNw2HNJMD5SNauTzggnGffBq46ky0LUcjxxMVw4xyVOaryXDJAFX5XY5IYZFVd0kKhJmdD1B28Y9cio5JBcyYRsMMbfc+xq1G7M6lbkiW7FZJpmjZk2f3hx+lbK/Z7VMkCYrwqtxisGzufJusSfvGHHAwR9avyaw0iFREhDcAuKbu3Y8uVRyd5Ed/fJIHVbZ1Y9CD0FUPtLsFXJidRgHHUU2a4lYfMFfK9Bxtp5kEkMZbazjg7xyB9actFY7MNFP3i1FA5iViQZlOMZwSPWtU3Ya2VXkYbV5yeDWXGTIjOEBxwADVyztttt5jR7lb5ipqqTYsXGDV+pahljdNse1hjHJyaV7hY4dgYjZ0OeKqLiKQmJAVIJUjqKgubg7/wB9FhuOowK6uY4LNIZqOopJMAoVZsYJHQ1Xtp5rIjz4WYEjDY6VamsYZVLeUUY8g5zVJre6LBDdMyL/AAk81Dve4m7I2lvobhWXaEkkONxGCKhaeWzu0KMGT7u4dDWc1oJYmP2hVdTwD1FLDZlDGWnV8nJG6k5dy4x00OrlWSSJJF6kZwKq3mnySR71O5s5A71dtIvKigcsSp/StgeVIgEaNyMB8d60tdlaNanP6ZDPDu2AqQerd60lvRGQ0iDzAedp4NWtS02O1OGk3s2DuB6VnSWkSEmOZHU9T6Um2nYIxRdN1aySEv8AumxyB3qJrhVOIC23HpWOIpEbfvVsnAYd60EO0hypBxzzxmlGZVRcuxOlwS7+ZFv443Cs8JLcsQoRDuwe1S3kt2kKsH3DOPl75punK9xMOBHt5JbrSqS0NMNTc53Og0+KVI0CMEdRtNWZVfHzShz34xUMbYfmXcvUkUrPbYLOzYY4HrXLue2rWGQW6l45ZpVyp4GelR6tZwzSsAzyK4zlRnBrQtbZXwzR/KOjY5qKRYoZC0Urq7cdKadiKijLc42TSZIomYnAzgVWXTZchgCxx2FdBrNrLN0uguDkgcUWck1qq4ZT6cZreME9zyKr5XZGIbK6iQExkKecgVXAdJAVk2n1rudzT27EnYmPm4rnb6BnkAt2R1UHqKuVO2qMlIxLhY25lumLegp8a25iyiSPjrxT7mC7UDMI/Kk8q/t4Q5+VD7UJO+xm5Fu3a2SPc1q7KehPatayuYAoZyq4/hz1rmHkvPJJ+ba/PIqrJIYeZpMEiq5uXoZvU7mS8tHz5jKmOeO9UZ9TjAdQAYzx71w810+8bHPHvQ07TEMJMH60/a9A9m9zp77xB5SBVbbt6D2rIn16eWZJFlIA6GsCS623RRyXB645qeCymupDtQhEGdvTiodVsapWV0i1c6zdzSbZZi/dcVSllmuXYJkt/dHWtaDSoZJFeLapA5QHnNb1np0dhbrcT+WikEEHrRbm1YR0ZySaPKYBPMCuT0Peto2xkihjW3dsdW7Vf0/y9RuwpUyQw9G/hJrrI/IitjGAOPbkVlOSjpE7qFDntKRV0SzjgiSN+WI4x0rSVgrAlc4HQdqrwNG68bg2cDFPmYxqTyo6HNYNo9JaaA9wqljjHFV7m4aePCLhR6mqNzdeWhZQGTPXFWLMNIQ0hC57VEpNgu49EZg24bSe+agkjLzndnA4NW5IgzERlmPrmp1WNF3SDBIxgUh3KfOAYz8o9O1TGeONCpPLCnyXCiLy0QAE9QKz/M2SlmII/PFCZDVytdbSrMqD5/4j2rl7/f8AaUSBTvzyQeK6eaQTEoq5UHJrAmt2NwcEhM9V600+pDjcZ/rgkaqzPjLVqWsDFGbBiVeMnmqwlVJBHHxIeMjvVmKSR4pBuLRjqBVJg1yrQ1IdIubu0zp8KzbcAkuFx+Zplz4Y1jbGfswIXnHmp/jVC1hNzcW0TsUMsixj2ycZrpruw8PrFI8trePFBci2c+fzzn5sfgeKlu70MpOUTkFtGsb26SaMecp2MMg7W+oorW1byNM1G6thbrEqOVVAd2B25PX1op3Qua5y8QRQqbWLHk4PFTNIETbHtdgejJyKrw3X7tlOwEnIJTHT3psjgFpOC3qhNZM0iy6Xk2BSQE68HFUrieVQqOSFPUAAiopxM6BoJWYnrnoKpzC4GBmNy3sRTXcrqWBe2u/EltF5YPO4kH8MUxpbJ3HkiRduclW3cfQ1BEZIlDeWkij+Hqy++KtSSwOqIEUE9Q0ZU5+orRO+iIaVxjIvkqIJMnsZMqB7VNExlwNioiHnZzk1Ve4iEjOiBV28Lndk9MYNETgXAyYyegY/J+BIqrtImPJKWxoxB4rqSfYkg6lk+9+RqpcOJXDLbPGj/ePbPtVma58th5ZKSY42kOKqb7hiHyC78qqcZ/Cr9poYyw8JS1EYPNbqI2iYrwQ3ykfWokikKsl1KAi8AIQaWbSvtEM00jbJwR8vQj/GqVtFNbubYSJ/skjljVcyZzOMqTdjotPtoB5civsY/d56ketL/aEqyNGEL4J60WcU8aIbtBlTnOMU2SPMsvC56/e4q1ojJvmJrUlkZ9mc9E6H86naIvGpXcx7buT9KisWlV02MqAHHzDrmra4G5WQiTOS6DINWtR8xAsboyN5IOOoBp8l01uPNS0RlzyHGae16N+1o1Mn3e4rBuZ5ZzMskoCZKlemMUOVthQjzscnmefJcXATy3Jbavb2qSRre5ijS3RlmZsgdqgitJEUDeGhUbhz+laX2mCRVKx7ZUwPlOBWKXM9TtnP2UUkjXhnmsFRd6FxjIJzWlba06wgMyAL1AHSucF3Gsoe7JIzj1xSTajvLfZrVnQKfnxjP+NaP1OaN5bI073VWvSyWqnP/PQdB7VFGssan7TCxzyrA43VmWM0ocl2WJWIx6GtmNZBtkndJFJ4GelYubbPRp0lGOpIlxyocpEnSnNFFO2Y5Nzvx7ClkjeeDchj3MSChGDj1qbTZliiEUgjbA+RiMEGnzO9h+xi/eZRl0yVP3bSvtXDE1oX6/ZrOHeVdufu9fxqrLclp1SBh5iZ3kn71NuL+6t5AhSGRJBk5PTihyvoaRpqmrxLNrfu+0KuI/p1/GtBriEspdCzDBAzXPWd3N9mUgKkQOCAP1q1HfNuGOce3Wp5Gi4V4SOlW8ITKL5fbOcioZTJIkm+YEAZyoxg+lZlnNDMd0jT7eQ6gdDVwiJ5MKJGXGAQvNPlY3Ui9ilcqIwP3gLHqGFJYXYmQhHXK+3NMuQbhd84LqpxgD5qq6Zbptcn92GPyBjgiuiN+qPLrqMXozVjup2jcPnacjB71lzx3GW2HZu96sJJ5UuCFcDueaW4kRojujJVucnitrJo5W7MzHN9JEU8wFV6ZIqvcf2g0RUoRt6c5qxKbT7xMqKeCV7UivY70L3spX2NYsb01MiWS/aEeczFF4A6YrPkSR8BnBI9a3rq300SMw1F8HnGetVHt9KhmBF08mecA0OLfUjnRlm1Zm+R0Hrk1GyeUwQEM5PAFaL3Gnq7vDAW553GpreQ3N9E6rFGBzj2qHoaQvJpEuh6IFQzzod5JwMV0aW8USeYY06YJJ5NOtpA8b75EVV5AHf2qB5IySxyE4A3DFZpu566glGxkz2StcM1sSHzwRwBT306a5QLPclgTzzWgHdy2EATHysmOfzplzFIqYzuJ5JFXZpHN7s5bFzR4ntT9ltwDGOnHf1rXMVwrgyBsnjhay9MgkTD/dYdgetaIjuHBdnYZOduawZ1xdthAEjSQBZfqTioZdzoVaQdM5NXyrLBsUgD35NVXigaYvIGC46D1pWBmNK7yyqN24Dgqq8VrwQrDB3LEflUcZSMt5alFHqKnRGl487apGeRUsFuSRk7l2YBHXJps8YUl8jnk81EYGDn58gdzSXSjy8FgCO4qH5lXV9BDL5rEL24HHSqjiNNwY89s96tRSbIsDnjoRWdfTQvJhicn07UK4JpsrCUG4LKCRjaR04qrJjzCwB2jgYqzFFvkHDc9z0xSSQRxKW3ls5yKtbakzK8Gxx0Ct296txfJhFYZx8wHeqtszSXA3JhAMLnjFTSyRwqxwPMHGPam2kZpNsWASSXEfkli+8BCOu7PH6106TXUGvXEd4+mu1yE83eD5XmqOM4/izwTXN2FxMpingjJVJFOdpxu6gfU10UyWF3ctPNp+sqxO97ZIPl3dSA/oTWYVF3MjWpH+13Bv1zebyZB2De1FJqjPf6jdXF0phkduYscr6Dn2oqkyFE4b7dCkS7GAc8N7Dt1qWC6EmVc8cZBXn26Vz/AJnz4yPfApz3MiFPLLN9fSlcm+hvySwwnAIBbk7ScVHNcbVBjdgO53Ak/hWE5Ugu6snc1PFMSFWOVU45Iz/WjZj5lYbPcTZLxuwjJ6sueamgnuJcoJVEgBfO4rn86r+S6ysDkrnqBUigq6/O5J42n5jj8aakHLclwzAIkw3Dhgfutn3p8fmQ9xgHLoTnAp0iRSJ+7k+b/aTB+mRxUUg27fPBCkfeGKbfMXFKIl20AkQM2FP3TgjFXbaVfs5SBg2wZUOc4PfB61zk88fmSRSR5I+VCCQT71YjnMWUB2jAzyNw981ooNo43ioxk9DVbUJ2Qxqp2k55PpRau9zMzOsjhRjAH3efWoG2uqsk24jBfBGVHrmrUJUqFAdXPRuoY1ahYzniec1rRJGJEEjAHIzu3A1chiMLeX5ql8clwOax1byI9jOq5GSP8KkjuJYYw28yr0Ulc/8A160v3MfQ11RY9yylWUjOehFU7i8WIjdKAccFulVhMZdvmPtVfmwOQf61X1HbelBsjbHKqDgNVXM5LUlaVjdAbWCEZyhB5pYra0wRLvdjkjJ+9+NULdV3SI5hjK9icn8CKniMwYJCkjxDkgDP8+lJtlJqOiJGDwQ5toH24+YE7h/9aiRLdrQja0c3B69x2pya5cJGYYYuEyCH61XaZ7krJNAzRE52qcVm0lqjshUlLRrQ1I2R9NJmLJKSMRryadFK0UMaT3j7QuQuM7Qe3FVYZl+0q8dqFXoyuc4FTzKJJPlhRnOMiLj86UrM1oXhsWvPCqhZVMWOCVzn8Kit7nDmabb5Rbgdx+FUVaO3kYSQ3BUdBmpr6IsokaHYpAJ39vShaajlJzdi3PdSzSAKzmM8LSXEcpQbcuwOevNV7e9RoI8NtfJ4jXKkYqzd3gkihyjpK5AyBgFfX2os27ov2sFG0mbcMiPao8iFWAwSOxx3qG3NuJjIE84Y+Zh2/CqttZOpWVZpVhZcsBgjI9apmeWCUxszIT0J5BFJxkio1oTWjGahEtvHE9q/712PynOetaOn6TKx81nKMeX3NwD7VlsZm+7cxMqsQCR0HtVs6lcW7CMSwyQZwXQ8irhLoctaL+KJvDYFkCsscwP3w/B/CphNO0K7JlZh1A7+4rBSaMXLDaZF67hUTXbggRQsR65OfyrbW5zqo7Gu1yNPTiSRXcZIYA1CLwyyefNIpOPuhccVj3cstw3mLG37sAE5zV4PMbcLdDy9v3cjFUjNyuzRi8p8MkmwHkpjJFOnuJAFQKWAOfnFZsReNkkMyYJ/KrFzcHyn84Bw3QjjNO+gR31J7i6eO0yLBHYtnK4OfrXO3F7G0rK2n7SRkjbir87xJCwRHRiMHBJH4Vh2rm41DYBKcDiTcSKxk7K5fK5OyK86SSO3l2u0e9LbaLeXORsCIBn3Nb6wvb3CvJEZM+prShhYbtrJAMduv0rnc+x308JHeTOZGhvgCSNt+ex5xWnpFisMzLLFs4wN9ayQHmQuC/oT1qaacNaEtICSMBVGcUua6OmNCEWOS5gSIxvCpBHDKwFDSJcQFESJIh1LNyaoxh2Iby1YnoGXHFXktlKu8ShmGBsVOtEZNl1EkipMoieNUjWQDtnipWdpJY2jQLjggUTRyG4zbu6svYAY+lS232rz9sMBYk/Mw5/Om5MyUUndIWNWRx5wYAdh2q8Wb7scZxjrupbiGAxO8rF3HYDABrKNxIinnaM5GaTdtwjqaUscqsm8Mq/xAmo4po1mBUEDPGTkiqZuZpEX94OvIINI75k3OBzxwai9y7GzvlKZdkVTkgDFVZZw0mHOR6DrVBGkZ0G0jvkc5HtTXn/eMQ2Se5GKnUV0jWjuCZMbcL65qC5kk+ZlGT2Gaofagv7tSGY/mKSRpD8pfGfTmkHUfK7iF2J+fH5VkuzkhtyBvXqa0JQWTBDcDr61U8sZOEbPU47UykySG4lKAbcAcc1LGfkcSDcDyCaaJdsQGza351Ety4wWAG09+ppolu4+RAyeUCGB5BB5FUmhWDPnSZ44ApZJ13MBxv5IU5NNIjYDcHMfqe1J9gjdF6wu2IigV5VjkmTCxnOWzwcetdZPcQpqBsz4n1BZQ2xmMfyhvQnNcIHFlIk0DhZY3Dx8Z5HIrshYtdML6Tw/Ot5IfNMH2tVVmPOdn3sHripIqvv+hR1yzMBuLtL57toZvKuFmTa6ORwT6g+tFZl9qzyW1xFND/pNxcGe7lJ6kZCqF7AUUaiSfU8wjuQeCNhPTcv9afvfnlSemV61ms+RgOwHuc1I0gDYjcHpye1WcCqGgsjghRMdh6gmo3J3ksx98D8qqeftjZAobt6mmxTGNyV3LxjHrSKVW2xqQOi5ZnCEc8Ec07zInY7yx3dCr5yayhM2W6kfQZp4kJHy5+pHNBXtTWgmjjl2xsSp55z/ACqwl3lNiSSrnPyscqfXr0rJE4wu4I3uByKkiu0+6VOM856U1oaxqrqaV1b2tygeaZzcMc8RDaB2HHOay4NEluLzZbSwvJ1Ck7M+3NWGu41ZM429CAf5UwXg37VDYHTvVqTOecKUtSGOOW1mkjcNFv4fcw4/xrTti7WTC3ZMdd+7BGOtZd3mc4RiWHONuT/+qmWo8hGzDux/eY/qK1U2ck4cr91Gt5sxLFiCp6KTuH+IpYLgQSp82c5zznisWRCJS29Uc8hVGBTkkkd1UFDkYNNSTJcpROnF1FOyCFHkYp8wxgg+nvURRbdvNMSiQdw3QVjgRAApNufOMhiMfQ1pSSpIcZk4Gc7txJq9LmbloXIRJNLGgjbLHdhOcjqTU63VrbDzrggpnGAMGsRjKJSIZ9u0dRw49eKkSzuJGIlklZeQDjaefrVNii0TalO0073NlGqIpBOG/wAatWks1yoZJUjVuDk81HHBCblUuQ8saqFAdhx+I6/jUlxAFYNAPLQ4OW6D0FZ2OtVrL3WSyRFtsRnjZVP93BP1qYRqyZieKD5RzuILEd/rWaLiR5QAw39gBgfnVy3tZHAkkmijB5xImOapJGcqsmyAGVLhzBP57EgjnIXmpZpSqne13BOT80YXK4/GoZd1vK8mFk3N82w7VoSdSPmXa4GQGkyGHpUSlbQ6aa5le+po2EtvAXLuiyAcBhjB9RUVxK10YkYqct94HoKrTbZVXMigggheoqOFZ1lBCxgh+VB/kKuE7kVaVtbl+S0+cRkyqrYx8xAJ9c0y4jxA4lkbeDhGZ8haDLKoLRrtI4++cGqy3YbKtGGY8scZb8KHHW5MKqUeViW37pszxyPljtMbAjn2rbJjwcQqkh6s/XGOlZqXCxDfLEnl7jjgCoZ9WUsRErCLIwrMCPrQlbcJVb7G6hCpuj2HICkE89KiV3LLnKhRjhjnNZ8V8rrtSSMHjBJ4H41G10WcBMBl7qxz+FaXM7mmzxKzlZpAxxkYyD+NT3M4dMSMzA9M1lRXrHcXxkdgBnFSy3MAj/0idMEbuDk9fSjmSQ022W43ZAjAqdpyA1Vprh9nkYdcnGS2QM1WmuS7H7NE7qvcjGfwqjPeXCFWEKAnnhuDUc1x2fYuTXJhiwZ5HdDgKoOCak0aGVn3y+aN3+zxiqs87zxqzsGkPH7scLVvTLkRAb5nbHA5xWVTyOnCNc12dBHGiS5kLnP3dx4q0yPLHiNVQf3yMc1Qh1B3XYyhf+A5I/GtJLkzIoZUY5AG4da5z1ObqRQp8p8xi7nnKnAPtRe2VuduyQgkAlM8VO0Y8wYCqw4KjioJlUFwkRZvVTxTTstQ0bumHkykL5bKV7HJq7b28YU+Y7u/9z7pqrbRTHlX2pj5hu6CrTTrHAQzPknrnrTRM30EMO+UOkiKozkMf1o+0x2+AXyB12nGaQYkjUnG3Ht1pkvkYJba5z1U0iW7j53MiJ9l81Q/3wOlVhaNHKWMZZfc85oSUMGZGA5wBnJNOWQkffO8c7CMDFN67kczWwy5eZFCJbcHnJ4FROGB+Yds9M4qSSRSSztKoAz8uTg+lQYZwdwDk9OoNSVfQZKLlV2qDuA5PTFRjesuGCs2Ogq0IZnjbA28ck9TULRCFgyt8w/vN3pOQJXJoUBbO1Yz/EcZIqeORBkKykYzluDiqkDSADa53EnccY4qUiKPLSFjgdhilcpscArcl1A54BqvhUXDSNn07kU5mUAFVOe1NZI2Yh2JPcDnFFxaIruybyw3NjoDxVR1jnkJdimO3JqWZ40IBkKL/sjJFRqYljLMzMw6D1oQXI45QsjbVCgcnA6inyzrNJhA+09icCqstyUZUjH0A/xond2cSbWVjwVPSmw5jSspIoNQtppoi/lSK5X1UHNdBd6WLrU5NRh1WzFtLL5v2h59roM55XrkdMVzFlaXd3HvtraeXBxmNC2PqRV2PSr/AMxd1jcgZH/LFjj9KV7ES33H6/dWt5rV5dxqfJdyV7FvfHv1oqTxO1vH4m1KMlc+btC7cAcDpRSuQrWPHQDycH6Ypx5wRhQeD61i/wBpyHnaKd/ar8fItaWPG9pJdDWO/pgZ6ZxSEOvXn2rPGrAkFkoOqLuztYUWD2rL2WyAoKn1qdA7cEkmsw6qrdjSjVU2gfMCO9FhqoajFww42kdzTiGyWYIe3FZq6wo4O4j0pU1dBnGRn2pWLVU0YmVwQ67h6CnsmEGEOVOazl1WEk5J/KnDU4D/AB/nQV7Y0MOPmY8dVApGdyD97161TF9bsPvrUgvI2I+dcemaabQnVT0Jre4VZHEigk9Pl/Sn3M6NGVKnOc4x0+lVjcBsbQMg07zH2HHNaKZk7PqNWWMMuFdSPxq4JJJSSWbjodvIrOdpd275V/Gp0vbhHBEvUc4NUpLqRJM14JC7GOWNUL4O4AqxHse1af2aEAb8kkZUs+cj0OK521n/AHgLSZ56kZA/xrUS/QXTPIsbc5G0Yx9BSlK+xtS5VuaEVnEUDKXUDOfmyB6VOmmWzRKwyectuJXNZqXse1mBYA8/Lx+GKuW92nk4BcMDng1nzM61KPYd9mtVYNC7ow698VJcRlsLukZR1Utxz6UC6VWBAJwMY29aesikMxLRkdO4o9oy/wB290SXlrGio9tCwj27WWSTc2fw7VmXMTRushSKPGOikmtCKaFsoxVlGWwx5z7Gq95IhiOyXzAeSjcmqU7haPQXToDdRM9rKqHGGUHB/WtK3uWtiqMI3KD/AJaHvisCNyW3oQHCk4wTioHuy7OZEIcgc7T81bRZxVXJXNm+v0kQuVQc4+9kCs9jbcPtTO0k4bJHpWc7P5QBG5iSQuzkVCqXDfNFEq461XOluZK72RakkDzASTKyBjtQj26U+GFWyQ5ibsXXj8qr+VeBTI0YIfk7SCc1cRLmcIJjGBjsSP5VDmr3uax5rWUS1bQkxZ89TyGHHNLIWzsDGXac/OuCKZZRyxk+XHGFGQCQTn1OCa0Y7Ka7Ci4mCIOSEQLnP86TqopUZvfQo20Et6scfmLgk5UHArSh0/7K2Xhw+AOgbj+lFvpaW0nylvlPQH7xq8GUzEssgyOQG/nmsZTud1OCiQrKvCh8AnJFVb2UZIkRdq8DjJH0rUWSQRkGKMx9QSKjuIbe5ADxqX6BhnH1NJM0aRkaaGaR1jVfLHBbB4PrinXkSQ3HlKyiU8src7h/IU2fThaSkx3UkZPUI2Qfrmq1vZRxSGWRTMv95m5P4VpznNGhNSujXtNUuEb508xcYBYDrWtbTMyl5EaM+/r+FYdsLUIFVQGzk+n5Vr2zwIsZkMojzzgdfwrLc7VKyLi7JkVld3287MnFPhZ3DCM7VPRBgCqqkHJG/HYqAM1Pb/Z8YZmfB75x70MfPY0BacDEijI7NTHtGdDjbgdWzn8KUeSdm35SOqg9RSSTx7vlKhf7pyc1KIc7kPkjBSNV5GTg9B9ar+XsAAZuDnK4/KpMtnLZMRJ4TjFIswGVUAPnJX+9THzAWVMh5AueQfT8RTbbMoDpMkjNwDnOPzprM75MyLyeFd+M0lw8aHyzGDgfNsbIFO4ronkLlmDOv+1t4qNEJJ2EqR2xVIMrjMjqqrwOeRSqY0UBAzkngqc5pWHexYZN7k+dkAdTTGgSNlAlbpzhec1XmkLMVkccckH/AApVlVGKAq7DsAWzSsHOTFWVmwwGP4m6j8KRJkR8h1OOmVzVWRpXYMxRCP7w6fhUilUU7SG9SVpJDcx0jO8mF3565zio2fO4PISe4Tk02SbzCAqkAdhxUTBQMluTxjdRawucRljPQMv6k1XuHWKLZs3Hdncxz+FTSkqNqyKoA7fMapM6swCSlmBz0NMaaHLKWUpGrlfX+7Twjqv77ezDkY6UnIUguWI5wFxUKrI5xv8AfJHNDFzGtZ39/axlNPnnt1Y5YpJjn3Aqca3qqk+Zqt2V6YEh5pfDmlW2qPOjaj9nuFUuIzEXLqBzt5GT7VbTS9FK7v7bBwMH/RWz/OpsQ5xuY73TTySSShpZSdxkfkk+pNFOvBHazTJa3Cyxg4WUoV3j1x2opWK5keGUYoFLW54gYoxRRQAY96KD0ooAKKO9FAB7UH0opaBXE59aXn1oooAUM3ZiPxqRZpV4EjY+tR0CgCX7TKM/OaeL2Zf4uKr0UAXF1CQDtUiaky4yv5Vn0UAay6pxjJAJye9WE1gDoxHOfesE9KKNAu0dSus5PzSAjr171ZTWmPAYYPv1rjaAOOtFh88jt/7XLLglPfPNPXVBuDbgB6CuHyfU0bm/vH86Vi/ayO4S/GSGYkdRz3qX7UjBMs2/v9K4QTSD+NvzpftExPMrn8adw9tI7tb1VDDeR+PA+lMa4jcnLNz6H9a4gXMw/wCWjY+tPW+nUcOT9aNxqs0douzOTIzD68VOlz8mAoUDgEiuJXUpguDzU8WsSp94Ej0zSsWq7R3qahsRRjIAwBjpUw1JSuDGVYnHbmuFTW1AOUY5OauR69AeGXbnqdtPkH9Y7nawX4KfKhwD19KmF9EVO52O7qCvFcWmt2owMk1aTW7cn5XUY7kYqeU0WIR1yuGUKgK5/ujipFiIYMq7yeCc8/lXNwa1G6/K/H1qxFqi7wUZiQexpWLVddzZucSEKFOR2IxTWQl1PlbHXG3kY+tZT6oTJ8zHjpyKcNQjLZ+TJ9+lDuaKujoYAA6lwgfsFFWVCEne8iMeM4yK5uLUCOfMi6YOTV+LUykeQ6Egcc8U4kyrGxLIPMKLHiEYwW7+tTm6bZ5cRHldFzjP5+lc6l6GIxKpHdcmrEd7EM/vDu+vFDJ9pc1hKu89zjnJyKtJcEw4WYIoPRBWEdRHCluO59KlF1AV8xWxt/vGpRXOajGUuA0kjJjoVpkk21GUrGN3ALHJHv7VkyXqOuCzMM8YY4xTJLrY/lBeevHORVIftLl+aSMgeYVUjncDwfrVNp4jgjbuY9B6fjUVyzOSA8ca44Awc1E0zKqh03hgCMcD86CuYsNcjcF8tVIH1zTDJvx5cUgxx3GPeoFld3yNybeADxg+tNnkfe298sBjcD3ouDlYuBCQ27Yzdtmcj3qESPvAWSNemG5z+dUUUu5cKB/tMcVYJ2INynB69KTFzk7kM53y/d6sc5NC43nAyMfeZuDVZ5FQEgM57MD+lBlO0lmbk5IJ6Uiuctg/MN2xQe3UYqFnj3ZTBI6c8VVmnGFII65AB5qB7hSGdQu7tlc4/ChC5ixIxPUIfbn+lKqHgk4x6DHFVDfqAimEFh/FnFL9pjZmaWTj+4hP86bBSdy/tD8Y46k76G+VBtIAJ6KRWdLcRZJAYJwMgGoFdWjIAw2ckE07C5+50ulxX08qzabb3EjwsMywKxKt25HerUmkauzM39n3qnk5FuxLGsbw/q15YXgFqrXEci+XJBHuHmqeo45B9D2p1ymuWyNIw1eOIEnc28gD60rEuV2F0XguJY54jHJCcMjjDKfQj1orImvJH3y7meRjkvI+S3vRTsxe0seYYpM80tGKo88KKKKACiiigA70UtJQAuKSloFAgxzRig0UAFLRRQAUUUUAFHHpRRQAUUUd6ADGBRRmgUAGaU8Cij60AHUUmKXtRQAmKU80lFAC0UDmk70ALRRRQAdugo49KKOKLiHByOhIp63My9JWH0qHIzQOaBltb+4UcP8AnU0eq3Kj7wrPpM0AbEWuSoRlAauDxCpxuQjHqa5ujNAXZ1tt4iRWY5AB6cVZXXInJJlGewFcSTRQVzM9Bh1dduAeoweaurfoEGwqp7gnrXmQYjoTUi3Eo4Ejce9A+dnpR1JQPnkVRjI2jNQLqsYHyvIeOprz9b24XpK1PTUbhDw2fwpFKozu/twdsgsT7tSm8Qhl3lE7Luya4capOPSpRq8gXDAEGiwe1Z2n20NgM544BJqQXUQyF3kjpiuIGrgf8s2P404ayc4KmnYaqncNcREfebd6ZpftI4O8EDueoNcKdXx0Vhn3pP7XPAw2B70rD9qdu92QS28KOnJ61Ab4Y5LPjjr0rjm1ZifunA96a2qE4OCD/OhIPanWS3ynkJtJ49c1EbsA5IDgjkZPFct/aRJJOR6ULqTKTx1ocRe1Om+1gtu8nAPbml+0DA4APYjHFc0NRAIODn0pW1JTjG73pqIe2Z0zXijIVmZR1Bbr9KrG9bOcFfTIzWB9vXuW+uacL6PH3iDTaF7Vno/g+9nl0nU7bSLiK31uWSMxvLIIzJCM7kRz0OcHHetCxs/GttcJKbqSyCsGaae8XywO5OWOR7VxOgNpUOhX2tavbzXsME8dtFaxyGMF2BO5mHIAAqfUbOw1DT49X8P+c9gkqR3tlM2+S0JIAJP8SH+92osL2jJ/FeqWs/iLUn051SwkmJj2DAPqQOwzk0Vi+OPs2m+LdWsbOPy7a3nKRqOcLgcZ/OimiednK0UUVIgooooAPpRRRQIXFFJmloATqeKdTaWgApaSjNAC0UmaAaLALQOtFGaAA0c0UZp2ADzijvS4oosAmKUUUdiaS3ATvS0UU2gDtRRRSsAUUUmaAFopOe9LmgAooPFJQAveikpTQAmBSig0mTQAppKAaWiwBnNIRS9KQ0WAKKKKACijoKKADJoopM0DFpO9FJQAvSjNFAoAMUlLmkoAKKKKACiiigAPWiigmgAoo7UA0Aami65d6RHdwwLBNa3abJoLiPej4+62OzDPBFQaBrN5ol+t1pc4SYAo4YBlkU9VdTwRW54O0mO6RryeCG5d5xa2sM7EReZtLvJLjkoijOO9W9N1AasNRj1GPSryztAZDFDaLbytCDhpYXUDBUYO1s5FAzmNd1KXWdYu9SuUjSa6k8x1jyFBwBxntxRRrmnnStYu7FpBL5D7VkH8anlW/EEUUCKVFFFAgooo7mgApRSUU0gA0opKcvWkAhopKdTsAlFLRRYBKWiimAUUUUrAFAopRTASloNFACDrS0UUWAKBRQKAAdKKBRQAUUUUtgCikNLRa4BRxQelIetFgFopG60UgFpOKUd6ShALRSHrQKoBe9IetLSHrQ9gCiiipAKKKO1AAKQ0oooGIaKDRQAGig0CgAHXrRmkooAKKKKACiiigAooooAKKTvS0AdN4R1aK1iazuLmO0ZZxd2lzKheNJQpVkkA/wCWbqcE9q2fK0+wjuWli0nS7W4Xy55bW/N5NLEeWjgQE7N2MZPQV5+etCqBkgAH6UDuXda1BtV1e8v5EERnk3LGDwi9FX8AAKKpUUCP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A retiform purpuric lesion with bullae and skin necrosis is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous necrosis: warfarin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral areas of cutaneous infarction with purple-to-black coloration of both breasts, surrounded by an area of erythema, occurred on the fifth day of warfarin therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick, TB, Johnson, AB, Wolff, K, Suurmond, D. Color Atlas and Synopsis of Clinical Dermatology: Common and Serious Diseases, 4th edition. McGraw-Hill, New York 2001. Copyright &copy; 2001 The McGraw-Hill Companies.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_62_38889=[""].join("\n");
var outline_f37_62_38889=null;
var title_f37_62_38890="Anorexia nervosa in adults and adolescents: Medical complications and their management";
var content_f37_62_38890=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anorexia nervosa in adults and adolescents: Medical complications and their management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/62/38890/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/62/38890/contributors\">",
"     Philip Mehler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/62/38890/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/62/38890/contributors\">",
"     Joel Yager, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/62/38890/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/62/38890/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/62/38890/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H31379336\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorexia nervosa (AN) is associated with numerous medical complications that are directly attributable to caloric restriction and weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/1\">",
"     1",
"    </a>",
"    ]. Some complications are pervasive and one of them, amenorrhea, is required to diagnose AN in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medical complications account for more than half of all deaths in patients with AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/3\">",
"     3",
"    </a>",
"    ]. A systematic review of 42 observational studies (3006 patients with AN) found that the crude rate of all-cause mortality was six percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/4\">",
"     4",
"    </a>",
"    ], and a review of 119 case series (5590 patients) found a rate of five percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/5\">",
"     5",
"    </a>",
"    ]. Standardized mortality ratios show that the rate of death in AN is 10 to 12 times greater than the rate in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The medical complications of AN and their management are reviewed here. The evaluation for medical complications and criteria for hospitalization of patients with AN; epidemiology, pathogenesis, clinical features, treatment, and outcome of AN; refeeding syndrome; and medical complications of bulimia nervosa and binge eating disorder are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16550?source=see_link\">",
"       \"Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=see_link\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44023?source=see_link\">",
"       \"Eating disorders: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/16/30982?source=see_link\">",
"       \"Anorexia nervosa in adults and adolescents: The refeeding syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33816?source=see_link\">",
"       \"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5206194\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF ANOREXIA NERVOSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AN refuse to maintain a minimally normal body weight of at least 85 percent of that expected for age and height [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/2\">",
"     2",
"    </a>",
"    ]. An alternative and stricter guideline requires that the patient have a body mass index (BMI) &le;17.5 (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?39/41/40593?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/9\">",
"     9",
"    </a>",
"    ]. AN is also characterized by intense fear of gaining weight and a disturbed perception of body weight and shape (",
"    <a class=\"graphic graphic_table graphicRef75110 \" href=\"mobipreview.htm?9/7/9339\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are two subtypes of AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Restricting &ndash; marked by weight loss through dieting, fasting, and excessive exercise",
"     </li>",
"     <li>",
"      Binge eating and purging &ndash; marked by episodes of binge eating and inappropriate compensatory behaviors to prevent weight gain, including self-induced vomiting and misuse of laxatives, diuretics, or enemas",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of AN are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=see_link&amp;anchor=H3#H3\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\", section on 'Anorexia nervosa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic reviews the medical complications of the restricting type of AN. Complications due to the binging and purging behaviors are discussed separately within the context of the medical complications that occur in patients with bulimia nervosa and binge eating disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33816?source=see_link\">",
"     \"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5205415\">",
"    <span class=\"h1\">",
"     MEDICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the food-restricting subtype of AN should be evaluated for medical complications (",
"    <a class=\"graphic graphic_table graphicRef67080 \" href=\"mobipreview.htm?29/44/30413\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. The complications and their signs and symptoms can occur in many organ systems. The evaluation of all patients with AN should include a history, physical examination and laboratory testing. The evaluation for medical complications of AN is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16550?source=see_link\">",
"     \"Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5205559\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical complications of anorexia nervosa (AN) are a direct result of weight loss and malnutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Starvation induces protein and fat catabolism that leads to loss of cellular volume and atrophy of the heart, brain, liver, intestines, kidneys, and muscles. As an example, muscle wasting, including the myocardium, occurs during starvation in order to provide amino acids for production of glucose. The number of organ systems adversely affected increases with the severity of weight loss (",
"    <a class=\"graphic graphic_table graphicRef67080 \" href=\"mobipreview.htm?29/44/30413\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The reported incidence of these medical complications varies, depending upon individual predilections and severity of the current episode of AN, as reported in cross-sectional studies and case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The primary risk factors for developing medical complications in AN are the degree of weight loss and the chronicity of the illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/13\">",
"     13",
"    </a>",
"    ]. There are no known sociodemographic risk factors for developing complications.",
"   </p>",
"   <p>",
"    Treatment for each complication includes nutritional replenishment, and many complications resolve with weight gain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/3\">",
"     3",
"    </a>",
"    ]. There are no randomized trials that have evaluated the management of medical complications from AN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31379357\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular complications of anorexia nervosa (AN) involve structural [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/15\">",
"     15",
"    </a>",
"    ] and functional abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8741290\">",
"    <span class=\"h2\">",
"     Structural changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structural changes include decreased cardiac mass, reduced cardiac chamber volumes, and mitral valve prolapse.",
"   </p>",
"   <p>",
"    Substantial weight loss in AN is accompanied by atrophy of cardiac muscle, decreased cardiac mass, and reduced cardiac chamber volumes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80083 \" href=\"mobipreview.htm?17/57/18324\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/15\">",
"     15",
"    </a>",
"    ]. This leads to decreased cardiac output, reduced exercise capacity, an attenuated blood pressure response to exercise, and subjective fatigue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/17\">",
"     17",
"    </a>",
"    ]. Some individuals may also display decreased contractility. Most cardiac changes become clinically significant only when the patient is below 80 percent of ideal body weight. The weakened heart muscle generally improves with weight gain, and heart size normalizes with clinical recovery over weeks to months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with AN may complain of chest pain or palpitations, which are often due to mitral valve prolapse. The valve prolapses as the patient loses weight because the heart muscle decreases in size while the structural tissue that comprises the mitral valve remains the same size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/19\">",
"     19",
"    </a>",
"    ]. One echocardiography study found mitral valve prolapse in 20 percent of patients with AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/15\">",
"     15",
"    </a>",
"    ]. By contrast, the Framingham Heart Study found an overall prevalence of 2.4 percent in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/20\">",
"     20",
"    </a>",
"    ]. Physical examination in patients with the mitral valve prolapse syndrome often reveals a systolic murmur and &ldquo;click,&rdquo; but there are no associated ECG findings. Clinically significant regurgitation is rare, and there are no known cases that required mitral valve surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/21\">",
"     21",
"    </a>",
"    ]. The prolapse generally recedes with weight gain. The mitral valve prolapse syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3476?source=see_link\">",
"     \"Mitral valve prolapse syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/24/13705?source=see_link\">",
"     \"Definition and diagnosis of mitral valve prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence of increased anginal pain in young patients with AN, and autopsy studies do not reveal evidence of obstructive coronary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/22\">",
"     22",
"    </a>",
"    ]. Although total levels of cholesterol may be elevated in as many as 50 percent of patients; this is due to a high level of cardioprotective HDL and insignificant elevations in LDL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/23\">",
"     23",
"    </a>",
"    ]. The presumptive cause of elevated HDL is excessive exercise and weight loss. An overview of risk factors for cardiovascular disease and management of cardiovascular risk in women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=see_link\">",
"     \"Determinants and management of cardiovascular risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pericardial effusion has been reported in adolescents with AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. A study of 128 female adolescents with AN revealed a pericardial effusion in 22 percent (29 patients), using two-dimensional Doppler echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/25\">",
"     25",
"    </a>",
"    ]. None of the patients with an effusion had a friction murmur and none had clinical or echocardiographic signs of cardiac tamponade. The effusion disappeared within three months of refeeding in 18 of the 29 (62 percent) patients with an effusion at baseline. Diagnosis and treatment of pericardial effusion are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8741312\">",
"    <span class=\"h2\">",
"     Functional changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional cardiovascular changes include bradycardia, hypotension, QT dispersion, and diminished heart rate variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/16,17,26\">",
"     16,17,26",
"    </a>",
"    ]. In addition, the long QT syndrome may be seen in some patients, but it is not clear whether AN directly causes the syndrome.",
"   </p>",
"   <p>",
"    There are no electrocardiogram (ECG) findings specific to AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/21\">",
"     21",
"    </a>",
"    ]. Aside from bradycardia, the ECG is often normal. Case reports describe ST and T-wave changes, atrioventricular block, or ventricular arrhythmia, particularly in patients with hypokalemia or hypomagnesemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. An ECG at baseline will screen for these potential abnormalities. ECG abnormalities should dissipate with weight restoration and correction of any underlying electrolyte abnormality. An overview of management of arrhythmias is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33223?source=see_link\">",
"     \"Arrhythmia management for the primary care clinician\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased QT dispersion is another marker of increased arrhythmic risk in patients with AN, particularly in patients who weigh less than 80 percent of ideal body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Normally, the length of the QT interval is similar between each of the ECG leads. QT dispersion refers to the difference between the maximum QT interval and the minimum QT interval occurring in any of the leads on a routine 12-lead ECG, and reflects heterogeneous ventricular depolarization. The etiology of increased QT dispersion in AN is unknown but may be due to direct injury of the myocardium during starvation. Patients with AN may have a twofold or greater increase in QT dispersion, which correlates with the severity of their weight loss and reduced metabolic rate. The abnormality normalizes with refeeding. QT dispersion is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/51/26425?source=see_link\">",
"     \"QT dispersion: Measurement and interpretation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/33/10778?source=see_link\">",
"     \"QT dispersion: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concerns have been raised that AN causes QT interval prolongation, which predisposes patients to life-threatening ventricular arrhythmias such as torsade de pointes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/3,35\">",
"     3,35",
"    </a>",
"    ]. Some studies have documented QT interval prolongation in severe AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/16\">",
"     16",
"    </a>",
"    ], which normalized after weight gain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/15,36\">",
"     15,36",
"    </a>",
"    ]. However, other studies have found that the QT interval is usually normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/37\">",
"     37",
"    </a>",
"    ]. Many authorities think that the QT interval is not inherently prolonged in AN, and that QT prolongation does not independently cause sudden death in patients with AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, the presence of a long QT interval in a patient with AN should prompt a search for an electrolyte disturbance or the presence of the congenital long QT syndrome. The long QT syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with AN, abnormal autonomic nervous system function appears to diminish heart rate variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/26\">",
"     26",
"    </a>",
"    ]. Normally, moment-to-moment fluctuations in heart rate reflect the underlying stability of the autonomic nervous system and integration of sympathetic and parasympathetic function. Reduced heart rate variability predicts sudden death in patients with heart failure, and may also be correlated with an increased incidence of sudden death in AN, especially in patients who weigh less than 80 percent of ideal body weight. A decreased rate of variability suggests that the patient needs a more comprehensive cardiac evaluation. Heart rate variability is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35449?source=see_link\">",
"     \"Heart rate variability: Uses other than after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients are hypotensive (systolic blood pressure &lt;90 mmHg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a diastolic blood pressure &lt;50 mmHg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/21\">",
"     21",
"    </a>",
"    ]. One study found hypotension in 16 percent of patients with AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/13\">",
"     13",
"    </a>",
"    ]. Symptoms of hypotension include fatigue and weakness. In addition, there may be orthostatic hypotension (decrease in systolic blood pressure of &ge;20 mmHg, decrease in diastolic blood pressure of &ge;10 mmHg, or symptoms of cerebral hypoperfusion, within two to five minutes of moving from a supine position to standing). Symptoms include lightheadedness upon standing, weakness, and cognitive impairment. Orthostasis may also indicate the need for hospitalization, depending upon the severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/10\">",
"     10",
"    </a>",
"    ]. Evaluation and treatment of orthostatic hypotension are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/41/12951?source=see_link\">",
"     \"Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5161?source=see_link\">",
"     \"Treatment of orthostatic and postprandial hypotension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8741319\">",
"    <span class=\"h3\">",
"     Bradycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradycardia (&lt;60 beats per minute) is often found in patients with AN, with heart rates as low as 25 beats per minute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/3,13,21,38\">",
"     3,13,21,38",
"    </a>",
"    ]. A study of 214 women with AN found that the average mean heart rate was 62 beats per minute, and that bradycardia was present in 41 percent and hypotension in 16 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/13\">",
"     13",
"    </a>",
"    ]. The reduced cardiac function and use of energy represent an adaptive, compensatory response to caloric deprivation. The cause appears to be increased parasympathetic (vagal) activity with unchanged sympathetic tone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients typically describe nonspecific symptoms related to bradycardia, such as fatigue, weakness, and lightheadedness. Bradycardia is expected with AN, and should not, in and of itself, result in therapy directed to increase the heart rate.",
"   </p>",
"   <p>",
"    Although clinicians might find comfort in a normal heart rate, &ldquo;relative tachycardia&rdquo; (pulse of 70 to 100) in patients with moderate to severe AN may have more sinister implications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/40\">",
"     40",
"    </a>",
"    ]. A normal heart rate, even if not strictly in the elevated range (pulse &gt;100), is probably due to a medication side effect, anxiety, or an impending medical complication, and should be viewed as a warning sign in need of medical evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/41\">",
"     41",
"    </a>",
"    ]. This is especially germane during the early stages of refeeding, in which it may be a harbinger of heart failure and the refeeding syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/16/30982?source=see_link&amp;anchor=H86792383#H86792383\">",
"     \"Anorexia nervosa in adults and adolescents: The refeeding syndrome\", section on 'Pathogenesis of the refeeding syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One clinical issue is deciding what degree of bradycardia requires hospitalization for continuous monitoring of cardiac function with telemetry or treatment in an intensive-care unit. There are no studies that have directly addressed this question in patients with AN. Nearly all authorities agree on the need for hospitalization and telemetry for any adult patient with a heart rate less than 30 beats per minute. Whether the patient is admitted to an intensive care unit depends upon the presence of other clinical problems and availability of resources. The American Psychiatric Association practice guideline suggests hospitalization for a heart rate of less than 40 beats per minute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/10\">",
"     10",
"    </a>",
"    ]. Based upon our clinical experience, we suggest telemetry if the patient has a cardiac rhythm other than sinus bradycardia, or a heart rate of less than 40 beats per minute and hypotension or symptoms of lightheadedness.",
"   </p>",
"   <p>",
"    Bradycardia in patients with AN generally resolves as weight is restored to a level greater than 80 percent of ideal body weight, or even earlier once a stable pattern of nutritional replenishment and progressive weight gain ensues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of bradycardia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3878?source=see_link\">",
"     \"Sinus bradycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31379371\">",
"    <span class=\"h1\">",
"     GYNECOLOGIC AND REPRODUCTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reproductive system is altered in anorexia nervosa (AN), causing a cascade of events that results in secondary amenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/43\">",
"     43",
"    </a>",
"    ]. By definition, all female patients with AN have amenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast, an epidemiologic study of 403 healthy, premenopausal women aged 18 to 39 years found that 5 percent had anovulatory menstrual cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Central nervous system reproductive functions are disrupted in AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Normally, nerve impulses within the hypothalamus trigger the pulsatile secretion of gonadotropin releasing hormone, which acts upon the pituitary. This initiates the release of luteinizing hormone and follicle-stimulating hormone, which in turn determine the onset of normal menstrual function. In patients with AN, secretion of gonadotropin releasing hormone is reduced, which ultimately prevents ovulation and causes a functional hypothalamic amenorrhea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=see_link&amp;anchor=H4#H4\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\", section on 'Functional hypothalamic amenorrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weight loss of between 10 to 15 percent of normal weight disrupts the menstrual cycle in most women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/43\">",
"     43",
"    </a>",
"    ]. However, amenorrhea may precede weight loss in up to 20 percent of women with AN. In addition, rigorous exercise in patients with AN contributes to the secondary amenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversely, normal menstrual cycles usually resume with weight gain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/49\">",
"     49",
"    </a>",
"    ]. The time course and amount of weight required for resumption of menses has varied among different studies. A two-year cohort study of 100 adolescent females with AN found that menses resumed in a mean average of nine months, required a weight of 4.5 pounds (2 kg) more than the weight at which menses were lost, and that 86 percent resumed their menses within six months of achieving a weight approximately 90 percent of ideal body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/49\">",
"     49",
"    </a>",
"    ]. Other studies support a goal of attaining 90 percent of ideal body weight in order to restore normal menses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/43\">",
"     43",
"    </a>",
"    ]. Another cohort study followed 56 adolescent females with AN and found that a return of menses occurred in 64 percent by one-year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/50\">",
"     50",
"    </a>",
"    ]. One study found the weight requirement for resumption of menses varied considerably and was predicted by the weight at which menstruation ceased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amenorrhea persists in about 10 to 30 percent of patients with AN despite weight gain, because of ongoing abnormal eating behaviors (binge eating and purging), exercise, or stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/43,52\">",
"     43,52",
"    </a>",
"    ]. For patients distressed by persistent amenorrhea, eventual recovery of menstrual periods may occur following psychotherapy. We do not suggest use of sex hormones for the purpose of treating amenorrhea in patients with AN. The etiology, diagnosis, and treatment of secondary amenorrhea are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31379385\">",
"    <span class=\"h2\">",
"     Fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AN may become pregnant despite their amenorrheic state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, there is a higher rate of complications of pregnancy, as well as neonatal complications, in AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/54\">",
"     54",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Although infertility is expected in AN due to amenorrhea and decreased libido, patients may nevertheless ovulate and become pregnant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/43,53\">",
"     43,53",
"    </a>",
"    ]. Many patients want to avoid pregnancy, and some of the pregnancies that occur are not planned and lead to an induced abortion. In the Norwegian Mother and Child Cohort study, an unplanned pregnancy occurred in a significantly higher percentage of the 62 patients with AN, compared with the 61,998 women with no eating disorder (50 versus 19 percent). Significantly more patients also had a history of induced abortion (24 versus 15 percent).",
"   </p>",
"   <p>",
"    Fertility is usually restored in patients who recover from AN and remain stable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/1,55\">",
"     1,55",
"    </a>",
"    ]. If pregnancy does occur, both pregnancy and lactation stress the maternal skeleton for mineralization of the fetus and newborn. Based upon clinical experience, clinicians should provide vitamin D and calcium supplementation, and suggest a diet enriched in protein and phosphate. In addition, pregnancy in AN is associated with a greater incidence of complications including miscarriages, premature birth, smaller head circumference, and low-birth-weight infants, especially if the disease is active [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/54\">",
"     54",
"    </a>",
"    ]. Nutrition during pregnancy and pregnancy outcomes in women with eating disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/44/28362?source=see_link\">",
"     \"Nutrition in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7781?source=see_link&amp;anchor=H3#H3\">",
"     \"Eating disorders in pregnant women\", section on 'Pregnancy outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with AN may conceal their eating disorder when seeking treatment for infertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/43\">",
"     43",
"    </a>",
"    ]. One study of 66 women treated in an infertility clinic found that 8 percent had covert AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/56\">",
"     56",
"    </a>",
"    ]. Although it is possible for amenorrheic women to conceive by inducing ovulation using pulsatile gonadotrophin-releasing hormone or gonadotrophins, the presence of active AN is commonly felt to be a contraindication for this type of infertility treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31379420\">",
"    <span class=\"h1\">",
"     ENDOCRINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with anorexia nervosa (AN) have abnormal levels of several hormones, including low levels of gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), insulin-like growth factor 1 (IGF-1), free testosterone, triiodothyronine (T",
"    <sub>",
"     3",
"    </sub>",
"    ), thyroxine (T",
"    <sub>",
"     4",
"    </sub>",
"    ), leptin, and antidiuretic hormone (ADH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/45,46,57-61\">",
"     45,46,57-61",
"    </a>",
"    ]. In addition, there are increased levels of growth hormone and cortisol.",
"   </p>",
"   <p>",
"    Reduced leptin levels correlate with weight, percentage of body fat, and IGF-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Amenorrhea in AN may in part be due to reduced leptin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=see_link&amp;anchor=H5#H5\">",
"     \"Amenorrhea and infertility associated with exercise\", section on 'Leptin and other peptides'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H278931821\">",
"    <span class=\"h2\">",
"     Hypothalamus and pituitary",
"    </span>",
"    &nbsp;&mdash;&nbsp;AN disrupts hypothalamic function, which results in abnormal levels of several hormones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/45,46,57-59\">",
"     45,46,57-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secretion of gonadotropin-releasing hormone is reduced in patients AN, which reduces levels of luteinizing hormone and follicle-stimulating hormone (despite low estrogen levels) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. This prevents ovulation and causes a functional hypothalamic amenorrhea. (See",
"    <a class=\"local\" href=\"#H31379371\">",
"     'Gynecologic and reproductive'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Increased activation of the hypothalamic-pituitary-adrenal axis in AN leads to elevated blood levels of cortisol (due to increased production and secretion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    from the adrenal glands, and decreased metabolic clearance) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/57,64\">",
"     57,64",
"    </a>",
"    ]. By contrast, adrenal production of androgens is diminished with decreased blood levels of total and free testosterone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/60,61,65\">",
"     60,61,65",
"    </a>",
"    ]. Increased cortisol and decreased testosterone may each contribute to osteoporosis. In addition, reduced testosterone leads to a diminished anabolic state and libido. There is no therapeutic role for testosterone replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27332237\">",
"     'Osteoporosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, many patients with AN have elevated growth hormone levels and decreased production of IGF-I, a profile observed in starvation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/58-60,67,68\">",
"     58-60,67,68",
"    </a>",
"    ]. Reduced IGF-I levels impede bone formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/60,67\">",
"     60,67",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27332237\">",
"     'Osteoporosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Antidiuretic hormone levels are also low, which may rarely cause central diabetes insipidus, with failure to concentrate urine, and resultant hypernatremia and polyuria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypothalamic abnormalities in thermoregulation are apparent with hypothermia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/69\">",
"     69",
"    </a>",
"    ]. One study found hypothermia in 22 percent of patients with AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27332237\">",
"    <span class=\"h2\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least 30 percent of female patients with AN have osteoporosis, which increases their risk of fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/13,70,71\">",
"     13,70,71",
"    </a>",
"    ]. An epidemiologic study identified 208 patients with AN, and found that they were nearly three times more likely to suffer a fracture, compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/72\">",
"     72",
"    </a>",
"    ], and an observational study found a seven-fold risk of fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/73\">",
"     73",
"    </a>",
"    ]. In addition, osteoporosis in AN may result in irreversible skeletal damage and long-term disability such as pain, kyphosis, and short stature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/3,74,75\">",
"     3,74,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteoporosis in AN is characterized by increased bone resorption without concomitant increased bone formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/75\">",
"     75",
"    </a>",
"    ]. Trabecular bone, found in the spine and hips, is affected more than cortical bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/21\">",
"     21",
"    </a>",
"    ]. The most severely affected site is the lumbar spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/75\">",
"     75",
"    </a>",
"    ]. Bone loss occurs at a rate of 4 to 10 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple factors contribute to osteoporosis in AN. Peak bone mass is generally acquired during adolescence and young adulthood, which frequently coincides with the onset of AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/75\">",
"     75",
"    </a>",
"    ]. The peak bone mass acquired by a patient with AN depends upon the time of onset and duration of the eating disorder, the degree of nutritional depletion, and changes in body composition.",
"   </p>",
"   <p>",
"    The degree of osteoporosis in AN is correlated with body loss and duration of amenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/3,76,77\">",
"     3,76,77",
"    </a>",
"    ]. It is generally accepted that a body mass index of 15",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and amenorrhea for 6 months can lead to loss of bone mineral density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/75\">",
"     75",
"    </a>",
"    ]. A study of 73 women with AN (mean average age 17 years) found that 20 months of amenorrhea was the threshold above which nearly all patients suffered significant bone loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The osteoporosis observed in AN differs from that found in the typical postmenopausal state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/65\">",
"     65",
"    </a>",
"    ]. In AN, patients have low serum levels of estrogen, androgens, IGF-1, and leptin. In addition, there are high levels of cortisol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/64\">",
"     64",
"    </a>",
"    ] and normal serum levels of calcium, vitamin D, and parathyroid hormone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone mineral density should be measured with dual-energy X-ray absorptiometry (DEXA) in patients with amenorrhea &gt; six months (",
"    <a class=\"graphic graphic_figure graphicRef56741 \" href=\"mobipreview.htm?43/24/44425\">",
"     figure 1",
"    </a>",
"    ). For patients who continue to suffer episodes of AN, a follow-up test should be done every two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/10,21,75\">",
"     10,21,75",
"    </a>",
"    ]. There may be a therapeutic benefit in providing patients their DEXA results, because visual evidence that patients are at risk for fractures may lead to positive behavioral changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology and etiology of osteoporosis in premenopausal women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/25/6553?source=see_link\">",
"     \"Epidemiology and etiology of premenopausal osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27332251\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight gain and resumption of menstrual function is the best established treatment for osteoporosis in patients with AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/75,79-82\">",
"     75,79-82",
"    </a>",
"    ]. There is limited evidence supporting the use of hormone therapy in the form of estrogen, recombinant human insulin-like growth factor 1 (IGF-1), or both. A systematic review identified five types of treatment that have been investigated: weight gain, hormone therapy, bisphosphonates, calcium, and exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Restoration of weight and menses is the cornerstone of treatment for AN, and is associated with improved bone mineral density in patients with AN and osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/75,79-81,83\">",
"     75,79-81,83",
"    </a>",
"    ]. However, it is not clear if bone loss is fully reversible. Some studies suggest that normal bone mass is restored following recovery from AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/84\">",
"     84",
"    </a>",
"    ], whereas other studies found that demineralization was not fully reversible despite weight gain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/85\">",
"     85",
"    </a>",
"    ], even after follow-up of one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supplemental estrogen in the form of oral contraceptive (estrogen plus progestin) or estrogen replacement therapy has a secondary role in minimizing and perhaps reversing osteoporosis in patients with AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/21,75\">",
"     21,75",
"    </a>",
"    ]. There is limited evidence from multiple studies to support this widespread practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/70,75,79,86\">",
"     70,75,79,86",
"    </a>",
"    ]. This contrasts with the unequivocal benefits seen in postmenopausal osteoporosis. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 112 adolescents with AN found that after six months, the mean average increase in bone mineral density was significantly higher in patients who received oral contraceptive, compared with patients who received placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/87\">",
"       87",
"      </a>",
"      ]. At one year, the mean increase was still higher in patients who received oral contraceptive, but the difference from placebo was no longer statistically significant.",
"     </li>",
"     <li>",
"      A randomized trial of oral contraceptive in 48 women with AN found that after approximately 1.5 years, bone mineral density did not differ significantly between patients who received oral contraceptive and patients who received placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/82\">",
"       82",
"      </a>",
"      ]. However, in severely ill patients with an initial body weight less than 70 percent of ideal body weight, patients who received oral contraceptive had a 4 percent increase in mean average bone density, compared to a 20 percent decrease in patients who received placebo. Furthermore, in control patients who started the study weighing less than 70 percent of ideal body weight and who spontaneously resumed their menses, there was a 19 percent increase in bone mineral density.",
"     </li>",
"     <li>",
"      An observational study of 130 women with AN found that use of estrogen did not predict bone mineral density, but that weight was associated with bone density [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An observational study of 75 women with AN found that bone mineral density did not increase in patients receiving oral contraceptives despite a mean average increase in weight of 12 percent. However, weight gain and resumption of menses were each associated with an increase in bone mineral density [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limited evidence suggests that recombinant human insulin-like growth factor 1 (IGF-1) is beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/88\">",
"     88",
"    </a>",
"    ]. A randomized trial assigned 60 women with AN to nine months of treatment with IGF-1 (30",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    sc twice daily) alone, IGF-1 plus estrogen and progestin, estrogen and progestin, or placebo. Bone mineral density increased significantly in both groups that received IGF-1 compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/89\">",
"     89",
"    </a>",
"    ]. In addition, the greatest increase occurred in patients who received IGF-1 plus estrogen and progestin. &nbsp;",
"   </p>",
"   <p>",
"    Bisphosphonates should not be used routinely in AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. Long-term side effects in young patients are unknown, and bisphosphonates are teratogenic and can persist in the body for many years after discontinuation of treatment. Bisphosphonates have been used for severe osteoporosis, especially when AN was unlikely to remit in the near future [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/75\">",
"     75",
"    </a>",
"    ]. This is based upon the known effectiveness of bisphosphonates in decreasing bone resorption and increasing bone mineral density in osteopenic postmenopausal women and adolescent patients with osteogenesis imperfecta. Studies of bisphosphonates include the following.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A one-year randomized trial in 32 adolescents with AN found a nonsignificant increase in bone mineral density in patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      , compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An open-label study compared bone mineral density in 10 women with AN who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      5 mg per day and 14 control patients with AN who did not receive risedronate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/91\">",
"       91",
"      </a>",
"      ]. Risedronate increased bone mineral density by 4 percent at six months and 5 percent at nine months. By contrast, the controls suffered bone loss despite weight gain. A five percent increase in bone mass over a three year period is generally deemed clinically significant and is associated with a 25 percent reduction in fracture risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of bisphosphonates to treat premenopausal and postmenopausal osteoporosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Bisphosphonates'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Bisphosphonates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Attempts to stimulate bone formation with anabolic medications such as dehydroepiandrosterone (DHEA) and transdermal testosterone have failed to demonstrate any benefit for increasing bone mineral density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/3,75\">",
"     3,75",
"    </a>",
"    ]. No randomized trials have found a benefit for other anabolic agents such as fluoride, teriparatide, or menatetrenone. The use of androgens for postmenopausal osteoporosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcitonin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    are used to treat postmenopausal osteoporosis and have been studied in premenopausal osteoporosis, but there are no credible studies in AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Calcitonin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Selective estrogen receptor modulators'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Other'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcium and vitamin D are not effective in restoring bone mineral content in patients with AN and osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/75\">",
"     75",
"    </a>",
"    ]. In addition, studies have found no correlation between calcium intake and bone mineral density in AN, suggesting that adequate calcium and vitamin D do not prevent osteoporosis. However, calcium is necessary for bone maintenance and restoration, and is considered standard treatment for patients with AN. The American Academy of Pediatrics and the Society for Adolescent Medicine both recommend that all adolescents ingest between 1200 and 1500 mg of calcium a day with 800 IU of vitamin D to achieve peak bone mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/92-94\">",
"     92-94",
"    </a>",
"    ]. Calcium and vitamin D supplementation in osteoporosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few observational studies have found that exercise exerts a protective effect upon bone mineral density in patients with AN, consistent with the known effect that weight bearing exercise has in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/75,95\">",
"     75,95",
"    </a>",
"    ]. However, other studies have found no relationship between the amount of physical activity in patients and their bone mineral density. In addition, a review of six studies found limited evidence supporting the use of moderate exercise to help patients with AN gain weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/96\">",
"     96",
"    </a>",
"    ]. Patients with osteoporosis should refrain from excessive exercise and activities that significantly increase the likelihood of fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/3\">",
"     3",
"    </a>",
"    ]. The use of exercise to treat premenopausal and osteoporosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Intensity of exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation and treatment of osteoporosis in premenopausal women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H163154010\">",
"    <span class=\"h2\">",
"     Thyroid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Euthyroid hypothyroxinemia may develop in AN, marked by normal to decreased serum levels of thyroxine (T",
"    <sub>",
"     4",
"    </sub>",
"    ) and triiodothyronine (T",
"    <sub>",
"     3",
"    </sub>",
"    ) levels, a normal level of thyroid stimulating hormone (TSH), and an increased level of reverse T",
"    <sub>",
"     3",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/21\">",
"     21",
"    </a>",
"    ]. Thyroid tests other than TSH are not indicated unless there is a strong suspicion of thyroid dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/10\">",
"     10",
"    </a>",
"    ]. When thyroid abnormalities are suspected, we suggest measuring total T",
"    <sub>",
"     4",
"    </sub>",
"    , free T",
"    <sub>",
"     3",
"    </sub>",
"    , and T",
"    <sub>",
"     3",
"    </sub>",
"    . Thyroid hormone replacement is not beneficial, may be harmful, and is thus not indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thyroid function in nonthyroidal illness and euthyroid hypothyroxinemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/856?source=see_link\">",
"     \"Euthyroid hyperthyroxinemia and hypothyroxinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86795515\">",
"    <span class=\"h2\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary restriction accompanied by weight loss and excessive exercise deplete hepatic glycogen stores and disrupt hepatic gluconeogenesis, resulting in hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/21\">",
"     21",
"    </a>",
"    ]. Hypoglycemia rarely causes symptoms in mild cases of AN. By contrast, individuals with advanced AN and persistent severe hypoglycemia have a poor prognosis; severe hypoglycemia has been associated with sudden death due to liver failure and a depletion of substrate to maintain safe blood glucose levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/98\">",
"     98",
"    </a>",
"    ]. An overview of hypoglycemia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44664?source=see_link\">",
"     \"Hypoglycemia in adults: Clinical manifestations, definition, and causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Severe complications can occur in patients with comorbid AN and diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/3\">",
"     3",
"    </a>",
"    ]. An overview of medical care in diabetes mellitus is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440145\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorexia nervosa (AN) consistently causes gastroparesis (delayed emptying of the stomach) and constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/99\">",
"     99",
"    </a>",
"    ], and there may be mild elevation of liver function tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/3\">",
"     3",
"    </a>",
"    ]. Acute pancreatitis in patients with AN has been described in case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/100\">",
"     100",
"    </a>",
"    ]. In addition, the superior mesenteric artery syndrome is a rare complication of AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440172\">",
"    <span class=\"h2\">",
"     Gastroparesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroparesis (delayed gastric emptying) frequently develops with food restriction and a weight loss of approximately 10 to 20 pounds (4.5 to 9.1 kg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/99,102\">",
"     99,102",
"    </a>",
"    ]. The main symptom is bloating (gas and distension), which often occurs after eating and may be severe. Bloating is worsened by a high-fiber diet or by fiber-based laxatives. Other symptoms of gastroparesis include early satiety, fullness, nausea, and vomiting (not self-induced). Heartburn may also occur as a result of acidic, vomitus-induced esophagitis from food remaining in the stomach for prolonged periods of time. In some cases it may be difficult to tell whether vomiting is spontaneous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    self-induced. The symptoms of gastroparesis may inhibit the patient from eating and hamper attempts at weight restoration.",
"   </p>",
"   <p>",
"    Gastroparesis in AN should be managed with the following conservative measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/1,21,35\">",
"     1,21,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reassure patients that eating is not causing gastroparesis, which will eventually resolve with weight restoration over four to six weeks",
"     </li>",
"     <li>",
"      Liquid food supplements should comprise half of the daily calories for the first week or two of refeeding",
"     </li>",
"     <li>",
"      Ingest liquid components as opposed to solids earlier in the meal",
"     </li>",
"     <li>",
"      Divide the daily calorie intake into three small meals and two to three snacks per day",
"     </li>",
"     <li>",
"      Avoid legume-type foods, excessive fiber, and bran products, which promote gas and distention",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients not responding to these measures, clinicians should use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , an oral medication that stimulates stomach contraction and hastens emptying of the stomach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/1\">",
"     1",
"    </a>",
"    ]. A dose of 5 or 10 mg, 30 minutes before meals and at bedtime, is useful to treat bloating and early satiety secondary to weight loss in AN. It also acts as an antiemetic medication. Metoclopramide increases risk for tardive dyskinesia with long-term use.",
"   </p>",
"   <p>",
"    Gastroparesis induced by weight loss generally improves with partial weight restoration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/35,103\">",
"     35,103",
"    </a>",
"    ]. A significant improvement often occurs with a 10 pound (4.5 kg) weight gain and the disorder largely resolves with weight gain back to 80 percent of ideal body weight. However, symptoms of bloating may persist despite weight gain, if there is ongoing psychopathological distress. Thus, in rare cases it may be necessary to obtain a nuclear medicine gastric emptying study to investigate persistent symptoms after refeeding and weight restoration.",
"   </p>",
"   <p>",
"    Additional information on gastroparesis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/12/43209?source=see_link\">",
"     \"Etiology and diagnosis of delayed gastric emptying\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/50/33576?source=see_link\">",
"     \"Treatment of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440179\">",
"    <span class=\"h2\">",
"     Constipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation frequently accompanies weight loss in AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/99\">",
"     99",
"    </a>",
"    ]. Symptoms include infrequent and small bowel movements and abdominal pain. Patients may incorrectly respond to their constipation or pain by starting treatment with bulking, fiber-containing laxatives or stimulant laxatives. These may worsen constipation. It is helpful to reassure patients that bowel patterns in healthy ambulatory patients normally vary from two or three times per day to three times per week, that patients with extensive weight loss have even fewer bowel movements, and that there is nothing fundamentally wrong with their bowels other than a need for weight gain. With weight restoration, the patient&rsquo;s prior bowel pattern should return over a few weeks. Additional conservative measures to manage constipation in AN include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/21,35\">",
"     21,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Water (six to eight glasses per day)",
"     </li>",
"     <li>",
"      Fiber in low doses (10 grams per day)",
"     </li>",
"     <li>",
"      Avoiding high doses of fiber, which can cause bloating",
"     </li>",
"     <li>",
"      Polyethylene glycol powder (one to three tablespoons per day)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"     Lactulose",
"    </a>",
"    , 30 to 60 mL one to two times per day, should be used as a last resort if the other measures have failed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/21,35\">",
"     21,35",
"    </a>",
"    ]. Additional information about the treatment of constipation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=see_link\">",
"     \"Management of chronic constipation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440186\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;AN can lead to other gastrointestinal complications, including elevated liver function tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/3\">",
"     3",
"    </a>",
"    ], the superior mesenteric artery (SMA) syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/101\">",
"     101",
"    </a>",
"    ], and acute pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weight loss and fasting can mildly elevate liver function tests (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and bilirubin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/104\">",
"     104",
"    </a>",
"    ]. A study of 214 women with AN found that alanine aminotransferase was elevated in 12 percent, with a range of 31 to 161",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    (normal 7 to 30",
"    <span class=\"nowrap\">",
"     U/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/13\">",
"     13",
"    </a>",
"    ]. Liver wasting may also cause decreased protein synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/11\">",
"     11",
"    </a>",
"    ]. Rarely, transaminases may be markedly elevated with severe AN and a sign of serious multiorgan failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/105\">",
"     105",
"    </a>",
"    ]. Nutritional rehabilitation is then required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/18\">",
"     18",
"    </a>",
"    ]. An overview of evaluating patients with elevated liver functions tests is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The superior mesenteric artery (SMA) syndrome is a rare complication that can occur in AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/10,101\">",
"     10,101",
"    </a>",
"    ]. It results from compression of the third portion of the duodenum between the aorta posteriorly and the SMA anteriorly. The SMA is normally covered with fatty tissue; weight loss reduces the fat pad and narrows the angle between the two vessels, entrapping the duodenum. Depending upon the severity of the complication, symptoms include early satiety, abdominal pain soon after starting a meal, nausea, and vomiting. Weight gain of as little as 5 to 10 pounds (2.3 to 4.5 kg) can lead to tolerance of normal feeding. The clinical manifestations, diagnosis, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/58/37799?source=see_link\">",
"     \"Superior mesenteric artery syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute pancreatitis in patients with AN has been described in multiple case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/100\">",
"     100",
"    </a>",
"    ]. The inflammation is usually marked by acute upper abdominal pain and elevated serum levels of pancreatic enzymes. The presumptive etiology is that malnutrition activates proteases, such as trypsin, which damage cells. In addition, rapid weight loss may cause retrograde pressure or reflux of duodenal contents into the pancreatic duct. The etiology, clinical manifestations and treatment of acute pancreatitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/35/7738?source=see_link\">",
"     \"Treatment of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H837225\">",
"    <span class=\"h1\">",
"     RENAL AND ELECTROLYTES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AN may demonstrate a reduced glomerular filtration rate and problems concentrating their urine, which leads to diuresis and dehydration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. Patients with restricting AN typically present with low creatinine due to reduced muscle mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/8\">",
"     8",
"    </a>",
"    ]. Renal function appears to recover with weight gain.",
"   </p>",
"   <p>",
"    Potassium, magnesium, and phosphate are occasionally depleted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/2\">",
"     2",
"    </a>",
"    ], and hypokalemia may induce nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/108\">",
"     108",
"    </a>",
"    ]. However, electrolytes in restricting AN are generally normal, and abnormalities may indicate covert purging. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6245?source=see_link\">",
"     \"Hypokalemia-induced renal dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rehydration and repletion of electrolytes should be corrected prior to refeeding the patient. Management of electrolyte abnormalities is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=see_link&amp;anchor=H8#H8\">",
"       \"Maintenance and replacement fluid therapy in adults\", section on 'Replacement fluid therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/9/9366?source=see_link\">",
"       \"Evaluation of the patient with hypokalemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=see_link\">",
"       \"Clinical manifestations and treatment of hypokalemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11254?source=see_link\">",
"       \"Evaluation and treatment of hypomagnesemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2167?source=see_link\">",
"       \"Diagnosis and treatment of hypophosphatemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1782633\">",
"    <span class=\"h1\">",
"     PULMONARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;AN can lead to weakness and wasting of respiratory muscles, dyspnea, reduced aerobic capacity, and decreased pulmonary capacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/10,109\">",
"     10,109",
"    </a>",
"    ]. Respiratory muscle weakness and diaphragmatic functioning may be slow to recover after refeeding. An overview of dyspnea and other causes and diagnosis of bilateral and unilateral diaphragmatic paralysis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16553?source=see_link\">",
"     \"Approach to the patient with dyspnea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/20/35142?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have found abnormal results of pulmonary function tests in patients with AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/109\">",
"     109",
"    </a>",
"    ]. As an example, one study of 27 patients with AN and 18 healthy controls demonstrated significant functional impairment in patients, which worsened progressively with the duration of AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/110\">",
"     110",
"    </a>",
"    ]. The nature of the impairment indicated enlargement of peripheral lung units without alveolar septa destruction, consistent with changes observed in elderly patients and not in patients with classic emphysema. It is not known whether this impairment is reversible with refeeding.",
"   </p>",
"   <p>",
"    Pneumothorax has been described in case reports, with prolonged air leak in patients with severe malnutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/111\">",
"     111",
"    </a>",
"    ]. It is not known whether the pulmonary changes that predispose to spontaneous pneumothorax or persistent air leak are reversible with refeeding. Pneumothorax and management of prolonged air leak are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link&amp;anchor=H11#H11\">",
"     \"Primary spontaneous pneumothorax in adults\", section on 'Initial management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link&amp;anchor=H16#H16\">",
"     \"Primary spontaneous pneumothorax in adults\", section on 'Persistent air leak'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumomediastinum has also been reported in severe cases of AN, due to alveolar wall weakness and rupture, with consequent air leak into the mediastinum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. Symptoms include chest pain, dyspnea, and anxiety, and physical examination reveals subcutaneous crepitation. In the absence of traumatic or iatrogenic events, the complication should be managed by radiographic surveillance and resolve within a few weeks without surgical drainage. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31379427\">",
"    <span class=\"h1\">",
"     HEMATOLOGIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytopenias and bone marrow changes are observed in AN, and are all reversible with nutritional rehabilitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/114-117\">",
"     114-117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The bone marrow is often affected in AN. In a study of 44 patients with AN, bone marrow biopsies were classified as normal in 11 percent, hypoplastic or aplastic in 39 percent, and gelatinous degeneration with serous fat atrophy in 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/117\">",
"     117",
"    </a>",
"    ]. The authors found that severity of bone marrow changes correlated with the degree of weight loss.",
"   </p>",
"   <p>",
"    Patients with AN may present with anemia, leukopenia, or thrombocytopenia in a pattern involving one, two, or all three cell lines simultaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/114\">",
"     114",
"    </a>",
"    ]. Approximately 33 percent of patients with AN are anemic, which tends to be normocytic and normochromic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/115\">",
"     115",
"    </a>",
"    ]. Approximately 33 percent of outpatients with AN and as many as 75 percent of inpatients are leukopenic, and both relative lymphopenia and neutropenia have been observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/13\">",
"     13",
"    </a>",
"    ]. Thrombocytopenia occurs in 5 to 10 percent of patients with AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/114\">",
"     114",
"    </a>",
"    ], but there are case reports describing both severe thrombocytopenia and bleeding complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians should have a lower threshold for considering infectious complications because signs of infection such as fever may be absent. A retrospective study matched 23 cases of bacterial infection in patients with AN to cases of bacterial infection in patients without AN, and found that the diagnosis of the infection was often delayed and that more complications occurred in the patients with AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/118\">",
"     118",
"    </a>",
"    ]. However, the majority of outpatients with AN and leukopenia do not seem to have infectious complications, and population-based surveys report that infection is not a major cause of death in AN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Petechiae and purpura may appear on the extremities as a result of these hematologic complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/2,119\">",
"     2,119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31379434\">",
"    <span class=\"h1\">",
"     NEUROLOGIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain atrophy is a complication of AN that is evident on neuroimaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. The specific clinical implications of brain atrophy are not known. A study found that gray matter volume was significantly smaller in adolescents with AN compared with controls, but that performance on neuropsychological tests was comparable except for one test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific findings on magnetic resonance imaging (MRI) and computerized tomography (CT) include gray matter (neuron cell bodies) volume loss and enlarged ventricles. An MRI study found that mean average gray matter volume in 32 women with AN was 5 percent less than in 21 control women, a statistically significant and moderate clinical difference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/122\">",
"     122",
"    </a>",
"    ]. In addition, an MRI study of 16 women with AN and 16 matched healthy women found that the right and left hippocampus were each significantly reduced by 8 percent in the patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/123\">",
"     123",
"    </a>",
"    ]. It remains unclear whether these brain changes are related to the loss of neurons, glia, and neuropil, or are merely due to fluid shifts.",
"   </p>",
"   <p>",
"    Results from different studies suggest that brain atrophy is at least partially reversible with weight restoration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. An MRI study of women with AN found that during short-term hospitalization and weight restoration to 90 percent of ideal body weight, gray matter volumes increased but remained significantly smaller, compared with control women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/122\">",
"     122",
"    </a>",
"    ]. A second MRI study of 12 female adolescents with AN and 9 controls found that gray matter volumes were significantly smaller in the patients at the beginning of their treatment, but that after seven months, there was no significant difference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31379441\">",
"    <span class=\"h1\">",
"     DERMATOLOGIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cutaneous manifestations of AN are numerous. Symptoms of starvation include, in order of frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/14,119\">",
"     14,119",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Xerosis (dry, scaly skin)",
"     </li>",
"     <li>",
"      Lanugo-like body hair (fine, downy, dark hair)",
"     </li>",
"     <li>",
"      Telogen effluvium (hair loss)",
"     </li>",
"     <li>",
"      Carotenoderma (yellowing)",
"     </li>",
"     <li>",
"      Acne",
"     </li>",
"     <li>",
"      Hyperpigmentation",
"     </li>",
"     <li>",
"      Seborrheic dermatitis (erythema and greasy scales)",
"     </li>",
"     <li>",
"      Acrocyanosis (cold, blue, and occasionally sweaty hands or feet)",
"     </li>",
"     <li>",
"      Perniosis (painful or pruritic erythema)",
"     </li>",
"     <li>",
"      Petechiae",
"     </li>",
"     <li>",
"      Livedo reticularis (reddish-cyanotic circular patches)",
"     </li>",
"     <li>",
"      Paronychia (inflamed lateral and posterior nail folds)",
"     </li>",
"     <li>",
"      Pruritus",
"     </li>",
"     <li>",
"      Striae distensae (erythematous or hypopigmented linear patches)",
"     </li>",
"     <li>",
"      Slower wound healing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Xerosis on the back and arms is frequently present due to reduced sebaceous gland secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/119,124,125\">",
"     119,124,125",
"    </a>",
"    ]. A case series of 62 patients with AN found xerosis in 97 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/126\">",
"     126",
"    </a>",
"    ]. Moisturizing ointments and humidifying the environment can ameliorate the problem and relieve pruritus. Lanugo hair on the back, abdomen, and forearms is not a sign of virilization. Carotenoderma is due to excess ingestion of carotenoid-rich vegetables that are low in calories, and decreased hepatic catabolism of carotene. Acne can be caused by starvation, but may also be a risk factor for AN, in that a new dieting behavior intended to control acne may additionally lead to weight loss and then AN. Seborrheic dermatitis (most commonly on the scalp) should be treated with medicated shampoos. Acrocyanosis is associated with arterial vasoconstriction and secondary dilation of venules, and may represent a mechanism by which the body conserves heat. Delayed wound healing may be the result of hypothyroidism and zinc deficiency.",
"   </p>",
"   <p>",
"    Although most complications improve or resolve with weight gain, striae distensae do not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/124\">",
"     124",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1862?source=see_link\">",
"     Topical tretinoin",
"    </a>",
"    may be used (but only for three months) if the areas are not too large.",
"   </p>",
"   <p>",
"    Self-injurious behavior is common in AN, and patients may show acute or chronic signs of trauma from cuts or burns (dermatitis artefacta) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/62/38890/abstract/3,10,125\">",
"     3,10,125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/16/25858?source=see_link\">",
"       \"Patient information: Anorexia nervosa (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1598714\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The numerous medical complications of anorexia nervosa (AN) are a direct result of weight loss and malnutrition. The number of organ systems adversely affected increases with the severity of weight loss (",
"      <a class=\"graphic graphic_table graphicRef67080 \" href=\"mobipreview.htm?29/44/30413\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5205559\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment for each complication includes nutritional replenishment, and many complications resolve with weight gain. There are few randomized trials that have evaluated the management of medical complications from AN. (See",
"      <a class=\"local\" href=\"#H5205559\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiovascular complications involve structural abnormalities, including decreased cardiac mass, reduced cardiac chamber volumes, and mitral valve prolapse. In addition, functional changes include bradycardia, increased QT dispersion, and hypotension. A prolonged QT interval may be seen in some patients, but it is not clear whether AN directly causes the syndrome. (See",
"      <a class=\"local\" href=\"#H8741290\">",
"       'Structural changes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8741312\">",
"       'Functional changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The reproductive system is altered, causing a cascade of events resulting in secondary amenorrhea. By definition, all patients with AN have amenorrhea (functional hypothalamic amenorrhea). Normal menstrual cycles usually resume with weight gain. However, amenorrhea persists in about 10 to 30 percent of patients with AN despite weight gain. (See",
"      <a class=\"local\" href=\"#H31379371\">",
"       'Gynecologic and reproductive'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients may become pregnant despite their amenorrheic state. Fertility is intact in patients who recover from AN, and remains stable. However, there is a higher rate of pregnancy and neonatal complications in AN. (See",
"      <a class=\"local\" href=\"#H31379385\">",
"       'Fertility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with AN have low levels of gonadotropin releasing hormone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), insulin-like growth factor 1 (IGF-1), free testosterone, triiodothyronine (T",
"      <sub>",
"       3",
"      </sub>",
"      ), thyroxine (T",
"      <sub>",
"       4",
"      </sub>",
"      ), leptin, and antidiuretic hormone (ADH). In addition, there are increased levels of growth hormone and cortisol. (See",
"      <a class=\"local\" href=\"#H31379420\">",
"       'Endocrine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteoporosis occurs in at least 30 percent of female patients with AN, which increases their risk of fractures (",
"      <a class=\"graphic graphic_figure graphicRef56741 \" href=\"mobipreview.htm?43/24/44425\">",
"       figure 1",
"      </a>",
"      ). The degree of osteoporosis is correlated with weight loss and duration of amenorrhea. For patients with AN who are amenorrheic for more than six months, a baseline index of bone mineral density should be established with dual-energy X-ray absorptiometry (DEXA). For patients who continue to suffer episodes of AN, a follow-up test should be done every two years. (See",
"      <a class=\"local\" href=\"#H27332237\">",
"       'Osteoporosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best established treatment for loss of bone mineral density in AN is weight gain and resumption of menses. For patients with AN, amenorrhea, and osteoporosis, it is reasonable to prescribe supplemental calcium and vitamin D. For the most severely ill patients with a body weight less than 70 percent of ideal body weight, there may possibly be a role for supplemental estrogen. (See",
"      <a class=\"local\" href=\"#H27332251\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastroparesis consistently occurs in AN. For patients with AN and gastroparesis, we suggest using liquid food supplements to provide half of the daily calories for the first week or two of refeeding; ingesting liquid components earlier in each meal; dividing the daily calorie intake into three small meals and two snacks per day; and avoiding legume-type foods, excessive fiber, and bran products; rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      to restore bowel function (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Unresponsive gastroparesis can be treated with metoclopramide 5 or 10 mg, 30 minutes before meals and at bedtime. (See",
"      <a class=\"local\" href=\"#H440172\">",
"       'Gastroparesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Constipation also occurs often in AN. For patients with AN and constipation, we suggest six to eight glasses of water per day, fiber 10 grams per day, and polyethylene glycol powder one to three tablespoons per day, rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"       lactulose",
"      </a>",
"      to restore bowel function (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Unresponsive constipation can be treated with lactulose 30 to 60 mL one to two times per day. (See",
"      <a class=\"local\" href=\"#H440179\">",
"       'Constipation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/1\">",
"      Mehler PS. Diagnosis and care of patients with anorexia nervosa in primary care settings. Ann Intern Med 2001; 134:1048.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     Eating Disorders: Core Interventions in the Treatment of and Management of Anorexia Nervosa, Bulimia Nervosa and Related Eating Disorders. National Institute for Clinical Excellence, Clinical Guideline 9. file://guidance.nice.org.uk (Accessed on December 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/4\">",
"      Sullivan PF. Mortality in anorexia nervosa. Am J Psychiatry 1995; 152:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/5\">",
"      Steinhausen HC. The outcome of anorexia nervosa in the 20th century. Am J Psychiatry 2002; 159:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/6\">",
"      L&ouml;we B, Zipfel S, Buchholz C, et al. Long-term outcome of anorexia nervosa in a prospective 21-year follow-up study. Psychol Med 2001; 31:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/7\">",
"      Keel PK, Dorer DJ, Eddy KT, et al. Predictors of mortality in eating disorders. Arch Gen Psychiatry 2003; 60:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/8\">",
"      Herzog W, Deter HC, Fiehn W, Petzold E. Medical findings and predictors of long-term physical outcome in anorexia nervosa: a prospective, 12-year follow-up study. Psychol Med 1997; 27:269.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. file://www.who.int/classifications/icd/en/bluebook.pdf (Accessed on December 07, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/10\">",
"      American Psychiatric Association. Treatment of patients with eating disorders,third edition. American Psychiatric Association. Am J Psychiatry 2006; 163:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/11\">",
"      Fuentebella J, Kerner JA. Refeeding syndrome. Pediatr Clin North Am 2009; 56:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/12\">",
"      Boateng AA, Sriram K, Meguid MM, Crook M. Refeeding syndrome: treatment considerations based on collective analysis of literature case reports. Nutrition 2010; 26:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/13\">",
"      Miller KK, Grinspoon SK, Ciampa J, et al. Medical findings in outpatients with anorexia nervosa. Arch Intern Med 2005; 165:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/14\">",
"      Mitchell JE, Crow S. Medical complications of anorexia nervosa and bulimia nervosa. Curr Opin Psychiatry 2006; 19:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/15\">",
"      Olivares JL, V&aacute;zquez M, Fleta J, et al. Cardiac findings in adolescents with anorexia nervosa at diagnosis and after weight restoration. Eur J Pediatr 2005; 164:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/16\">",
"      Cooke RA, Chambers JB, Singh R, et al. QT interval in anorexia nervosa. Br Heart J 1994; 72:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/17\">",
"      Goldberg SJ, Comerci GD, Feldman L. Cardiac output and regional myocardial contraction in anorexia nervosa. J Adolesc Health Care 1988; 9:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/18\">",
"      Mehler PS, Winkelman AB, Andersen DM, Gaudiani JL. Nutritional rehabilitation: practical guidelines for refeeding the anorectic patient. J Nutr Metab 2010; 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/19\">",
"      Johnson GL, Humphries LL, Shirley PB, et al. Mitral valve prolapse in patients with anorexia nervosa and bulimia. Arch Intern Med 1986; 146:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/20\">",
"      Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999; 341:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/21\">",
"      Mehler PS, Krantz M. Anorexia nervosa medical issues. J Womens Health (Larchmt) 2003; 12:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/22\">",
"      Isner JM, Roberts WC, Heymsfield SB, Yager J. Anorexia nervosa and sudden death. Ann Intern Med 1985; 102:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/23\">",
"      Mehler PS, Lezotte D, Eckel R. Lipid levels in anorexia nervosa. Int J Eat Disord 1998; 24:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/24\">",
"      Fr&ouml;lich J, von Gontard A, Lehmkuhl G, et al. Pericardial effusions in anorexia nervosa. Eur Child Adolesc Psychiatry 2001; 10:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/25\">",
"      Docx MK, Gewillig M, Simons A, et al. Pericardial effusions in adolescent girls with anorexia nervosa: clinical course and risk factors. Eat Disord 2010; 18:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/26\">",
"      Melanson EL, Donahoo WT, Krantz MJ, et al. Resting and ambulatory heart rate variability in chronic anorexia nervosa. Am J Cardiol 2004; 94:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/27\">",
"      Casiero D, Frishman WH. Cardiovascular complications of eating disorders. Cardiol Rev 2006; 14:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/28\">",
"      Kanbur NO, Goldberg E, Pinhas L, et al. Second-degree atrioventricular block (Mobitz Type I) in an adolescent with anorexia nervosa: intrinsic or acquired conduction abnormality. Int J Eat Disord 2009; 42:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/29\">",
"      Ulger Z, G&uuml;rses D, Ozyurek AR, et al. Follow-up of cardiac abnormalities in female adolescents with anorexia nervosa after refeeding. Acta Cardiol 2006; 61:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/30\">",
"      Walder A, Baumann P. Cardiac left bundle branch block and pancytopenia in anorexia nervosa: higher risk with mirtazapine and pantoprazole? Case report. Pharmacopsychiatry 2009; 42:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/31\">",
"      Bravender T, Kanter R, Zucker N. Anorexia nervosa and second-degree atrioventricular block (Type I). Int J Eat Disord 2006; 39:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/32\">",
"      Krantz MJ, Donahoo WT, Melanson EL, Mehler PS. QT interval dispersion and resting metabolic rate in chronic anorexia nervosa. Int J Eat Disord 2005; 37:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/33\">",
"      Mehler PS, Krantz MJ. QT dispersion in anorexia nervosa. Am J Cardiol 2005; 96:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/34\">",
"      Mont L, Castro J, Herreros B, et al. Reversibility of cardiac abnormalities in adolescents with anorexia nervosa after weight recovery. J Am Acad Child Adolesc Psychiatry 2003; 42:808.",
"     </a>",
"    </li>",
"    <li>",
"     Mehler, PS, Birmingham, LC, Crow, SJ, Jahraus, JP. Medical complications of eating disorders. In: The Treatment of Eating Disorders: A Clinical Handbook, Grilo, CM, Mitchell, JE (Eds), The Guilford Press, New York 2010. p.66.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/36\">",
"      Roche F, Barth&eacute;l&eacute;my JC, Mayaud N, et al. Refeeding normalizes the QT rate dependence of female anorexic patients. Am J Cardiol 2005; 95:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/37\">",
"      Facchini M, Sala L, Malfatto G, et al. Low-K+ dependent QT prolongation and risk for ventricular arrhythmia in anorexia nervosa. Int J Cardiol 2006; 106:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/38\">",
"      Awazu M, Matsuoka S, Kamimaki T, et al. Absent circadian variation of blood pressure in patients with anorexia nervosa. J Pediatr 2000; 136:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/39\">",
"      Galetta F, Franzoni F, Prattichizzo F, et al. Heart rate variability and left ventricular diastolic function in anorexia nervosa. J Adolesc Health 2003; 32:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/40\">",
"      Derman T, Szabo CP. Why do individuals with anorexia die? A case of sudden death. Int J Eat Disord 2006; 39:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/41\">",
"      Krantz MJ, Mehler PS. Resting tachycardia, a warning sign in anorexia nervosa: case report. BMC Cardiovasc Disord 2004; 4:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/42\">",
"      Shamim T, Golden NH, Arden M, et al. Resolution of vital sign instability: an objective measure of medical stability in anorexia nervosa. J Adolesc Health 2003; 32:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/43\">",
"      Katz MG, Vollenhoven B. The reproductive endocrine consequences of anorexia nervosa. BJOG 2000; 107:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/44\">",
"      Waller K, Swan SH, Windham GC, et al. Use of urine biomarkers to evaluate menstrual function in healthy premenopausal women. Am J Epidemiol 1998; 147:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/45\">",
"      Doufas AG, Mastorakos G. The hypothalamic-pituitary-thyroid axis and the female reproductive system. Ann N Y Acad Sci 2000; 900:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/46\">",
"      Vyver E, Steinegger C, Katzman DK. Eating disorders and menstrual dysfunction in adolescents. Ann N Y Acad Sci 2008; 1135:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/47\">",
"      Dalle Grave R, Calugi S, Marchesini G. Is amenorrhea a clinically useful criterion for the diagnosis of anorexia nervosa? Behav Res Ther 2008; 46:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/48\">",
"      Golden NH, Carlson JL. The pathophysiology of amenorrhea in the adolescent. Ann N Y Acad Sci 2008; 1135:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/49\">",
"      Golden NH, Jacobson MS, Schebendach J, et al. Resumption of menses in anorexia nervosa. Arch Pediatr Adolesc Med 1997; 151:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/50\">",
"      Golden NH, Jacobson MS, Sterling WM, Hertz S. Treatment goal weight in adolescents with anorexia nervosa: use of BMI percentiles. Int J Eat Disord 2008; 41:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/51\">",
"      Swenne I. Weight requirements for return of menstruations in teenage girls with eating disorders, weight loss and secondary amenorrhoea. Acta Paediatr 2004; 93:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/52\">",
"      Poyastro Pinheiro A, Thornton LM, Plotonicov KH, et al. Patterns of menstrual disturbance in eating disorders. Int J Eat Disord 2007; 40:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/53\">",
"      Bulik CM, Hoffman ER, Von Holle A, et al. Unplanned pregnancy in women with anorexia nervosa. Obstet Gynecol 2010; 116:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/54\">",
"      Koubaa S, Kouba S, H&auml;llstr&ouml;m T, et al. Pregnancy and neonatal outcomes in women with eating disorders. Obstet Gynecol 2005; 105:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/55\">",
"      Bulik CM, Sullivan PF, Fear JL, et al. Fertility and reproduction in women with anorexia nervosa: a controlled study. J Clin Psychiatry 1999; 60:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/56\">",
"      Stewart DE, Robinson E, Goldbloom DS, Wright C. Infertility and eating disorders. Am J Obstet Gynecol 1990; 163:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/57\">",
"      Lo Sauro C, Ravaldi C, Cabras PL, et al. Stress, hypothalamic-pituitary-adrenal axis and eating disorders. Neuropsychobiology 2008; 57:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/58\">",
"      Fazeli PK, Lawson EA, Prabhakaran R, et al. Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2010; 95:4889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/59\">",
"      Mastorakos G, Pavlatou MG, Mizamtsidi M. The hypothalamic-pituitary-adrenal and the hypothalamic- pituitary-gonadal axes interplay. Pediatr Endocrinol Rev 2006; 3 Suppl 1:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/60\">",
"      Estour B, Germain N, Diconne E, et al. Hormonal profile heterogeneity and short-term physical risk in restrictive anorexia nervosa. J Clin Endocrinol Metab 2010; 95:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/61\">",
"      Miller KK, Wexler TL, Zha AM, et al. Androgen deficiency: association with increased anxiety and depression symptom severity in anorexia nervosa. J Clin Psychiatry 2007; 68:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/62\">",
"      Mehler, PS, Eckel, R, Donahoo, WT. Leptin levels in anorexia nervosa. Int J Eat Disord 1990; 150:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/63\">",
"      Misra M, Miller KK, Almazan C, et al. Hormonal and body composition predictors of soluble leptin receptor, leptin, and free leptin index in adolescent girls with anorexia nervosa and controls and relation to insulin sensitivity. J Clin Endocrinol Metab 2004; 89:3486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/64\">",
"      Misra M, Miller KK, Almazan C, et al. Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J Clin Endocrinol Metab 2004; 89:4972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/65\">",
"      Miller KK, Lawson EA, Mathur V, et al. Androgens in women with anorexia nervosa and normal-weight women with hypothalamic amenorrhea. J Clin Endocrinol Metab 2007; 92:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/66\">",
"      Miller KK, Grieco KA, Klibanski A. Testosterone administration in women with anorexia nervosa. J Clin Endocrinol Metab 2005; 90:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/67\">",
"      Golden NH, Kreitzer P, Jacobson MS, et al. Disturbances in growth hormone secretion and action in adolescents with anorexia nervosa. J Pediatr 1994; 125:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/68\">",
"      Grinspoon S, Baum H, Lee K, et al. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab 1996; 81:3864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/69\">",
"      D&iacute;az M, Becker DE. Thermoregulation: physiological and clinical considerations during sedation and general anesthesia. Anesth Prog 2010; 57:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/70\">",
"      Grinspoon S, Thomas E, Pitts S, et al. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann Intern Med 2000; 133:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/71\">",
"      Winston AP, Alwazeer AE, Bankart MJ. Screening for osteoporosis in anorexia nervosa: prevalence and predictors of reduced bone mineral density. Int J Eat Disord 2008; 41:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/72\">",
"      Lucas AR, Melton LJ 3rd, Crowson CS, O'Fallon WM. Long-term fracture risk among women with anorexia nervosa: a population-based cohort study. Mayo Clin Proc 1999; 74:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/73\">",
"      Rigotti NA, Neer RM, Skates SJ, et al. The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA 1991; 265:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/74\">",
"      Aud&iacute; L, Vargas DM, Gussiny&eacute; M, et al. Clinical and biochemical determinants of bone metabolism and bone mass in adolescent female patients with anorexia nervosa. Pediatr Res 2002; 51:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/75\">",
"      Mehler PS, MacKenzie TD. Treatment of osteopenia and osteoporosis in anorexia nervosa: a systematic review of the literature. Int J Eat Disord 2009; 42:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/76\">",
"      Wong S, Au B, Lau E, et al. Osteoporosis in Chinese patients with anorexia nervosa. Int J Eat Disord 2004; 36:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/77\">",
"      Baker D, Roberts R, Towell T. Factors predictive of bone mineral density in eating-disordered women: a longitudinal study. Int J Eat Disord 2000; 27:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/78\">",
"      Stoffman N, Schwartz B, Austin SB, et al. Influence of bone density results on adolescents with anorexia nervosa. Int J Eat Disord 2005; 37:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/79\">",
"      Miller KK, Lee EE, Lawson EA, et al. Determinants of skeletal loss and recovery in anorexia nervosa. J Clin Endocrinol Metab 2006; 91:2931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/80\">",
"      Bolton JG, Patel S, Lacey JH, White S. A prospective study of changes in bone turnover and bone density associated with regaining weight in women with anorexia nervosa. Osteoporos Int 2005; 16:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/81\">",
"      Bass SL, Saxon L, Corral AM, et al. Near normalisation of lumbar spine bone density in young women with osteopenia recovered from adolescent onset anorexia nervosa: a longitudinal study. J Pediatr Endocrinol Metab 2005; 18:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/82\">",
"      Klibanski A, Biller BM, Schoenfeld DA, et al. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab 1995; 80:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/83\">",
"      Golden NH, Lanzkowsky L, Schebendach J, et al. The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa. J Pediatr Adolesc Gynecol 2002; 15:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/84\">",
"      Wentz E, Mellstr&ouml;m D, Gillberg C, et al. Bone density 11 years after anorexia nervosa onset in a controlled study of 39 cases. Int J Eat Disord 2003; 34:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/85\">",
"      Ward A, Brown N, Treasure J. Persistent osteopenia after recovery from anorexia nervosa. Int J Eat Disord 1997; 22:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/86\">",
"      Robinson E, Bachrach LK, Katzman DK. Use of hormone replacement therapy to reduce the risk of osteopenia in adolescent girls with anorexia nervosa. J Adolesc Health 2000; 26:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/87\">",
"      Strokosch GR, Friedman AJ, Wu SC, Kamin M. Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study. J Adolesc Health 2006; 39:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/88\">",
"      Grinspoon S, Herzog D, Klibanski A. Mechanisms and treatment options for bone loss in anorexia nervosa. Psychopharmacol Bull 1997; 33:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/89\">",
"      Grinspoon S, Thomas L, Miller K, et al. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 2002; 87:2883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/90\">",
"      Golden NH, Iglesias EA, Jacobson MS, et al. Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2005; 90:3179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/91\">",
"      Miller KK, Grieco KA, Mulder J, et al. Effects of risedronate on bone density in anorexia nervosa. J Clin Endocrinol Metab 2004; 89:3903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/92\">",
"      Golden NH, Katzman DK, Kreipe RE, et al. Eating disorders in adolescents: position paper of the Society for Adolescent Medicine. J Adolesc Health 2003; 33:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/93\">",
"      Baker SS, Cochran WJ, Flores CA, et al. American Academy of Pediatrics. Committee on Nutrition. Calcium requirements of infants, children, and adolescents. Pediatrics 1999; 104:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/94\">",
"      Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/95\">",
"      Gordon CM, Goodman E, Emans SJ, et al. Physiologic regulators of bone turnover in young women with anorexia nervosa. J Pediatr 2002; 141:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/96\">",
"      Zunker C, Mitchell JE, Wonderlich SA. Exercise interventions for women with anorexia nervosa: A review of the literature. Int J Eat Disord 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/97\">",
"      Utiger RD. Altered thyroid function in nonthyroidal illness and surgery. To treat or not to treat? N Engl J Med 1995; 333:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/98\">",
"      Rich LM, Caine MR, Findling JW, Shaker JL. Hypoglycemic coma in anorexia nervosa. Case report and review of the literature. Arch Intern Med 1990; 150:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/99\">",
"      Zipfel S, Sammet I, Rapps N, et al. Gastrointestinal disturbances in eating disorders: clinical and neurobiological aspects. Auton Neurosci 2006; 129:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/100\">",
"      Morris LG, Stephenson KE, Herring S, Marti JL. Recurrent acute pancreatitis in anorexia and bulimia. JOP 2004; 5:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/101\">",
"      Mehler PS, Weiner KL. Use of total parenteral nutrition in the refeeding of selected patients with severe anorexia nervosa. Int J Eat Disord 2007; 40:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/102\">",
"      Kamal N, Chami T, Andersen A, et al. Delayed gastrointestinal transit times in anorexia nervosa and bulimia nervosa. Gastroenterology 1991; 101:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/103\">",
"      Benini L, Todesco T, Dalle Grave R, et al. Gastric emptying in patients with restricting and binge/purging subtypes of anorexia nervosa. Am J Gastroenterol 2004; 99:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/104\">",
"      Narayanan V, Gaudiani JL, Harris RH, Mehler PS. Liver function test abnormalities in anorexia nervosa--cause or effect. Int J Eat Disord 2010; 43:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/105\">",
"      De Caprio C, Alfano A, Senatore I, et al. Severe acute liver damage in anorexia nervosa: two case reports. Nutrition 2006; 22:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/106\">",
"      Boag F, Weerakoon J, Ginsburg J, et al. Diminished creatinine clearance in anorexia nervosa: reversal with weight gain. J Clin Pathol 1985; 38:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/107\">",
"      Lowinger K, Griffiths RA, Beumont PJ, et al. Fluid restriction in anorexia nervosa: a neglected symptom or new phenomenon? Int J Eat Disord 1999; 26:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/108\">",
"      Brown NW. Medical consequences of eating disorders. South Med J 1985; 78:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/109\">",
"      Birmingham CL, Tan AO. Respiratory muscle weakness and anorexia nervosa. Int J Eat Disord 2003; 33:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/110\">",
"      Gardini Gardenghi G, Boni E, Todisco P, et al. Respiratory function in patients with stable anorexia nervosa. Chest 2009; 136:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/111\">",
"      Biffl WL, Narayanan V, Gaudiani JL, Mehler PS. The management of pneumothorax in patients with anorexia nervosa: A case report and review of the literature. Patient Saf Surg 2010; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/112\">",
"      Filosso PL, Garabello D, Lyberis P, et al. Spontaneous pneumomediastinum: a rare complication of anorexia nervosa. J Thorac Cardiovasc Surg 2010; 139:e79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/113\">",
"      Hochlehnert A, L&ouml;we B, Bludau HB, et al. Spontaneous pneumomediastinum in anorexia nervosa: a case report and review of the literature on pneumomediastinum and pneumothorax. Eur Eat Disord Rev 2010; 18:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/114\">",
"      H&uuml;tter G, Ganepola S, Hofmann WK. The hematology of anorexia nervosa. Int J Eat Disord 2009; 42:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/115\">",
"      Misra M, Aggarwal A, Miller KK, et al. Effects of anorexia nervosa on clinical, hematologic, biochemical, and bone density parameters in community-dwelling adolescent girls. Pediatrics 2004; 114:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/116\">",
"      Saito S, Kita K, Morioka CY, Watanabe A. Rapid recovery from anorexia nervosa after a life-threatening episode with severe thrombocytopenia: report of three cases. Int J Eat Disord 1999; 25:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/117\">",
"      Abella E, Feliu E, Granada I, et al. Bone marrow changes in anorexia nervosa are correlated with the amount of weight loss and not with other clinical findings. Am J Clin Pathol 2002; 118:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/118\">",
"      Brown RF, Bartrop R, Beumont P, Birmingham CL. Bacterial infections in anorexia nervosa: delayed recognition increases complications. Int J Eat Disord 2005; 37:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/119\">",
"      Strumia R. Skin signs in anorexia nervosa. Dermatoendocrinol 2009; 1:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/120\">",
"      Castro-Fornieles J, Bargall&oacute; N, L&aacute;zaro L, et al. A cross-sectional and follow-up voxel-based morphometric MRI study in adolescent anorexia nervosa. J Psychiatr Res 2009; 43:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/121\">",
"      Ehrlich S, Burghardt R, Weiss D, et al. Glial and neuronal damage markers in patients with anorexia nervosa. J Neural Transm 2008; 115:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/122\">",
"      Roberto CA, Mayer LE, Brickman AM. Brain tissue volume changes following weight gain in adults with anorexia nervosa. Int J Eat Disord 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/123\">",
"      Connan F, Murphy F, Connor SE, et al. Hippocampal volume and cognitive function in anorexia nervosa. Psychiatry Res 2006; 146:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/124\">",
"      Strumia R. Dermatologic signs in patients with eating disorders. Am J Clin Dermatol 2005; 6:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/125\">",
"      Tyler I, Wiseman MC, Crawford RI, Birmingham CL. Cutaneous manifestations of eating disorders. J Cutan Med Surg 2002; 6:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/62/38890/abstract/126\">",
"      Glorio R, Allevato M, De Pablo A, et al. Prevalence of cutaneous manifestations in 200 patients with eating disorders. Int J Dermatol 2000; 39:348.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14705 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_62_38890=[""].join("\n");
var outline_f37_62_38890=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1598714\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31379336\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5206194\">",
"      DIAGNOSIS OF ANOREXIA NERVOSA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5205415\">",
"      MEDICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5205559\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31379357\">",
"      CARDIOVASCULAR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8741290\">",
"      Structural changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8741312\">",
"      Functional changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8741319\">",
"      - Bradycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31379371\">",
"      GYNECOLOGIC AND REPRODUCTIVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31379385\">",
"      Fertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31379420\">",
"      ENDOCRINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H278931821\">",
"      Hypothalamus and pituitary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27332237\">",
"      Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27332251\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H163154010\">",
"      Thyroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86795515\">",
"      Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H440145\">",
"      GASTROINTESTINAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H440172\">",
"      Gastroparesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H440179\">",
"      Constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H440186\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H837225\">",
"      RENAL AND ELECTROLYTES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1782633\">",
"      PULMONARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31379427\">",
"      HEMATOLOGIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31379434\">",
"      NEUROLOGIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31379441\">",
"      DERMATOLOGIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1598714\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14705\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14705|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/57/18324\" title=\"diagnostic image 1\">",
"      Anorexia nervosa heart and lung changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14705|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/24/44425\" title=\"figure 1\">",
"      DEXA scan from adult female with anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14705|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/7/9339\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/44/30413\" title=\"table 2\">",
"      Medical complications of anorexia nervosa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?39/41/40593?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body mass index (BMI; Quetelet's index)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=related_link\">",
"      Amenorrhea and infertility associated with exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/16/30982?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: The refeeding syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16550?source=related_link\">",
"      Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16553?source=related_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33223?source=related_link\">",
"      Arrhythmia management for the primary care clinician",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33816?source=related_link\">",
"      Bulimia nervosa and binge eating disorder in adults: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/24/13705?source=related_link\">",
"      Definition and diagnosis of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=related_link\">",
"      Determinants and management of cardiovascular risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2167?source=related_link\">",
"      Diagnosis and treatment of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/59/4025?source=related_link\">",
"      Diagnosis and treatment of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7781?source=related_link\">",
"      Eating disorders in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44023?source=related_link\">",
"      Eating disorders: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/25/6553?source=related_link\">",
"      Epidemiology and etiology of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/12/43209?source=related_link\">",
"      Etiology and diagnosis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/856?source=related_link\">",
"      Euthyroid hyperthyroxinemia and hypothyroxinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11254?source=related_link\">",
"      Evaluation and treatment of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=related_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/9/9366?source=related_link\">",
"      Evaluation of the patient with hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35449?source=related_link\">",
"      Heart rate variability: Uses other than after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44664?source=related_link\">",
"      Hypoglycemia in adults: Clinical manifestations, definition, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6245?source=related_link\">",
"      Hypokalemia-induced renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=related_link\">",
"      Management of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/41/12951?source=related_link\">",
"      Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3476?source=related_link\">",
"      Mitral valve prolapse syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/16/25858?source=related_link\">",
"      Patient information: Anorexia nervosa (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=related_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/33/10778?source=related_link\">",
"      QT dispersion: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/51/26425?source=related_link\">",
"      QT dispersion: Measurement and interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/20/35142?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3878?source=related_link\">",
"      Sinus bradycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/58/37799?source=related_link\">",
"      Superior mesenteric artery syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44663?source=related_link\">",
"      Thyroid function in nonthyroidal illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/35/7738?source=related_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/50/33576?source=related_link\">",
"      Treatment of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5161?source=related_link\">",
"      Treatment of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_62_38891="Bacterial skin infections OLT";
var content_f37_62_38891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bacterial skin infections after liver transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Bacteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atypical mycobacteria (M. kansasii, M. chelonae, M. fortuitum, M. marinum)",
"       </td>",
"       <td>",
"        Cutaneous lesions most common on the extremities. Isolated nodules with a violet color, necrotic or even ulcerative. These lesions can appear months to years after transplantation. The possibility of environmental contamination of the cultures, causing false positive results, should be taken into account. Sequencing the hsp65 gene from the skin biopsy may accelerate the diagnosis and improve its accuracy [1].",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nocardia",
"       </td>",
"       <td>",
"        Usually appear as subcutaneous abscesses or nodules in association with other manifestations of disseminated nocardiosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Staphylococcus aureus",
"       </td>",
"       <td>",
"        Responsible for pyoderma, wound infections, and toxic shock syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treponema pallidum",
"       </td>",
"       <td>",
"        Skin lesions of secondary syphilis accompanying a hepatitis with prolonged fever has been reported following liver transplantation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bartonella henselae",
"       </td>",
"       <td>",
"        Localized bacillary angiomatosis. Skin lesions occur in only 24 percent&nbsp;of cases [2].",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. Lau SK, Curreem SO, Ngan AH, et al. First report of disseminated Mycobacterium skin infections in two liver transplant recipients and rapid diagnosis by hsp65 gene sequencing. J Clin Microbiol 2011; 49:3733.",
"     <br>",
"      2. Psarros G, Riddell J 4th, Gandhi T, et al. Bartonella henselae infections in solid organ transplant recipients: report of 5 cases and review of the literature. Medicine (Baltimore) 2012; 91:111.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_62_38891=[""].join("\n");
var outline_f37_62_38891=null;
var title_f37_62_38892="Delivered FIO2 using HeO2";
var content_f37_62_38892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Delivered FIO2 during Heliox utilization",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        FIO",
"        <sub>",
"         2",
"        </sub>",
"        set",
"       </td>",
"       <td class=\"subtitle1\">",
"        Veolar FT",
"       </td>",
"       <td class=\"subtitle1\">",
"        Galileo",
"       </td>",
"       <td class=\"subtitle1\">",
"        Evita 2",
"       </td>",
"       <td class=\"subtitle1\">",
"        Evita 4",
"       </td>",
"       <td class=\"subtitle1\">",
"        Servo 900C",
"       </td>",
"       <td class=\"subtitle1\">",
"        Servo 300",
"       </td>",
"       <td class=\"subtitle1\">",
"        7200 series",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.21",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"       <td>",
"        0.22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.24",
"       </td>",
"       <td>",
"        0.24",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.26",
"       </td>",
"       <td>",
"        0.56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        0.31",
"       </td>",
"       <td>",
"        0.31",
"       </td>",
"       <td>",
"        0.28",
"       </td>",
"       <td>",
"        0.27",
"       </td>",
"       <td>",
"        0.33",
"       </td>",
"       <td>",
"        0.33",
"       </td>",
"       <td>",
"        0.73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.35",
"       </td>",
"       <td>",
"        0.37",
"       </td>",
"       <td>",
"        0.35",
"       </td>",
"       <td>",
"        0.31",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        0.35",
"       </td>",
"       <td>",
"        0.38",
"       </td>",
"       <td>",
"        0.83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        04",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        0.41",
"       </td>",
"       <td>",
"        0.35",
"       </td>",
"       <td>",
"        0.34",
"       </td>",
"       <td>",
"        0.46",
"       </td>",
"       <td>",
"        0.43",
"       </td>",
"       <td>",
"        0.88",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.51",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.42",
"       </td>",
"       <td>",
"        0.41",
"       </td>",
"       <td>",
"        0.51",
"       </td>",
"       <td>",
"        0.52",
"       </td>",
"       <td>",
"        0.95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        0.61",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        0.52",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.62",
"       </td>",
"       <td>",
"        0.63",
"       </td>",
"       <td>",
"        0.99",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        0.98",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        0.98",
"       </td>",
"       <td>",
"        0.97",
"       </td>",
"       <td>",
"        0.99",
"       </td>",
"       <td>",
"        0.99",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tassaux D, Jolliet P, Thouret J, et al. Calibration of seven ICU ventilators for mechanical ventilation with helium-oxygen mixtures. Am J Respir Crit Care Med 1999; 160:22. Copyright &copy;1999 American Lung Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_62_38892=[""].join("\n");
var outline_f37_62_38892=null;
var title_f37_62_38893="Circadian pattern SCD I";
var content_f37_62_38893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Circadian variability in sudden death",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 320px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Analysis of death certificates of 2203 individuals with out-of-hospital sudden death demonstrates that the peak frequency is between 9 and 11 am.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Muller, JE, Ludmer, PL, Willich, SN, et al. Circulation 1987; 75:131.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_62_38893=[""].join("\n");
var outline_f37_62_38893=null;
var title_f37_62_38894="Pulmonary angioscopy I";
var content_f37_62_38894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary angioscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal angioscopic appearance of the pulmonary artery. The normal pulmonary artery has a round or oval contour with a smooth, pale, glistening appearance to the intima.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter F Fedullo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_62_38894=[""].join("\n");
var outline_f37_62_38894=null;
var title_f37_62_38895="Open cardiac massage";
var content_f37_62_38895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F86033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F86033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Open cardiac massage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 458px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Open chest cardiac massage is performed with the heart compressed between the palms of both hands. Cardiac compression with one hand should be",
"    <strong>",
"     avoided",
"    </strong>",
"    because the pulmonary outflow tract is vulnerable to penetration by the thumb.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_62_38895=[""].join("\n");
var outline_f37_62_38895=null;
